Oligonucleotide conjugate, composition comprising oligonucleotide conjugate, preparation method therefor, and use thereof

Abstract

The present application provides an oligonucleotide conjugate and a pharmaceutical composition comprising the oligonucleotide conjugate. The oligonucleotide conjugate comprises a functional double-stranded oligonucleotide, a lipophilic moiety, and a peptide chain, wherein the functional double-stranded oligonucleotide, the lipophilic moiety, and the peptide chain are connected by means of linkers. The oligonucleotide conjugate and the pharmaceutical composition provided in the present application can effectively regulate the expression level of a target gene in vivo or in vitro, and have excellent tissue specificity. Therefore, the oligonucleotide conjugate and the pharmaceutical composition can effectively treat and / or prevent disease symptoms related to the level of mRNA expressed by the target gene. The present application holds promise.

Description

Oligonucleotide conjugate, composition containing the same, and preparation method and use thereof TECHNICAL FIELD The present application relates to an oligonucleotide conjugate capable of binding to transferrin receptor (TfR), and also relates to a composition containing the oligonucleotide conjugate, and a preparation method and use thereof. BACKGROUND Oligonucleotides are a new class of emerging therapeutic agents that are currently being actively developed for treating various diseases through numerous mechanisms of action (MOA). Oligonucleotide therapeutic agents mainly include duplex (double-stranded) RNA (dsRNA). dsRNA can be further divided into two categories: small interfering RNA (siRNA) and small activating RNA (saRNA), both of which require Argonaute (AGO) protein as their protein partner to function. siRNA mainly binds to target mRNA in the cytoplasm to down-regulate gene expression at the post-transcriptional level via the RNA interference (RNAi) mechanism. saRNA targets regulatory sequences such as gene promoters in the nucleus to up-regulate gene expression at the transcriptional level via the RNAa (RNA activation) mechanism. In recent years, oligonucleotides, particularly double-stranded oligonucleotides, have been known to the public as pharmaceutically active ingredients, and considerable progress has been made in the development of double-stranded oligonucleotide drugs. However, many double-stranded oligonucleotides that show excellent pharmaceutical activity in preclinical pharmacological research centers are difficult to effectively reach specific target organs or target tissues due to the lack of effective delivery carriers, and thus are difficult to be used in actual drug development, especially for some nervous system diseases, including central nervous system diseases and peripheral nervous system diseases, muscle diseases. Therefore, there is still a great practical need in the art for oligonucleotide drugs that can be effectively delivered to specific target organs or target tissues, particularly brain, spinal cord, optic nerve tissue, olfactory nerve tissue, ear nerve and other peripheral nerve tissue, neuromuscular junction or muscle tissue, tumor tissue. Therefore, there is a continuing need for oligonucleotide molecules for in vivo delivery to address these challenges with improved delivery efficiency and / or tissue specificity. SUMMARY The present application provides an oligonucleotide conjugate with high delivery efficiency, which can effectively deliver oligonucleotides to target organs or target tissues, such as the central nervous system, and exhibit high pharmaceutical activity. In one aspect, the present application provides an oligonucleotide conjugate, comprising: a functional double-stranded oligonucleotide comprising a sense strand and an antisense strand, at least one peptide chain conjugated to one of the above strands, and at least one lipophilic moiety or at least one peptide chain conjugated to one of the above strands, wherein at least one of the peptide chains is CHRPYIAH. In another aspect, the present application also provides a pharmaceutical composition comprising the oligonucleotide conjugate of the present application and a pharmaceutically acceptable carrier thereof. In yet another aspect, the present application also provides the use of the oligonucleotide conjugate and / or the pharmaceutical composition of the present application in the manufacture of a medicament for treating and / or preventing a pathological condition or disease associated with a target gene. In yet another aspect, the present application also provides a method for inhibiting the expression of a target gene in a cell, which comprises contacting an effective amount of the oligonucleotide conjugate of the present application and / or the pharmaceutical composition of the present application with the cell. In yet another aspect, the present application also provides a kit comprising an effective dose of the oligonucleotide conjugate and / or the pharmaceutical composition of the present application. Beneficial effects Compared with the oligonucleotide conjugated with only C16 hydrocarbon group (e.g., Reference Conjugate 1, Reference Conjugate 3) or the oligonucleotide conjugated with only one peptide chain (e.g., Reference Conjugate 2), the oligonucleotide conjugate of the present application conjugated with both C16 hydrocarbon group and peptide chain or the oligonucleotide conjugate conjugated with two or more peptide chains and / or the pharmaceutical composition thereof have good delivery efficiency in the central nervous system, higher target gene expression regulation activity, excellent tissue specificity, and show high pharmaceutical activity. The double-stranded oligonucleotide conjugate and / or the pharmaceutical composition of the present application show excellent inhibitory effect on the mRNA of the expression of the target gene in the central nervous system in vivo, have excellent function of regulating the mRNA level of the expression of the target gene in the tissue or cell expressing TfR, such as various tissues in the central nervous system, and thus can effectively treat and / or prevent the disease symptoms related to the mRNA level of the expression of the target gene, and have good application prospect. DETAILED DESCRIPTION The detailed description of the present application is described below. It should be understood that the detailed description described herein is only used to illustrate and explain the present application, and is not used to limit the present application. In the present application, SOD1 mRNA refers to the mRNA with Genbank registration number NM_011434.2 or NM_000454.5. MGMT mRNA refers to the mRNA with Genbank registration number NM_002412.5. Definitions The nomenclature used in connection with, and the methods and techniques of, the biological, analytical, synthetic organic, and medicinal and pharmaceutical chemistry described herein are those familiar to and conventionally employed by those skilled in the art, unless specifically defined otherwise. Standard techniques can be used for chemical syntheses and chemical analyses. Certain of these techniques and procedures can be found, for example, in "Carbohydrate Modifications in Antisense Research" by Sangvi and Cook, American Chemical Society, Washington, 1994; "Remington's Pharmaceutical Sciences," Mack Publishing Co., Easton, Pa., 18th edition, 1990; and "Antisense Drug Technology, Principles, Strategies, and Applications" by Stanley T. Crooke, CRC Press, Boca Raton, Fla.; in Sambrook et al., "Molecular Cloning, A laboratory Manual," 2nd edition, Cold Spring Harbor Laboratory Press, 1989, incorporated by reference for any purpose. All patents, applications, published applications, and other publications and other data cited herein are incorporated by reference in their entirety, to the extent allowed by law. As used herein, the term "target gene" or "target mRNA" refers to any nucleic acid molecule whose expression or activity can be modulated by an siRNA compound; including, but not limited to, RNA transcribed from the transcription of DNA encoding a target protein (including, but not limited to, mRNA precursors and mRNAs or portions thereof), as well as cDNAs derived from such RNAs, and miRNAs. For example, a target gene can be a cellular gene (or mRNA transcribed from a gene) whose expression is associated with a particular disorder or disease state. In some embodiments, a target gene can be a nucleic acid molecule from an infectious agent. In the foregoing and hereinafter, unless specifically stated otherwise, the capital letters C, G, U, A represent the base composition of a nucleotide; the lower case letter m represents that the nucleotide adjacent to the left of the letter m is a methoxy-modified nucleotide; the lower case letter f represents that the nucleotide adjacent to the left of the letter f is a fluoro-modified nucleotide; the lower case letter s represents that the two nucleotides adjacent to the left and right of the letter s are connected by a phosphorothioate group or the nucleotide is connected to the peptide chain DRI-T8 by a phosphorothioate group; UHD represents 2'-O-hexadecyluridine; AHD represents 2'-O-hexadecyl-adenosine; DRI-T8 represents the peptide chain: CHRPYIAH; the letter combination VP represents that the nucleotide adjacent to the right of the letter combination VP is a (5'-(E)-vinyl phosphonate, E-VP) modified nucleotide. In the context of the present document, the expressions "complementary" or "reverse complementary" are used interchangeably and have the meaning well known to the person skilled in the art, i.e. in a double-stranded nucleic acid molecule, the bases of one strand each pair with the bases on the other strand in a complementary manner. In DNA, the purine base adenine (A) always pairs with the pyrimidine base thymine (T) (or in RNA with uracil (U)); the purine base guanine (G) always pairs with the pyrimidine base cytosine (C). Each base pair comprises one purine and one pyrimidine. When the adenine on one strand always pairs with the thymine (or uracil) on the other strand and the guanine always pairs with the cytosine, the two strands are considered to be complementary to each other and the sequence of one strand can be deduced from the sequence of its complementary strand. Correspondingly, "mismatch" means in the art that the bases at the corresponding positions in a double-stranded nucleic acid do not pair in a complementary manner. In the foregoing and hereinafter, unless specifically stated otherwise, "substantially reverse complementary" means that there are not more than 3 base mismatches between the two nucleotide sequences concerned; "essentially reverse complementary" means that there are not more than 1 base mismatch between the two nucleotide sequences; "completely reverse complementary" means that there are no base mismatches between the two nucleotide sequences. In the foregoing and hereinafter, especially in the context of the description of the preparation of a double-stranded oligonucleotide, a pharmaceutical composition or a double-stranded oligonucleotide conjugate, unless specifically stated otherwise, the nucleoside monomers refer to modified or unmodified nucleoside phosphoramidite monomers used in the phosphoramidite solid phase synthesis according to the kind and order of the nucleotides in the double-stranded oligonucleotide or double-stranded oligonucleotide conjugate to be prepared. The phosphoramidite solid phase synthesis is a method well known to the person skilled in the art for use in RNA synthesis. The nucleoside monomers used in the present application are all commercially available. In the context of the present application, "conjugated" means that two or more chemical moieties, each having a specific function, are connected to each other in a covalent linkage, unless otherwise indicated; correspondingly, "conjugate" means a compound formed by the covalent linkage between the respective chemical moieties. Further, "oligonucleotide conjugate" means a compound formed by the covalent linkage of one or more chemical moieties having a specific function to an oligonucleotide or siRNA. Oligonucleotide conjugate should be understood in the context of a general term for a plurality of oligonucleotide conjugates or a certain chemical formula shown for an oligonucleotide conjugate. In the foregoing or hereinafter, a "substituted" group includes, but is not limited to, a substituted alkyl, a substituted alkoxy, a substituted amino, a substituted aliphatic, a substituted heteroaliphatic, a substituted acyl, a substituted aryl, or a substituted heteroaryl. Where no indication is given, a "substituted" group means that one or more hydrogen atoms of the group are replaced with a substituent. For example, a "substituted alkoxy" means that one or more hydrogen atoms of the alkoxy group are replaced with a substituent. Those skilled in the art will appreciate that a variety of substituents can be used in the compounds of the application, provided that the introduction of the substituent does not interfere with the function of the application and the purpose of the application is achieved. In some embodiments, the substituents are selected from the group consisting of C1-C10 alkyl, C6-C10 aryl, C5-C10 heteroaryl, C1-C10 haloalkyl, -OC1-C10 alkyl, -OC1-C10 alkylphenyl, -C1-C10 alkyl-OH, -OC1-C10 haloalkyl, -SC1-C10 alkyl, -SC1-C10 alkylphenyl, -C1-C10 alkyl-SH, -SC1-C10 haloalkyl, halogen substituent, -OH, -SH, -NH2, -C1-C10 alkyl-NH2, -N(C1-C10 alkyl)(C1-C10 alkyl), -NH(C1-C10 alkyl), -N(C1-C10 alkyl)(C1-C10 alkylphenyl), -NH(C1-C10 alkylphenyl), -CN, -NO2, -CO2H, -C(O)O(C1-C10 alkyl), -CON(C1-C10 alkyl)(C1-C10 alkyl), -CONH(C1-C10 alkyl), -CONH2, -NHC(O)(C1-C10 alkyl), -NHC(O)(phenyl), -N(C1-C10 alkyl)C(O)(C1-C10 alkyl), -N(C1-C10 alkyl)C(O)(phenyl), -C(O)C1-C10 alkyl, -C(O)C1-C10 alkylphenyl, -C(O)C1-C10 haloalkyl, -OC(O)C1-C10 alkyl, -SO2(C1-C10 alkyl), -SO2(phenyl), -SO2(C1-C10 haloalkyl), -SO2NH2, -SO2NH(C1-C10 alkyl), -SO2NH(phenyl), -NHSO2(C1-C10 alkyl), -NHSO2(phenyl), and -NHSO2(C1-C10 haloalkyl). In some embodiments, the substituents are one of C1-C3 alkyl, C6-C8 aryl, -OC1-C3 alkyl, -OC1-C3 alkylphenyl, halogen, -OH, -NH2, -CN, or -NO2.Those skilled in the art will appreciate that, for any given group containing one or more substituents, such groups do not intend to introduce any substitution or substitution pattern that is spatially impractical, synthetically infeasible, and / or inherently unstable. As used herein, "alkyl" refers to straight and branched chain alkyl groups having the indicated number of carbon atoms, typically from 1 to 30 carbon atoms, for example, from 4 to 30 carbon atoms, such as from 6 to 18 or from 6 to 16 carbon atoms. For example, C1-C6alkyl groups refer to groups having from 1 to 6 carbon atoms. Examples of alkyl groups include methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl, t-butyl, n-pentyl, 2-pentyl, 3-pentyl, 2-methyl-2-butyl, hexyl, 2-hexyl, 3-hexyl, and the like. Alkyl groups can be substituted or unsubstituted. 30 Alkyl groups include straight chain and branched chain alkyl groups of from 1 to 30 carbon atoms. When reference is made to an alkyl residue having a particular number of carbons, it is intended to encompass all branched and straight chain forms having that number of carbons; thus, for example, "butyl" is intended to include n-butyl, sec-butyl, i-butyl, and t-butyl; "propyl" includes n-propyl and i-propyl. Alkylene groups are a subset of alkyl groups, referring to the same groups as alkyl, but having two points of attachment. As used herein, "saturated alkyl" refers to alkyl groups in which all carbon atoms are connected by single bonds, containing no carbon-carbon double and / or triple bonds. As used herein, "alkenyl" refers to unsaturated branched or straight chain alkyl groups having at least one carbon-carbon double bond, obtained by removing one molecule of hydrogen from adjacent carbon atoms of the parent alkyl group. The group can be in either the cis or trans configuration for the double bond. Typical alkenyl groups include, but are not limited to: ethenyl; propenyl, such as prop-1-en-1-yl, prop-1-en-2-yl, prop-2-en-1-yl (allyl), prop-2-en-2-yl; butenyl, for example but-1-en-1-yl, but-1-en-2-yl, 2-methylprop-1-en-1-yl, but-2-en-1-yl, but-2-en-2-yl, buta-1,3-dien-1-yl, buta-1,3-dien-2-yl, and the like. In certain embodiments, alkenyl groups have from 2 to 30 carbon atoms, while in other embodiments, from 4 to 30, from 6 to 18, or from 6 to 16 carbon atoms. Alkenylene groups are a subset of alkenyl groups, referring to the same groups as alkenyl, but having two points of attachment. The term "subject," as used herein, refers to any animal, such as a mammal or marsupial. Subjects of the present application include, but are not limited to, humans, non-human primates (e.g., rhesus or other type of macaque monkey), mice, pigs, horses, donkeys, cows, rabbits, sheep, rats, and any species of poultry. As used herein, "treatment" refers to an approach for obtaining beneficial or desired results, including but not limited to therapeutic benefit. "Therapeutic benefit" means eradication or amelioration of the underlying disorder being treated. Also, a therapeutic benefit is achieved with the improvement of one or more signs or symptoms of the underlying disorder being addressed, even though a subject can still be afflicted with the disorder. The term "transferrin receptor" as used herein refers to transferrin receptor 1 (TfRl) and / or transferrin receptor 2 (TfR2). Transferrin receptors (TfRs) mediate the import of iron-containing transferrins from the extracellular into the intracellular space and are present on the surface of many cells and are expressed in many target tissues or target organs, such as skeletal muscle, smooth muscle, brain, eye, tumor tissue, etc. Lipophilic moiety In certain embodiments, the lipophilic moiety is an aliphatic, cyclic such as alicyclic, or polycyclic such as a polyalicyclic compound, such as a steroid (e.g., a sterol) or a straight or branched aliphatic hydrocarbon. The lipophilic moiety can generally comprise a hydrocarbon chain, which can be cyclic or acyclic. Such lipophilic aliphatic moieties include, but are not limited to, saturated or unsaturated C4-C30 hydrocarbon groups (e.g., C6-C18 hydrocarbon groups), saturated or unsaturated fatty acids, waxes (e.g., monoalcohol esters of fatty acids and fatty diamides), terpenes (e.g., C10 terpenes, C15 sesquiterpenes, C20 diterpenes, C30 triterpenes, and C40 tetraterpenes), and other polyalicyclic hydrocarbons. For example, the lipophilic moiety can contain a C4-C30 hydrocarbon chain (e.g., a C4-C30 alkyl or alkenyl group, a C6-C18 alkyl or alkenyl group). In some embodiments, the lipophilic moiety contains a saturated or unsaturated C6-C18 hydrocarbon chain (e.g., a straight chain C6-C18 alkyl or alkenyl group). In one embodiment, the lipophilic moiety contains a saturated or unsaturated C16 hydrocarbon chain (e.g., a straight chain C16 alkyl or alkenyl group). Peptide chain The peptide chain includes a naturally occurring or modified peptide, such as a D or L peptide; an alpha, beta, or gamma peptide; an N-methyl peptide; an azapeptide; a peptide having one or more amides, i.e., a peptide in which the bond is replaced by one or more urea, thiourea, carbamate, or sulfonylurea linkages; or a cyclic peptide. The peptide chain can be about 5-50 amino acids long, such as about 5, 10, 15, 20, 25, 30, 35, 40, 45, or 50 amino acids long. In some embodiments, the peptide chain is selected from a peptide chain having 7-18 amino acids, preferably a 15, 10, or 8 peptide chain, such as HAIYPRHC or CHRPYIAH. In some embodiments, the exemplary peptide chains include, but are not limited to, cecropin, lycotoxin, paradaxin, butorin, CPF, bombinin-like peptide (BLP), cathelicidin, ceratotoxin, S. clava peptide, hagfish intestinal antimicrobial peptide (HFIAP), magainin, brevinin-2, dermaseptin, melittin, pleurocidin, H2A peptide, Xenopus peptide, esculentini-1, caerin, HAIYPRHC, or CHRPYIAH. Linker Linker of the lipophilic moiety The lipophilic moiety can be attached to the oligonucleotide by any method known in the art, including via a functional group already present in the lipophilic moiety or introduced into the oligonucleotide, such as a hydroxyl group (e.g., -CO-CH2-OH). Functional groups already present in the lipophilic moiety or introduced into the oligonucleotide include, but are not limited to, hydroxyl, amine, carboxylic acid, sulfonate, phosphate, thiol, azido, and alkyne. Conjugation of the oligonucleotide to the lipophilic moiety can occur, for example, by formation of an ether linkage or a carboxyl or carbamoyl ester linkage between a hydroxyl and an alkyl R-, alkanoyl RCO-, or substituted carbamoyl RNHCO-. R can be cyclic (e.g., cyclohexyl) or acyclic (e.g., straight or branched; and saturated or unsaturated). R can be butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl, dodecyl, tridecyl, tetradecyl, pentadecyl, hexadecyl, heptadecyl, or octadecyl or similar groups. An “ether linkage linker” as described herein refers to conjugation of the oligonucleotide to the lipophilic moiety (hydrocarbyl (e.g., alkyl R-)) by formation of an ether linkage between a hydroxyl of the oligonucleotide and a hydrocarbyl (e.g., alkyl R-). “the linker contains a thioether, urea, carbonate, amine, amide, maleimide-thioether, disulfide, phosphate, phosphodiester, sulfonamide, or carbamate, a hydrazone, an ester, an acetal, or a ketal, a peptide bond” as described herein refers to conjugation of the oligonucleotide to the lipophilic moiety by a linker, while the entire linker is of the above structural type or a portion of the entire linker is of the above structural type. In some embodiments, the lipophilic moiety is conjugated to the double-stranded oligonucleotide via a linker containing an ether, thioether, urea, carbonate, amine, amide, maleimide-thioether, disulfide, phosphate, phosphodiester, sulfonamide, or carbamate, a hydrazone group, an ester group, an acetal group, or a ketal group, a peptide bond. In some embodiments, at least one of the linkers can be a redox-cleavable linker, an acid-cleavable linker, an esterase-cleavable linker, a phosphatase-cleavable linker, or a peptidase-cleavable linker. One class of cleavable linkers is redox-cleavable linkers, which cleave upon reduction or oxidation. An example of a reduction-cleavable linker is a disulfide linker (-S-S-). An acid-cleavable linker is a linker that cleaves under acidic conditions. In preferred embodiments, the acid-cleavable linker cleaves in an acidic environment having a pH of about 6.5 or less (e.g., about 6.0, 5.5, 5.0 or less), or by an agent such as an enzyme that can act as a general acid. In cells, specific low-pH organelles, such as endosomes and lysosomes, can provide a cleavage environment for acid-cleavable linkers. Examples of acid-cleavable linkers include, but are not limited to, hydrazones, ketals, acetals, esters, and esters of amino acids. Acid-cleavable groups can have the general formula C(O)O- or -OC(O). Phosphate-based linkers cleave by agents that degrade or hydrolyze the phosphate. An example of an agent that cleaves phosphate groups in cells is an enzyme in the cell, such as a phosphatase. Examples of phosphate-based linkers are -O-P(O)(OH)-O-, -O-P(S)(OH)-O-, -O-P(S)(SH)-O-, -S-P(O)(OH)-O-, -O-P(O)(OH)-S-, -S-P(O)(OH)-S-, -O-P(S)(OH)-S-, -S-P(S)(OH)-O-, -O-P(O)(H)-O-, -O-P(S)(H)-O-, -S-P(O)(H)-O-, -S-P(S)(H)-O-, -S-P(O)(H)-S-, -O-P(S)(H)-S-. Ester-based linkers cleave by enzymes in the cell, such as esterases and amidases. Examples of ester-based cleavable linkers include, but are not limited to, esters of alkylene, alkenylene, and alkynylene. Ester-cleavable linkers have the general formula -C(O)O- or -OC(O)-. Peptide-based linkers are cleaved by enzymes in the cell, such as peptidases and proteases. Peptide-based cleavable linkers are peptide bonds formed between amino acids to create oligopeptides (e.g., dipeptides, tripeptides, etc.) and polypeptides. Peptide-based cleavable groups do not include amide groups (-C(O)NH-). Amide groups can be formed between any alkylene, alkenylene, or alkynylene groups. Peptide bonds are a special type of amide bond formed between amino acids to create peptides and proteins. Peptide-based cleavage groups are generally limited to peptide bonds (i.e., amide bonds) formed between amino acids to create peptides and proteins, and do not include the entire amide functional group. Peptide cleavable linkers have the general formula -NHCHR1C(O)NHCHR2C(O)-, where R1and R2are alkyl groups of two adjacent amino acids. Each of the above classes of cleavable linkers are susceptible to cleavage by a cleaving agent (e.g., pH, presence of an oxidizing or reducing potential, or a degrading molecule). Generally, cleaving agents are found more commonly or at higher levels or activities within a cell than in serum or blood. Examples of such degrading agents include: redox agents selected for a particular substrate or without substrate specificity, including, for example, oxidizing or reducing enzymes or reducing agents present in the cell, such as thiols, which can degrade the redox cleavable linker by reduction; esterases; endosomes or agents that can create an acidic environment, for example, endosomes or agents that result in a pH of 5 or less; enzymes that can hydrolyze or degrade the acid cleavable linker by acting as general acids, peptidases (which can be substrate specific), and phosphatases. Cleavable linkers, such as disulfide bonds, can be sensitive to pH. The pH of human serum is 7.4, while the average intracellular pH is slightly lower, ranging from about 7.1-7.3. Endosomes have a more acidic pH in the range of 5.5-6.0, and lysosomes have an even more acidic pH of about 5.0. Some linkers will have a linker that cleaves at the preferred pH to release the oligonucleotide from the ligand within the cell (e.g., a targeting or cell-penetrating ligand, such as cholesterol), or to enter the desired compartment of the cell. Additionally, the linker can also include a bio-cleavable linker selected from the group consisting of DNA, RNA, disulfide, amide, functionalized monosaccharides or oligosaccharides of galactosamine, glucosamine, glucose, galactose, and mannose, and combinations thereof. Hereinafter, the following will be collectively referred to as "linkers other than ether bond linkers" in "lipophilic moiety linkers": a linker containing a thioether, urea, carbonate, amine, amide, maleimide-thioether, disulfide, phosphate, phosphodiester, sulfonamide or carbamate, hydrazone, ester, acetal, or ketal, peptide bond, or a bio-cleavable linker selected from the group consisting of DNA, RNA, disulfide, amide, functionalized monosaccharides or oligosaccharides of galactosamine, glucosamine, glucose, galactose, mannose, and combinations thereof. Linker of the peptide chain The peptide chain moiety can be attached to the oligonucleotide by any method known in the art. In some embodiments, the peptide chain moiety is linked to the oligonucleotide by a linker having the structure: wherein end 1 of the linker is conjugated to the end of the 1 strand by a phosphoester linkage and end 2 is conjugated to the end of the peptide chain (e.g., a thiol group). As used herein, "the linker contains an ether, thioether, urea, carbonate, amine, amide, maleimide-thioether, disulfide, phosphate, phosphodiester, sulfonamide or carbamate, a hydrazone, an ester, an acetal or ketal, a peptide bond" means that the conjugation of the oligonucleotide to the peptide chain moiety is achieved through a linker, and the entire linker is of the above structural type or a portion of the entire linker is of the above structural type. In some embodiments, the peptide chain moiety is conjugated to the double-stranded oligonucleotide via a linker containing an ether, thioether, urea, carbonate, amine, amide, maleimide-thioether, disulfide, phosphate, phosphodiester, sulfonamide or carbamate, a hydrazone, an ester, an acetal or ketal, a peptide bond. In some embodiments, the linker is a branched linker. The branch-point of the branched linker can be at least a trivalent, but can be a tetravalent, pentavalent or hexavalent atom, or a group that exhibits such a multiple valence. In certain embodiments, the branch-point can be -N, -N(Q)-C, -O-C, -S-C, -SS-C, -C(O)N(Q)-C, -OC(O)N(Q)-C, -N(Q)C(O)-C or -N(Q)C(O)O-C; wherein Q is independently at each occurrence H or optionally substituted alkyl. In other embodiments, the branch-point can be glycerol or a glycerol derivative. In some embodiments, the linker is a branched linker, wherein the linker is selected from the group consisting of -(CH2) n , n is an integer selected from the group consisting of 4-100, preferably 4-50, more preferably 4-18. In some embodiments, the linker is derived from Hereinafter, for ease of description, the following are collectively referred to as "a linker of custom type I of the peptide chain": a linker containing an ether, thioether, urea, carbonate, amine, amide, maleimide-thioether, disulfide, phosphate, phosphodiester, sulfonamide or carbamate, a hydrazone, an ester, an acetal or ketal, a peptide bond; a biologically cleavable linker selected from the group consisting of DNA, RNA, disulfide, amide, functionalized monosaccharides or oligosaccharides of galactosamine, glucosamine, glucose, galactose, mannose, and combinations thereof. In the following, the following are collectively referred to as "self-defined type II linker" in "linker of the peptide chain": a linker containing an ether, a thioether, a urea, a carbonate, an amine, an amide, a maleimide-thioether, a disulfide, a phosphate, a phosphodiester, a sulfonamide or a carbamate, a hydrazone group, an ester group, an acetal group or a ketal group, a peptide bond; a biologically cleavable linker selected from the group consisting of DNA, RNA, disulfide, amide, functionalized monosaccharides or oligosaccharides of galactosamine, glucosamine, glucose, galactose, mannose, and combinations thereof; a branched linker, wherein the linker is selected from -(CH2) n -, n is an integer selected from 4-100, preferably an integer from 4-50, more preferably an integer from 4-18; or a linker derived from . oligonucleotide An oligonucleotide should include a region of sufficient homology to a target gene and of sufficient length in nucleotides such that the oligonucleotide or a fragment thereof can mediate down- or up-regulation of the target gene. Thus, the oligonucleotide is or includes a region that is at least partially, and in some embodiments completely, complementary to the target RNA. Perfect complementarity between the oligonucleotide and the target is not necessary, but the correspondence must be sufficient to enable the oligonucleotide or its cleavage products to direct sequence-specific silencing / activation, e.g., siRNA cleaves a target RNA, e.g., mRNA; saRNA activates a target RNA, e.g., mRNA. The degree of complementarity or homology to the target strand is most critical in the antisense strand. As used herein, the term "RNAi activity" refers to gene silencing by siRNA. In some embodiments, a double-stranded oligonucleotide comprises a sense strand and an antisense strand, wherein the antisense strand has a region of complementarity that is complementary to at least a portion of a target sequence, and the duplex region is 14-30 nucleotides in length. Similarly, the region of complementarity of the target sequence is 15 to 30, more typically 17 to 25, and still more typically 19 to 23 nucleotides in length. As used herein, the phrase "antisense strand" refers to an oligomeric compound which is substantially or 100% complementary to a target sequence of interest. The phrase "sense strand" refers to an oligomeric compound which has a nucleoside sequence identical to all or a portion of a target sequence, such as a messenger RNA or DNA sequence. "Complementary" means that a nucleic acid can form hydrogen bonds with another nucleic acid sequence by either the traditional Watson-Crick or other non-traditional types of bonding. With respect to the nucleic molecules of the present application, the binding free energy of a nucleic acid molecule to its complementary sequence is sufficient to allow the relevant function of the nucleic acid, such as RNAi activity. Determination of the binding free energy of a nucleic acid molecule is well known in the art (see, e.g., Turner et al., 1987, CSH Symp. Quant. Biol. LII pp. 123-133; Frier et al., 1986, Proc. Nat. Acad. Sci. USA 83:9373-9377; Turner et al., 1987,.Am. Chem. Soc. 109:3783-3785). The term "intermediate positions of the sense strand 5' end and 3' end" refers to any position on the sense strand of nucleotides other than the two positions of the 5' end and 3' end. Oligonucleotide conjugates of the present application The present application provides oligonucleotide conjugates comprising: a functional double-stranded oligonucleotide comprising: a sense strand and an antisense strand, at least one peptide chain conjugated to one of the strands above, and at least one lipophilic moiety or at least one peptide chain conjugated to one of the strands above, wherein at least one of the peptide chains is CHRPYIAH. In some embodiments, in the oligonucleotide conjugates, the functional double-stranded oligonucleotide comprises: a sense strand and an antisense strand, one or two or three or four peptide chains conjugated to one of the strands above via a linker described in the section "Linkers for Peptide Chains" above, and one or two or three or four (preferably one or two) lipophilic moieties conjugated to one of the strands above via a linker described in the section "Linkers for Lipophilic Moieties" above, wherein at least one of the peptide chains is CHRPYIAH; or a sense strand and an antisense strand, two to four peptide chains conjugated to one or two of the strands above via "Linkers for Peptide Chains", wherein at least one of the peptide chains is CHRPYIAH. The lipophilic moieties, the peptide chains, and the respective linkers are as defined above. In some embodiments, in the oligonucleotide conjugate, the peptide chain is conjugated at a position selected from the group consisting of: a nucleotide at the 5' end of the sense strand, a nucleotide at the 3' end of the sense strand, a nucleotide at the 5' end of the antisense strand, a nucleotide at the 3' end of the antisense strand, a middle position nucleotide other than the two positions at the 5' and 3' ends of the sense strand. In some embodiments, in the oligonucleotide conjugate, the lipophilic moiety is conjugated at a position selected from the group consisting of: a nucleotide at the 5' end of the sense strand, a middle position nucleotide other than the two positions at the 5' and 3' ends of the sense strand, a nucleotide at the 3' end of the antisense strand; preferably, the lipophilic moiety is conjugated at the 2 position of the nucleotide sugar ring at the above-mentioned position. In some embodiments, in the oligonucleotide conjugate, the sense strand contains a nucleotide sequence I, the antisense strand contains a nucleotide sequence II, the nucleotide sequence I and the nucleotide sequence II are at least partially reverse complementary to form a double-stranded region, the nucleotide sequence II is at least partially reverse complementary to a target gene or a target mRNA, the target gene or the target mRNA is a target gene or a mRNA expressed by a target gene in a target cell in a target tissue or a target organ, the target cell is a TfR receptor present on the cell surface. In some embodiments, in the oligonucleotide conjugate, the nucleotide sequence I and the nucleotide sequence II each has a length of 15 to 30 nucleotides, or the nucleotide sequence I and the nucleotide sequence II each has a length of 17 to 25 nucleotides, or the nucleotide sequence I and the nucleotide sequence II each has a length of 19 to 23 nucleotides, for example, the nucleotide sequence I and the nucleotide sequence II each has a length of 19 to 21 nucleotides; the nucleotide sequence II is substantially reverse complementary, substantially reverse complementary, or completely reverse complementary to the nucleotide sequence I; the substantially reverse complementary means that there are no more than 3 base mismatches between the two nucleotide sequences; the substantially reverse complementary means that there are no more than 1 base mismatch between the two nucleotide sequences; the completely reverse complementary means that there is no base mismatch between the two nucleotide sequences. In some embodiments, in the oligonucleotide conjugate, the functional double-stranded oligonucleotide is a saRNA or a siRNA, preferably the double-stranded oligonucleotide is a siRNA. The nucleotides in the oligonucleotide conjugate described in the present application are modified or unmodified nucleotides. In some embodiments, the nucleotides in the oligonucleotide conjugate are unmodified nucleotides; in some embodiments, part or all of the nucleotides in the oligonucleotide conjugate are modified nucleotides. In some embodiments, at least one nucleotide in the sense strand and the antisense strand is a modified nucleotide. In the context of the present application, the term "modified nucleotide" refers to a nucleotide or a nucleotide analog in which the ribosyl 2' position hydroxyl group is replaced with another group, or a nucleotide in which the base is a modified base. In some embodiments, at least one nucleotide in the sense strand or the antisense strand of the oligonucleotide conjugate provided herein is a modified nucleotide, and / or at least one phosphate group is a phosphate group with a modification group; that is, at least one of the phosphate-sugar backbone of at least one single strand of the sense strand and the antisense strand is a phosphate group with a modification group and / or at least one of the ribosyl groups is a ribosyl group with a modification group. In some embodiments, all of the nucleotides in the sense strand and / or the antisense strand are modified nucleotides. In some embodiments, each of the nucleotides in the sense strand and the antisense strand of the oligonucleotide conjugate provided herein is a fluorine-modified nucleotide or a non-fluorine-modified nucleotide. In the context of the present application, "fluorine-modified nucleotide" refers to a nucleotide in which the ribosyl 2' position hydroxyl group is replaced with fluorine. "Non-fluorine-modified nucleotide" refers to a nucleotide or a nucleotide analog in which the ribosyl 2' position hydroxyl group is replaced with a non-fluorine group. In some embodiments, each non-fluorine-modified nucleotide is selected from one of a nucleotide or a nucleotide analog in which the ribosyl 2' position hydroxyl group is replaced with a non-fluorine group. These nucleotides in which the ribosyl 2' position hydroxyl group is replaced with a non-fluorine group are well known to those skilled in the art, and can be selected from one of a 2'-alkoxy-modified nucleotide, a 2'-substituted alkoxy-modified nucleotide, a 2'-alkyl-modified nucleotide, a 2'-substituted alkyl-modified nucleotide, a 2'-amino-modified nucleotide, a 2'-substituted amino-modified nucleotide, and a 2'-deoxynucleotide. In some embodiments, the 2'-alkoxy-modified nucleotide is a methoxy-modified nucleotide (2'-OMe). In some embodiments, the 2'-substituted alkoxy-modified nucleotide can be a 2'-O-methoxyethyl-modified nucleotide (2'-MOE). In some embodiments, the 2'-amino-modified nucleotide (2'-NH2). Nucleotide analog refers to a group that can replace a nucleotide in a nucleic acid, but is structurally different from an adenine ribonucleotide, a guanine ribonucleotide, a cytosine ribonucleotide, a uracil ribonucleotide, or a thymine deoxyribonucleotide. In some embodiments, the nucleotide analog can be an isonucleotide, a bridged nucleic acid (BNA), or an acyclic nucleotide. BNA refers to a constrained or inaccessible nucleotide. A BNA can contain a five-, six-, or seven-membered ring bridged structure with a "fixed" C3'-endo sugar conformation. The bridge is typically incorporated at the 2'-, 4'-position of the ribose to provide a 2',4'-BNA nucleotide. Acoyclic nucleotide is a class of nucleotides in which the sugar ring of the nucleotide is opened. In some embodiments, an acyclic nucleotide can be an unlocked nucleic acid (UNA) or a glycerol nucleic acid (GNA). Heteronucleotide refers to a compound in which the base in a nucleotide is changed in position on the ribose ring. In some embodiments, a heteronucleotide can be a compound in which the base is moved from the 1'-position to the 2'-position or 3'-position of the ribose ring. An oligonucleotide conjugate can comprise a phosphorus-containing group at the 5' end of the sense strand or the antisense strand. The 5' end phosphorus-containing group can be a 5' phosphate (5'-P), a 5' phosphorothioate (5'-PS), a 5' phosphorodithioate (5'-PS2), a 5' vinylphosphonate group (5'-VP), a 5' methylphosphonate group (MePhos), or a 5'-deoxy-5'-C-malonate group. In some embodiments, the 5' terminal nucleotide of the antisense strand in the functional double-stranded oligonucleotide is a 5'-phosphate nucleotide or a 5'-phosphate analog modified nucleotide. The 5'-phosphate nucleotide or 5'-phosphate analog modified nucleotide commonly used is well known to those skilled in the art, such as a 5'-phosphate nucleotide can have the following structure: For another example, the following four 5'-phosphate analog modified nucleotides are disclosed in Anastasia Khvorova and Jonathan K. Watts, The chemical evolution of oligonucleotide therapies of clinical utility. Nature Biotechnology, 2017, 35(3): 238-48: wherein, Ra is selected from H, OH, methoxy, fluorine; Base represents a base, selected from A, U, C, G or T. In some embodiments, in an oligonucleotide conjugate, one end (e.g., 5' end) of the antisense strand comprises a phosphorus-containing group, and the 5' end phosphorus-containing group is selected from a 5' phosphate (5'-P), a 5' phosphorothioate (5'-PS), a 5' phosphorodithioate (5'-PS2), a 5' vinylphosphonate group (5'-VP), a 5' methylphosphonate group (MePhos), preferably a 5' vinylphosphonate group (5'-VP). In some embodiments, the functional double-stranded oligonucleotide provided herein has a phosphorothioate linkage present at at least one of the following positions: between the first and second nucleotides at either end of the sense strand; between the second and third nucleotides at either end of the sense strand; or any combination thereof. In some embodiments, the phosphorothioate linkage is present at all of the above positions except the 5' end of the sense strand. In some embodiments, the phosphorothioate linkage is present at all of the above positions except the 3' end of the sense strand. In some embodiments, the phosphorothioate linkage is present at at least one of the following positions: between the first and second nucleotides at the 5' end of the sense strand; between the second and third nucleotides at the 5' end of the sense strand; between the first and second nucleotides at the 3' end of the sense strand; between the second and third nucleotides at the 3' end of the sense strand; between the first and second nucleotides at the 5' end of the antisense strand; between the second and third nucleotides at the 5' end of the antisense strand; between the first and second nucleotides at the 3' end of the antisense strand; and between the second and third nucleotides at the 3' end of the antisense strand. In addition, in the oligonucleotide or oligonucleotide conjugate provided herein, each of the non-bridging oxygen atoms or sulfur atoms in the phosphodiester linkage or the phosphorothioate linkage bears a negative charge, which can exist as a hydroxyl group or a thiol group, and the hydrogen ion in the hydroxyl group or the thiol group can be partially or completely replaced by a cation. The cation can be any cation, such as a metal cation, an ammonium cation NH4 + , an organic ammonium cation. For the purpose of improving solubility, in some embodiments, the cation is selected from one or more of an alkali metal ion, an ammonium cation formed by a tertiary amine, and a quaternary ammonium cation. The alkali metal ion can be K + and / or Na +The cation formed by the tertiary amine can be an ammonium ion formed by triethylamine and / or an ammonium ion formed by N,N-diisopropylethylamine. Thus, the oligonucleotide conjugates described herein can exist at least in part in the form of a salt. In some embodiments, the non-bridging oxygen atom or sulfur atom in the phosphodiester linkage or the phosphorothioate linkage is at least in part bound to a sodium ion, and the oligonucleotide or oligonucleotide conjugate described herein exists in the form of a sodium salt or a partial sodium salt. Thus, when referring to the oligonucleotide or oligonucleotide conjugate described herein, including but not limited to the oligonucleotide conjugate represented by any of the structural formulae described herein, the sodium salt or partial sodium salt form of the oligonucleotide or oligonucleotide conjugate is intended to be encompassed. In some specific embodiments, in the oligonucleotide conjugate, the pattern of the lipophilic moiety conjugated via a linker to one strand of the siRNA and the peptide chain conjugated via a linker to one strand of the siRNA is selected from the following: 1) one C16 hydrocarbon group is conjugated via an ether linkage to a nucleotide at the 5' end of the sense strand and one peptide chain CHRPYIAH is conjugated via a linker as defined above to a nucleotide at the 3' end of the sense strand; 2) one C16 hydrocarbon group is conjugated via a linker other than an "ether linkage" in the "linkers for lipophilic moieties" as defined above to a nucleotide at the 5' end of the sense strand and one peptide chain CHRPYIAH is conjugated via a linker as defined above to a nucleotide at the 3' end of the sense strand; 3) one C16 hydrocarbon group is conjugated via an ether linkage to a nucleotide at the 3' end of the sense strand and one peptide chain CHRPYIAH is conjugated via a linker as defined above to a nucleotide at the 3' end of the sense strand; 4) one C16 hydrocarbon group is conjugated via a linker other than an "ether linkage" in the "linkers for lipophilic moieties" as defined above to a nucleotide at the 3' end of the sense strand and one peptide chain CHRPYIAH is conjugated via a linker as defined above to a nucleotide at the 3' end of the sense strand; 5) one C16 hydrocarbon group is conjugated via an ether linkage to a nucleotide at a position intermediate to the 5' end and the 3' end of the sense strand and one peptide chain CHRPYIAH is conjugated via a linker as defined above to a nucleotide at the 3' end of the sense strand; 6) one C16alkyl group is conjugated to a nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via a "linkage other than an ether linkage" within the "linker for lipophilic moieties" defined above, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 3' end of the sense strand via a linker as defined above conjugated to a nucleotide at the 3' end of the sense strand; 7) one C16alkyl group is conjugated to a nucleotide at the 3' end of the antisense strand via an ether linkage, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 3' end of the sense strand via a linker as defined above conjugated to a nucleotide at the 3' end of the sense strand; 8) one C16alkyl group is conjugated to a nucleotide at the 3' end of the antisense strand via a "linkage other than an ether linkage" within the "linker for lipophilic moieties" defined above, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 3' end of the sense strand via a linker as defined above conjugated to a nucleotide at the 3' end of the sense strand; 9) one C16alkyl group is conjugated to a nucleotide at the 5' end of the sense strand via an ether linkage, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 3' end of the sense strand via a "self-defined Type I linker" within the "linkers for peptide chains" described above; 10) one C16alkyl group is conjugated to a nucleotide at the 5' end of the sense strand via a "linkage other than an ether linkage" within the "linker for lipophilic moieties" defined above, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 3' end of the sense strand via a "self-defined Type I linker" within the "linkers for peptide chains" described above; 11) one C16alkyl group is conjugated to a nucleotide at the 3' end of the sense strand via an ether linkage, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 3' end of the sense strand via a "self-defined Type I linker" within the "linkers for peptide chains" described above; 12) one C16alkyl group is conjugated to a nucleotide at the 3' end of the sense strand via a "linkage other than an ether linkage" within the "linker for lipophilic moieties" defined above, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 3' end of the sense strand via a "self-defined Type I linker" within the "linkers for peptide chains" described above; 13) one C16alkyl group is conjugated to a nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via an ether linkage, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 3' end of the sense strand via a "self-defined Type I linker" within the "linkers for peptide chains" described above; 14) One C16 hydrocarbon group is attached to a nucleotide at an intermediate position other than the two positions at the 5' and 3' ends of the positive chain via a "linker other than the ether linker" in the "linker of the lipophilic part" defined above, and one peptide chain CHRPYIAH is attached to a nucleotide at the 3' end of the positive chain via a "linker of custom type I" in the "linker of the peptide chain" described above. 15) One C16 hydrocarbon group is attached to the nucleotide at the 3' end of the antisense strand via an ether bond, and one peptide chain CHRPYIAH is attached to the nucleotide at the 3' end of the sense strand via a "custom type I linker" in the "peptide linker" described above. 16) One C16 hydrocarbon group is attached to the nucleotide at the 3' end of the antisense strand via a "linker other than the ether linker" in the "linker of the lipophilic part" defined above, and one peptide chain CHRPYIAH is attached to the nucleotide at the 3' end of the sense strand via a "linker of custom type I" in the "linker of the peptide chain" described above. 17) A C16 hydrocarbon group is attached to a nucleotide at the 5' end of the positive strand via an ether bond, and a peptide chain CHRPYIAH is attached via a linker as defined above. Nucleotides attached to the 5' end of the positive strand; 18) One C16 hydrocarbon group is attached to a nucleotide at the 5' end of the positive chain via a "linker other than the ether linker" in the "linker of the lipophilic moiety" defined above, and one peptide chain CHRPYIAH is attached via a linker defined above. Nucleotides attached to the 5' end of the positive strand; 19) A C16 hydrocarbon group is attached to a nucleotide at the 3' end of the positive strand via an ether bond, and a peptide chain CHRPYIAH is attached via a linker as defined above. Nucleotides attached to the 5' end of the positive strand; 20) One C16 hydrocarbon group is attached to the 3' end nucleotide of the positive chain via a "linker other than the ether linker" in the "linker of the lipophilic moiety" defined above, and one peptide chain CHRPYIAH is attached via a linker defined above. Nucleotides attached to the 5' end of the positive strand; 21) One C16 hydrocarbon group is attached to an intermediate nucleotide position other than the 5' and 3' ends of the positive strand via an ether bond, and one peptide chain CHRPYIAH is attached via a linker as defined above. Nucleotides attached to the 5' end of the positive strand; 22) one C16alkyl group is conjugated to a nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via a "linkage other than an ether linkage" within the "linkage of a lipophilic moiety" as defined above, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 5' end of the sense strand via a linker as defined above conjugated to a nucleotide at the 5' end of the sense strand; 23) one C16alkyl group is conjugated to a nucleotide at the 3' end of the antisense strand via an ether linkage, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 5' end of the sense strand via a linker as defined above conjugated to a nucleotide at the 5' end of the sense strand; 24) one C16alkyl group is conjugated to a nucleotide at the 3' end of the antisense strand via a "linkage other than an ether linkage" within the "linkage of a lipophilic moiety" as defined above, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 5' end of the sense strand via a linker as defined above conjugated to a nucleotide at the 5' end of the sense strand; 25) one C16alkyl group is conjugated to a nucleotide at the 5' end of the sense strand via an ether linkage, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 5' end of the sense strand via a "self-defined Type I linker" within the "linkers of a peptide chain" as described above; 26) one C16alkyl group is conjugated to a nucleotide at the 5' end of the sense strand via a "linkage other than an ether linkage" within the "linkage of a lipophilic moiety" as defined above, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 5' end of the sense strand via a "self-defined Type I linker" within the "linkers of a peptide chain" as described above; 27) one C16alkyl group is conjugated to a nucleotide at the 3' end of the sense strand via an ether linkage, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 5' end of the sense strand via a "self-defined Type I linker" within the "linkers of a peptide chain" as described above; 28) one C16alkyl group is conjugated to a nucleotide at the 3' end of the sense strand via a "linkage other than an ether linkage" within the "linkage of a lipophilic moiety" as defined above, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 5' end of the sense strand via a "self-defined Type I linker" within the "linkers of a peptide chain" as described above; 29) one C16alkyl group is conjugated to a nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via an ether linkage, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 5' end of the sense strand via a "self-defined Type I linker" within the "linkers of a peptide chain" as described above; 30) one C16alkyl group is conjugated to a nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via a "linkage other than an ether linkage" within the "linker for lipophilic moieties" defined above, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 5' end of the sense strand via a "self-defined Type I linker" within the "linker for peptide chains" described above; 31) one C16alkyl group is conjugated to a nucleotide at the 3' end of the antisense strand via an ether linkage, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 5' end of the sense strand via a "self-defined Type I linker" within the "linker for peptide chains" described above; 32) one C16alkyl group is conjugated to a nucleotide at the 3' end of the antisense strand via a "linkage other than an ether linkage" within the "linker for lipophilic moieties" defined above, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 5' end of the sense strand via a "self-defined Type I linker" within the "linker for peptide chains" described above; 33) one C16alkyl group is conjugated to a nucleotide at the 5' end of the sense strand via an ether linkage, and one peptide chain CHRPYIAH is conjugated to a nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via a "self-defined Type I linker" within the "linker for peptide chains" defined above; a "self-defined Type I linker" within the "linker for peptide chains" described above; 34) one C16alkyl group is conjugated to a nucleotide at the 5' end of the sense strand via a "linkage other than an ether linkage" within the "linker for lipophilic moieties" defined above, and one peptide chain CHRPYIAH is conjugated to a nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via a "self-defined Type I linker" within the "linker for peptide chains" defined above; a "self-defined Type I linker" within the "linker for peptide chains" described above; 35) one C16alkyl group is conjugated to a nucleotide at the 3' end of the sense strand via an ether linkage, and one peptide chain CHRPYIAH is conjugated to a nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via a "self-defined Type I linker" within the "linker for peptide chains" defined above; a "self-defined Type I linker" within the "linker for peptide chains" described above; 36) one C16alkyl group is conjugated to a nucleotide at the 3' end of the sense strand via a "linkage other than an ether linkage" within the "linker for lipophilic moieties" defined above, and one peptide chain CHRPYIAH is conjugated to a nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via a "self-defined Type I linker" within the "linker for peptide chains" defined above; a "self-defined Type I linker" within the "linker for peptide chains" described above; 37) one C16alkyl group is conjugated to a nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via an ether linkage, and one peptide chain CHRPYIAH is conjugated to a nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via a "self-defined Type I linker" within the "linker for peptide chains" defined above; conjugated to the nucleotide at the 5' end of the sense strand via a "linker other than an ether linkage" of the "linkers for lipophilic moieties" defined above, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' end of the sense strand via a "linker other than an ether linkage" of the "linkers for lipophilic moieties" defined above; 38) one C16 hydrocarbon group is conjugated to the nucleotide at the 5' end of the sense strand via a "linker other than an ether linkage" of the "linkers for lipophilic moieties" defined above, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' end of the sense strand via a "linker other than an ether linkage" of the "linkers for lipophilic moieties" defined above, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' end of the sense strand via a "linker other than an ether linkage" of the "linkers for lipophilic moieties" defined above; conjugated to the nucleotide at the 5' end of the sense strand via a "linker other than an ether linkage" of the "linkers for lipophilic moieties" defined above, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' end of the sense strand via a "linker other than an ether linkage" of the "linkers for lipophilic moieties" defined above; 39) one C16 hydrocarbon group is conjugated to the nucleotide at the 3' end of the antisense strand via an ether linkage, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand via a "linker other than an ether linkage" of the "linkers for lipophilic moieties" defined above, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' end of the sense strand via a "linker other than an ether linkage" of the "linkers for lipophilic moieties" defined above; conjugated to the nucleotide at the 5' end of the sense strand via a "linker other than an ether linkage" of the "linkers for lipophilic moieties" defined above, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' end of the sense strand via a "linker other than an ether linkage" of the "linkers for lipophilic moieties" defined above; 40) one C16 hydrocarbon group is conjugated to the nucleotide at the 3' end of the antisense strand via a "linker other than an ether linkage" of the "linkers for lipophilic moieties" defined above, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand via a "linker other than an ether linkage" of the "linkers for lipophilic moieties" defined above, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' end of the sense strand via a "linker other than an ether linkage" of the "linkers for lipophilic moieties" defined above; conjugated to the nucleotide at the 5' end of the sense strand via a "linker other than an ether linkage" of the "linkers for lipophilic moieties" defined above, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' end of the sense strand via a "linker other than an ether linkage" of the "linkers for lipophilic moieties" defined above; 41) one C16 hydrocarbon group is conjugated to the nucleotide at the 5' end of the sense strand via an ether linkage, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand via a "self-defined Type I linker" of the "linkers for peptide chains" described above, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' end of the sense strand via a "self-defined Type I linker" of the "linkers for peptide chains" described above; 42) one C16 hydrocarbon group is conjugated to the nucleotide at the 5' end of the sense strand via a "linker other than an ether linkage" of the "linkers for lipophilic moieties" defined above, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand via a "self-defined Type I linker" of the "linkers for peptide chains" described above, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' end of the sense strand via a "self-defined Type I linker" of the "linkers for peptide chains" described above; 43) one C16 hydrocarbon group is conjugated to the nucleotide at the 3' end of the sense strand via an ether linkage, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand via a "self-defined Type I linker" of the "linkers for peptide chains" described above, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' end of the sense strand via a "self-defined Type I linker" of the "linkers for peptide chains" described above; 44) one C16 hydrocarbon group is conjugated to the nucleotide at the 3' end of the sense strand via a "linker other than an ether linkage" of the "linkers for lipophilic moieties" defined above, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand via a "self-defined Type I linker" of the "linkers for peptide chains" described above, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' end of the sense strand via a "self-defined Type I linker" of the "linkers for peptide chains" described above; 45) One C16 hydrocarbon group is attached to an intermediate nucleotide outside the two positions at the 5' and 3' ends of the positive chain via an ether bond, and one peptide chain CHRPYIAH is attached to an intermediate nucleotide outside the two positions at the 5' and 3' ends of the positive chain via a "custom type I linker" in the "peptide linker" described above. 46) One C16 hydrocarbon group is attached to an intermediate nucleotide outside the two positions at the 5' and 3' ends of the positive chain via a "linker other than the ether linker" in the "linker of the lipophilic part" defined above, and one peptide chain CHRPYIAH is attached to an intermediate nucleotide outside the two positions at the 5' and 3' ends of the positive chain via a "linker of custom type I" in the "linker of the peptide chain" described above; 47) One C16 hydrocarbon group is attached to the nucleotide at the 3' end of the antisense strand via an ether bond, and one peptide chain CHRPYIAH is attached to the nucleotide at the middle position other than the two positions at the 5' and 3' ends of the sense strand via the "custom type I linker" in the "peptide linker" described above. 48) One C16 hydrocarbon group is conjugated to the nucleotide at the 3' end of the antisense strand via a "connector other than the ether linker" in the "connector of the lipophilic part" as defined above, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the middle position other than the two positions at the 5' and 3' ends of the sense strand via a "connector of custom type I" in the "connector of the peptide chain" as described above. 49) One C16 hydrocarbon group is attached to a nucleotide at the 5' end of the positive strand via an ether bond, and one peptide chain CHRPYIAH is attached via a linker as defined above. Nucleotides attached to the 3' end of the antisense strand; 50) One C16 hydrocarbon group is attached to the 5' end of the positive chain via a "linker other than the ether linker" in the "linker of the lipophilic moiety" defined above, and one peptide chain CHRPYIAH is attached via a linker defined above. Nucleotides attached to the 3' end of the antisense strand; 51) One C16 hydrocarbon group is attached to a nucleotide at the 3' end of the positive chain via an ether bond, and one peptide chain CHRPYIAH is attached via a linker as defined above. Nucleotides attached to the 3' end of the antisense strand; 52) One C16 hydrocarbon group is attached to the 3' end nucleotide of the positive chain via a "linker other than the ether linker" in the "linker of the lipophilic moiety" defined above, and one peptide chain CHRPYIAH is attached via a linker defined above. Nucleotides attached to the 3' end of the antisense strand; 53) one C16 alkyl group is conjugated to a nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand, via an ether linkage, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 3' end of the antisense strand via a linker as defined above conjugated to a nucleotide at the 3' end of the antisense strand; 54) one C16 alkyl group is conjugated to a nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand, via a linker other than an "ether linkage", of the "linkers for lipophilic moieties" as defined above, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 3' end of the antisense strand via a linker as defined above conjugated to a nucleotide at the 3' end of the antisense strand; 55) one C16 alkyl group is conjugated to a nucleotide at the 3' end of the antisense strand, via an ether linkage, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 3' end of the antisense strand via a linker as defined above conjugated to a nucleotide at the 3' end of the antisense strand; 56) one C16 alkyl group is conjugated to a nucleotide at the 3' end of the antisense strand, via a linker other than an "ether linkage", of the "linkers for lipophilic moieties" as defined above, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 3' end of the antisense strand via a linker as defined above conjugated to a nucleotide at the 3' end of the antisense strand; 57) one C16 alkyl group is conjugated to a nucleotide at the 5' end of the sense strand, via an ether linkage, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 3' end of the antisense strand, via a "linker for a peptide chain" as defined above, of the "linkers of self-defined type I"; 58) one C16 alkyl group is conjugated to a nucleotide at the 5' end of the sense strand, via a linker other than an "ether linkage", of the "linkers for lipophilic moieties" as defined above, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 3' end of the antisense strand, via a "linker for a peptide chain" as defined above, of the "linkers of self-defined type I"; 59) one C16 alkyl group is conjugated to a nucleotide at the 3' end of the sense strand, via an ether linkage, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 3' end of the antisense strand, via a "linker for a peptide chain" as defined above, of the "linkers of self-defined type I"; 60) one C16 alkyl group is conjugated to a nucleotide at the 3' end of the sense strand, via a linker other than an "ether linkage", of the "linkers for lipophilic moieties" as defined above, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 3' end of the antisense strand, via a "linker for a peptide chain" as defined above, of the "linkers of self-defined type I"; 61) one C16alkyl group is conjugated to a nucleotide at a position intermediate to the 5' and 3' terminal two positions of the sense strand via an ether linkage and one peptide CHRPYIAH is conjugated to a nucleotide at the 3' terminus of the antisense strand via a "self- defined Type I linker" of "linkers for peptide chains" as defined above; 62) one C16alkyl group is conjugated to a nucleotide at a position intermediate to the 5' and 3' terminal two positions of the sense strand via a "linkage other than an ether linkage" of "linkers for lipophilic moieties" as defined above and one peptide CHRPYIAH is conjugated to a nucleotide at the 3' terminus of the antisense strand via a "self-defined Type I linker" of "linkers for peptide chains" as defined above; 63) one C16alkyl group is conjugated to a nucleotide at the 3' terminus of the antisense strand via an ether linkage and one peptide CHRPYIAH is conjugated to a nucleotide at the 3' terminus of the antisense strand via a "self-defined Type I linker" of "linkers for peptide chains" as defined above; 64) one C16alkyl group is conjugated to a nucleotide at the 3' terminus of the antisense strand via a "linkage other than an ether linkage" of "linkers for lipophilic moieties" as defined above and one peptide CHRPYIAH is conjugated to a nucleotide at the 3' terminus of the antisense strand via a "self-defined Type I linker" of "linkers for peptide chains" as defined above; 65) one C16alkyl group is conjugated to a nucleotide at the 5' terminus of the sense strand via an ether linkage and one peptide CHRPYIAH is conjugated to a nucleotide at the 3' terminus of the sense strand via a "self-defined Type I linker" of "linkers for peptide chains" as defined above and another peptide CHRPYIAH is conjugated to a nucleotide at the 5' terminus of the sense strand via a "self-defined Type I linker" of "linkers for peptide chains" as defined above; 66) one C16alkyl group is conjugated to a nucleotide at the 5' terminus of the sense strand via a "linkage other than an ether linkage" of "linkers for lipophilic moieties" as defined above and one peptide CHRPYIAH is conjugated to a nucleotide at the 3' terminus of the sense strand via a "self-defined Type I linker" of "linkers for peptide chains" as defined above and another peptide CHRPYIAH is conjugated to a nucleotide at the 5' terminus of the sense strand via a "self-defined Type I linker" of "linkers for peptide chains" as defined above; 67) one C16alkyl group is conjugated to a nucleotide at the 3' terminus of the sense strand via an ether linkage and one peptide CHRPYIAH is conjugated to a nucleotide at the 5' terminus of the sense strand via a "self-defined Type I linker" of "linkers for peptide chains" as defined above and another peptide CHRPYIAH is conjugated to a nucleotide at the 3' terminus of the sense strand via a "self-defined Type I linker" of "linkers for peptide chains" as defined above; 68) one C16alkyl group is conjugated to a nucleotide at the 3' terminus of the sense strand via a "linkage other than an ether linkage" of "linkers for lipophilic moieties" as defined above and one peptide CHRPYIAH is conjugated to a nucleotide at the 5' terminus of the sense strand via a "self-defined Type I linker" of "linkers for peptide chains" as defined above and another peptide CHRPYIAH is conjugated to a nucleotide at the 3' terminus of the sense strand via a "self-defined Type I linker" of "linkers for peptide chains" as defined above; 69) one C16alkyl group is conjugated to a nucleotide at the 5' terminus of the sense strand via an ether linkage and one peptide CHRPYIAH is conjugated to a nucleotide at the 5' terminus of the sense strand via a "self-defined Type I linker" of "linkers for peptide chains" as defined above and another peptide CHRPYIAH is conjugated to a nucleotide at the 3' terminus of the sense strand via a "self-defined Type I linker" of "linkers for peptide chains" as defined above; 70) one C16alkyl group is conjugated to a nucleotide at the 5' terminus of the sense strand via a "linkage other than an ether linkage" of "linkers for lipophilic moieties" as defined above and one peptide CHRPYIAH is conjugated to a nucleotide at the 5' terminus of the sense strand via a "self-defined Type I linker" of "linkers for peptide chains" as defined above and another peptide CHRPYIAH is conjugated to a nucleotide at the 3' terminus of the sense strand via a "self-defined Type I linker" of "linkers for peptide chains" as defined above; 71) one C16alkyl group is conjugated to a nucleotide at the 3' terminus of the sense strand via an ether linkage and one peptide CHRPYIAH is conjugated to a nucleotide at the 5' terminus of the sense strand via a "self-defined Type I linker" of "linkers for peptide chains" as defined above and another peptide CHRPYIAH is conjugated to a nucleotide at the 3' terminus of the sense strand via a "self-defined Type I linker" of "linkers for peptide chains" as defined above; 72) one C16alkyl group is conjugated to a nucleotide at the 3' terminus of the sense strand via a "linkage other than an ether linkage" of "linkers for lipophilic moieties" as defined above and one peptide CHRPYIAH is conjugated to a nucleotide at the 5' terminus of the sense strand via a "self-defined Type I linker" of "linkers for peptide chains" as defined above and another peptide CHRPYIAH is conjugated to a nucleotide at the 3' terminus of the sense strand via a "self-defined Type I linker" of "linkers for peptide chains" as defined above; ​68) one C16alkyl group is conjugated to a nucleotide at the 3' end of the sense strand via a "linkage other than an ether linkage" within the "linkage of the lipophilic moiety" defined above, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 5' end of the sense strand via a linker defined above one C16alkyl group is conjugated to a nucleotide at the 3' end of the sense strand via a "linkage other than an ether linkage" within the "linkage of the lipophilic moiety" defined above, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 5' end of the sense strand via a linker defined above conjugated to a nucleotide at the 5' end of the sense strand; 69) one C16alkyl group is conjugated to a nucleotide at the 5' end and at the 3' end of the sense strand via an ether linkage, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the middle position between the two positions defined above via a linker defined above one C16alkyl group is conjugated to a nucleotide at the 3' end of the sense strand via a "linkage other than an ether linkage" within the "linkage of the lipophilic moiety" defined above, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 5' end of the sense strand via a linker defined above conjugated to a nucleotide at the 5' end of the sense strand; 70) one C16alkyl group is conjugated to a nucleotide at the 5' end and at the 3' end of the sense strand via a "linkage other than an ether linkage" within the "linkage of the lipophilic moiety" defined above, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the middle position between the two positions defined above via a linker defined above one C16alkyl group is conjugated to a nucleotide at the 3' end of the sense strand via a "linkage other than an ether linkage" within the "linkage of the lipophilic moiety" defined above, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 5' end of the sense strand via a linker defined above conjugated to a nucleotide at the 5' end of the sense strand; 71) one C16alkyl group is conjugated to a nucleotide at the 3' end of the antisense strand via an ether linkage, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 5' end of the sense strand via a linker defined above one C16alkyl group is conjugated to a nucleotide at the 3' end of the sense strand via a "linkage other than an ether linkage" within the "linkage of the lipophilic moiety" defined above, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 5' end of the sense strand via a linker defined above conjugated to a nucleotide at the 5' end of the sense strand; 72) one C16alkyl group is conjugated to a nucleotide at the 3' end of the antisense strand via a "linkage other than an ether linkage" within the "linkage of the lipophilic moiety" defined above, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 5' end of the sense strand via a linker defined above one C16alkyl group is conjugated to a nucleotide at the 3' end of the sense strand via a "linkage other than an ether linkage" within the "linkage of the lipophilic moiety" defined above, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 5' end of the sense strand via a linker defined above conjugated to a nucleotide at the 5' end of the sense strand; 73) one C16alkyl group is conjugated to the 5' terminal nucleotide of the sense strand via an ether linkage and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 3' terminal end of the sense strand via a "self-defmed Type I linker" of "linkers for peptide chains" as defined above and another peptide chain CHRPYIAH is conjugated to a nucleotide at the 5' terminal end of the sense strand via a "self-defmed Type I linker" of "linkers for peptide chains" as defined above; 74) one C16alkyl group is conjugated to the 5' terminal nucleotide of the sense strand via a "linker other than an ether linkage" of "linkers for lipophilic moieties" as defined above and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 3' terminal end of the sense strand via a "self-defmed Type I linker" of "linkers for peptide chains" as defined above and another peptide chain CHRPYIAH is conjugated to a nucleotide at the 5' terminal end of the sense strand via a "self-defmed Type I linker" of "linkers for peptide chains" as defined above; 75) one C16alkyl group is conjugated to the 3' terminal nucleotide of the sense strand via an ether linkage and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 3' terminal end of the sense strand via a "self-defmed Type I linker" of "linkers for peptide chains" as defined above and another peptide chain CHRPYIAH is conjugated to a nucleotide at the 5' terminal end of the sense strand via a "self-defmed Type I linker" of "linkers for peptide chains" as defined above; 76) one C16alkyl group is conjugated to the 3' terminal nucleotide of the sense strand via a "linker other than an ether linkage" of "linkers for lipophilic moieties" as defined above and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 3' terminal end of the sense strand via a "self-defmed Type I linker" of "linkers for peptide chains" as defined above and another peptide chain CHRPYIAH is conjugated to a nucleotide at the 5' terminal end of the sense strand via a "self-defmed Type I linker" of "linkers for peptide chains" as defined above; 77) one C16alkyl group is conjugated to a nucleotide at a position intermediate to the 5' and 3' terminal ends of the sense strand and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 3' terminal end of the sense strand via a "self-defmed Type I linker" of "linkers for peptide chains" as defined above and another peptide chain CHRPYIAH is conjugated to a nucleotide at the 5' terminal end of the sense strand via a "self-defmed Type I linker" of "linkers for peptide chains" as defined above; 78) one C16alkyl group is conjugated to a nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand by a "linkage other than an ether linkage" within the "linker for lipophilic moieties" defined above, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 3' end of the sense strand by a "self-defined Type I linker" within the "linker for peptide chains" described above, and another peptide chain CHRPYIAH is conjugated to a nucleotide at the 5' end of the sense strand by a "self-defined Type I linker" within the "linker for peptide chains" described above; 79) one C16alkyl group is conjugated to a nucleotide at the 3' end of the antisense strand by an ether linkage, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 3' end of the sense strand by a "self-defined Type I linker" within the "linker for peptide chains" described above, and another peptide chain CHRPYIAH is conjugated to a nucleotide at the 5' end of the sense strand by a "self-defined Type I linker" within the "linker for peptide chains" described above; 80) one C16alkyl group is conjugated to a nucleotide at the 3' end of the antisense strand by a "linkage other than an ether linkage" within the "linker for lipophilic moieties" defined above, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 3' end of the sense strand by a "self-defined Type I linker" within the "linker for peptide chains" described above, and another peptide chain CHRPYIAH is conjugated to a nucleotide at the 5' end of the sense strand by a "self-defined Type I linker" within the "linker for peptide chains" described above; 81) one C16alkyl group is conjugated to a nucleotide at the 5' end of the sense strand by an ether linkage, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 3' end of the sense strand by a "self-defined Type I linker" within the "linker for peptide chains" described above, and another peptide chain CHRPYIAH is conjugated to a nucleotide at the 5' end of the sense strand by a "self-defined Type I linker" within the "linker for peptide chains" described above; 81) one C16alkyl group is conjugated to a nucleotide at the 5' end of the sense strand by an ether linkage, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 3' end of the sense strand by a "self-defined Type I linker" within the "linker for peptide chains" described above, and another peptide chain CHRPYIAH is conjugated to a nucleotide at the 5' end of the sense strand by a "self-defined Type I linker" within the "linker for peptide chains" described above; 82) one C16alkyl group is conjugated to a nucleotide at the 5' end of the sense strand by a "linkage other than an ether linkage" within the "linker for lipophilic moieties" defined above, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 3' end of the sense strand by a "self-defined Type I linker" within the "linker for peptide chains" described above, and another peptide chain CHRPYIAH is conjugated to a nucleotide at the 5' end of the sense strand by a "self-defined Type I linker" within the "linker for peptide chains" described above; 82) one C16alkyl group is conjugated to a nucleotide at the 5' end of the sense strand by a "linkage other than an ether linkage" within the "linker for lipophilic moieties" defined above, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 3' end of the sense strand by a "self-defined Type I linker" within the "linker for peptide chains" described above, and another peptide chain CHRPYIAH is conjugated to a nucleotide at the 5' end of the sense strand by a "self-defined Type I linker" within the "linker for peptide chains" described above; 83) one C16alkyl group is conjugated to a nucleotide at the 3' end of the sense strand by an ether linkage, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 3' end of the sense strand by a "self-defined Type I linker" within the "linker for peptide chains" described above, and another peptide chain CHRPYIAH is conjugated to a nucleotide at the 5' end of the sense strand by a "self-defined Type I linker" within the "linker for peptide chains" described above; one C16alkyl group is conjugated to the nucleotide at the 3' end of the sense strand via a "linker other than an ether linkage" within the "linkers for lipophilic moieties" defined above, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand via a "self-made Type I linker" within the "linkers for peptide chains" defined above; 84) one C16alkyl group is conjugated to the nucleotide at the 3' end of the sense strand via a "linker other than an ether linkage" within the "linkers for lipophilic moieties" defined above, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand via a "self-made Type I linker" within the "linkers for peptide chains" defined above; one C16alkyl group is conjugated to the nucleotide at the 3' end of the sense strand via a "linker other than an ether linkage" within the "linkers for lipophilic moieties" defined above, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand via a "self-made Type I linker" within the "linkers for peptide chains" defined above; 85) one C16alkyl group is conjugated to the nucleotide at the 5' end and at the 3' end of the sense strand via an ether linkage, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the middle position between the two positions via a "self-made Type I linker" within the "linkers for peptide chains" defined above; one C16alkyl group is conjugated to the nucleotide at the 3' end of the sense strand via a "linker other than an ether linkage" within the "linkers for lipophilic moieties" defined above, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand via a "self-made Type I linker" within the "linkers for peptide chains" defined above; 86) one C16alkyl group is conjugated to the nucleotide at the 5' end and at the 3' end of the sense strand via a "linker other than an ether linkage" within the "linkers for lipophilic moieties" defined above, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the middle position between the two positions via a "self-made Type I linker" within the "linkers for peptide chains" defined above; one C16alkyl group is conjugated to the nucleotide at the 3' end of the sense strand via a "linker other than an ether linkage" within the "linkers for lipophilic moieties" defined above, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand via a "self-made Type I linker" within the "linkers for peptide chains" defined above; 87) one C16alkyl group is conjugated to the nucleotide at the 3' end of the antisense strand via an ether linkage, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the antisense strand via a "self-made Type I linker" within the "linkers for peptide chains" defined above; one C16alkyl group is conjugated to the nucleotide at the 3' end of the sense strand via a "linker other than an ether linkage" within the "linkers for lipophilic moieties" defined above, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand via a "self-made Type I linker" within the "linkers for peptide chains" defined above; 88) one C16alkyl group is conjugated to the nucleotide at the 3' end of the antisense strand via a "linker other than an ether linkage" within the "linkers for lipophilic moieties" defined above, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the antisense strand via a "self-made Type I linker" within the "linkers for peptide chains" defined above; one C16alkyl group is conjugated to the nucleotide at the 3' end of the sense strand via a "linker other than an ether linkage" within the "linkers for lipophilic moieties" defined above, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand via a "self-made Type I linker" within the "linkers for peptide chains" defined above; 89) one C16alkyl group is conjugated to the 5' terminal nucleotide of the sense strand via an ether linkage and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 3' terminal end of the sense strand via a "self-defmed Type I linker" within the "linkers for peptide chains" described hereinabove and another one of the peptide chains CHRPYIAH is conjugated via a linker as defined hereinabove conjugated to the 5' terminal nucleotide of the sense strand; 90) one C16alkyl group is conjugated to the 5' terminal nucleotide of the sense strand via a "linker other than an ether linkage" within the "linkers for lipophilic moieties" defined hereinabove and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 3' terminal end of the sense strand via a "self-defmed Type I linker" within the "linkers for peptide chains" described hereinabove and another one of the peptide chains CHRPYIAH is conjugated via a linker as defined hereinabove conjugated to the 5' terminal nucleotide of the sense strand; 91) one C16alkyl group is conjugated to the 3' terminal nucleotide of the sense strand via an ether linkage and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 3' terminal end of the sense strand via a "self-defmed Type I linker" within the "linkers for peptide chains" described hereinabove and another one of the peptide chains CHRPYIAH is conjugated via a linker as defined hereinabove conjugated to the 5' terminal nucleotide of the sense strand; 92) one C16alkyl group is conjugated to the 3' terminal nucleotide of the sense strand via a "linker other than an ether linkage" within the "linkers for lipophilic moieties" defined hereinabove and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 3' terminal end of the sense strand via a "self-defmed Type I linker" within the "linkers for peptide chains" described hereinabove and another one of the peptide chains CHRPYIAH is conjugated via a linker as defined hereinabove conjugated to the 5' terminal nucleotide of the sense strand; 93) one C16alkyl group is conjugated to a nucleotide at a position intermediate to the 5' and 3' terminal ends of the sense strand and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 3' terminal end of the sense strand via a "self-defmed Type I linker" within the "linkers for peptide chains" described hereinabove and another one of the peptide chains CHRPYIAH is conjugated via a linker as defined hereinabove conjugated to the 5' terminal nucleotide of the sense strand; 94) one C16alkyl group is conjugated to a nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via a "linkage other than an ether linkage" within the "linker for lipophilic moieties" defined above, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 3' end of the sense strand via a "self-defined Type I linker" within the "linker for peptide chains" described above, and another one peptide chain CHRPYIAH is conjugated to a nucleotide at the 5' end of the sense strand via a "self-defined Type I linker" within the "linker for peptide chains" defined above; conjugated to a nucleotide at the 5' end of the sense strand; 95) one C16alkyl group is conjugated to a nucleotide at the 3' end of the antisense strand via an ether linkage, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 3' end of the sense strand via a "self-defined Type I linker" within the "linker for peptide chains" described above, and another one peptide chain CHRPYIAH is conjugated to a nucleotide at the 5' end of the sense strand via a "self-defined Type I linker" within the "linker for peptide chains" defined above; conjugated to a nucleotide at the 5' end of the sense strand; 96) one C16alkyl group is conjugated to a nucleotide at the 3' end of the antisense strand via a "linkage other than an ether linkage" within the "linker for lipophilic moieties" defined above, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 3' end of the sense strand via a "self-defined Type I linker" within the "linker for peptide chains" described above, and another one peptide chain CHRPYIAH is conjugated to a nucleotide at the 5' end of the sense strand via a "self-defined Type I linker" within the "linker for peptide chains" defined above; conjugated to a nucleotide at the 5' end of the sense strand; 97) one C16alkyl group is conjugated to a nucleotide at the 5' end of the sense strand via an ether linkage, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 3' end of the sense strand via a "self-defined Type I linker" within the "linker for peptide chains" defined above; conjugated to a nucleotide at the 3' end of the sense strand, and another one peptide chain CHRPYIAH is conjugated to a nucleotide at the 5' end of the sense strand via a "self-defined Type I linker" within the "linker for peptide chains" defined above; conjugated to a nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand; 98) one C16alkyl group is conjugated to a nucleotide at the 5' end of the sense strand via a "linkage other than an ether linkage" within the "linker for lipophilic moieties" defined above, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 3' end of the sense strand via a "self-defined Type I linker" within the "linker for peptide chains" defined above; conjugated to a nucleotide at the 3' end of the sense strand, and another one peptide chain CHRPYIAH is conjugated to a nucleotide at the 5' end of the sense strand via a "self-defined Type I linker" within the "linker for peptide chains" defined above; conjugated to a nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand; 99) one C16alkyl group is conjugated to a nucleotide at the 3' end of the sense strand via an ether linkage, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 5' end of the sense strand via a "self-defined Type I linker" within the "linker for peptide chains" defined above. one other peptide chain CHRPYIAH is conjugated to a nucleotide at the 3' end of the sense strand via a linker as defined above a nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand; 100) one C16 hydrocarbon group is conjugated to a nucleotide at the 3' end of the sense strand via a "linker other than an ether linkage" within the "linkers for lipophilic moieties" defined above, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 5' end of the sense strand via a linker as defined above one other peptide chain CHRPYIAH is conjugated to a nucleotide at the 3' end of the sense strand via a linker as defined above a nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand; 101) one C16 hydrocarbon group is conjugated to a nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via an ether linkage, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 5' end of the sense strand via a linker as defined above one other peptide chain CHRPYIAH is conjugated to a nucleotide at the 3' end of the sense strand via a linker as defined above a nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand; 102) one C16 hydrocarbon group is conjugated to a nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via a "linker other than an ether linkage" within the "linkers for lipophilic moieties" defined above, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 5' end of the sense strand via a linker as defined above one other peptide chain CHRPYIAH is conjugated to a nucleotide at the 3' end of the sense strand via a linker as defined above a nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand; 103) one C16 hydrocarbon group is conjugated to a nucleotide at the 3' end of the antisense strand via an ether linkage, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 5' end of the sense strand via a linker as defined above one other peptide chain CHRPYIAH is conjugated to a nucleotide at the 3' end of the sense strand via a linker as defined above a nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand; 104) one C16alkyl group is conjugated to the nucleotide at the 3' end of the sense strand via a "linkage other than an ether linkage" within the "lipophilic moiety linkages" defined above, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand via a "self-defined Type I linkage" within the "peptidyl linker linkages" described above, and another peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' end of the sense strand via a "self-defined Type I linkage" within the "peptidyl linker linkages" described above; another peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' end of the sense strand via a "self-defined Type I linkage" within the "peptidyl linker linkages" described above; a nucleotide intermediate the two positions at the 5' and 3' ends of the sense strand; 105) one C16alkyl group is conjugated to the nucleotide at the 5' end of the sense strand via an ether linkage, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' end of the sense strand via a "self-defined Type I linkage" within the "peptidyl linker linkages" described above, and another peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand via a "self-defined Type I linkage" within the "peptidyl linker linkages" described above; 106) one C16alkyl group is conjugated to the nucleotide at the 5' end of the sense strand via a "linkage other than an ether linkage" within the "lipophilic moiety linkages" defined above, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' end of the sense strand via a "self-defined Type I linkage" within the "peptidyl linker linkages" described above, and another peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand via a "self-defined Type I linkage" within the "peptidyl linker linkages" described above; 107) one C16alkyl group is conjugated to the nucleotide at the 3' end of the sense strand via an ether linkage, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' end of the sense strand via a "self-defined Type I linkage" within the "peptidyl linker linkages" described above, and another peptide chain CHRPYIAH is conjugated to a nucleotide intermediate the two positions at the 5' and 3' ends of the sense strand via a "self-defined Type I linkage" within the "peptidyl linker linkages" described above; 108) one C16alkyl group is conjugated to the nucleotide at the 3' end of the sense strand via a "linkage other than an ether linkage" within the "lipophilic moiety linkages" defined above, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' end of the sense strand via a "self-defined Type I linkage" within the "peptidyl linker linkages" described above, and another peptide chain CHRPYIAH is conjugated to a nucleotide intermediate the two positions at the 5' and 3' ends of the sense strand via a "self-defined Type I linkage" within the "peptidyl linker linkages" described above; 109) one C16alkyl is conjugated to a nucleotide at a position intermediate to the 5' and 3' terminal two positions of the sense strand via an ether linkage, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 3' terminus of the sense strand via a "self- defining Type I linker" of "linkers for peptide chains" described hereinabove, and one other peptide chain CHRPYIAH is conjugated to a nucleotide at a position intermediate to the 5' and 3' terminal two positions of the sense strand via a "self-defining Type I linker" of "linkers for peptide chains" described hereinabove; 110) one C16alkyl is conjugated to a nucleotide at a position intermediate to the 5' and 3' terminal two positions of the sense strand via a "linker other than an ether linkage" of "linkers for lipophilic moieties" defined hereinabove, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 3' terminus of the sense strand via a "self-defining Type I linker" of "linkers for peptide chains" described hereinabove, and one other peptide chain CHRPYIAH is conjugated to a nucleotide at a position intermediate to the 5' and 3' terminal two positions of the sense strand via a "self-defining Type I linker" of "linkers for peptide chains" described hereinabove; 111) one C16alkyl is conjugated to a nucleotide at the 3' terminus of the antisense strand via an ether linkage, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 3' terminus of the sense strand via a "self-defining Type I linker" of "linkers for peptide chains" described hereinabove, and one other peptide chain CHRPYIAH is conjugated to a nucleotide at a position intermediate to the 5' and 3' terminal two positions of the sense strand via a "self-defining Type I linker" of "linkers for peptide chains" described hereinabove; 112) one C16alkyl is conjugated to a nucleotide at the 3' terminus of the antisense strand via a "linker other than an ether linkage" of "linkers for lipophilic moieties" defined hereinabove, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 3' terminus of the sense strand via a "self-defining Type I linker" of "linkers for peptide chains" described hereinabove, and one other peptide chain CHRPYIAH is conjugated to a nucleotide at a position intermediate to the 5' and 3' terminal two positions of the sense strand via a "self-defining Type I linker" of "linkers for peptide chains" described hereinabove; 113) one C16alkyl is conjugated to a nucleotide at the 5' terminus of the sense strand via an ether linkage, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 3' terminus of the sense strand via a "self-defining Type I linker" of "linkers for peptide chains" defined hereinabove, and one other peptide chain CHRPYIAH is conjugated to a nucleotide at a position intermediate to the 5' and 3' terminal two positions of the sense strand via a "self-defining Type I linker" of "linkers for peptide chains" described hereinabove; 113) one C16alkyl is conjugated to a nucleotide at the 5' terminus of the sense strand via an ether linkage, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 3' terminus of the sense strand via a "self-defining Type I linker" of "linkers for peptide chains" defined hereinabove, and one other peptide chain CHRPYIAH is conjugated to a nucleotide at a position intermediate to the 5' and 3' terminal two positions of the sense strand via a "self-defining Type I linker" of "linkers for peptide chains" described hereinabove; 114) one C16alkyl group is conjugated to the nucleotide at the 5' end of the sense strand via a "linker other than an ether linkage" in the "linkers for lipophilic moieties" defined above, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' end of the sense strand via a "linker for peptide chains" as defined above one other peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end and the 3' end of the sense strand via a "self-defined Type I linker" in the "linkers for peptide chains" described above; 115) one C16alkyl group is conjugated to the nucleotide at the 3' end of the sense strand via an ether linkage, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand via a "linker for peptide chains" as defined above one other peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end and the 3' end of the sense strand via a "self-defined Type I linker" in the "linkers for peptide chains" described above; 116) one C16alkyl group is conjugated to the nucleotide at the 3' end of the sense strand via a "linker other than an ether linkage" in the "linkers for lipophilic moieties" defined above, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand via a "linker for peptide chains" as defined above one other peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end and the 3' end of the sense strand via a "self-defined Type I linker" in the "linkers for peptide chains" described above; 117) one C16alkyl group is conjugated to the nucleotide at the 5' end and the 3' end of the sense strand via an ether linkage, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand via a "linker for peptide chains" as defined above one other peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end and the 3' end of the sense strand via a "self-defined Type I linker" in the "linkers for peptide chains" described above; 118) one C16alkyl group is conjugated to the nucleotide at the 5' end and the 3' end of the sense strand via a "linker other than an ether linkage" in the "linkers for lipophilic moieties" defined above, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand via a "linker for peptide chains" as defined above one other peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end and the 3' end of the sense strand via a "self-defined Type I linker" in the "linkers for peptide chains" described above; 119) one C16alkyl group is conjugated to the nucleotide at the 3' terminus of the antisense strand via an ether linkage and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' terminus of the sense strand via a linker as defined above one other peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' terminus and the 3' terminus of the sense strand via a "self-defined Type I linker" as described above in "Linkers for Peptide Chains" other than the two positions at the 5' terminus and the 3' terminus of the sense strand; 120) one C16alkyl group is conjugated to the nucleotide at the 3' terminus of the antisense strand via a linker other than an "ether linkage" as defined above in "Linkers for Lipophilic Moieties" and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' terminus of the sense strand via a linker as defined above one other peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' terminus and the 3' terminus of the sense strand via a "self-defined Type I linker" as described above in "Linkers for Peptide Chains" other than the two positions at the 5' terminus and the 3' terminus of the sense strand; 121) one C16alkyl group is conjugated to the nucleotide at the 5' terminus of the sense strand via an ether linkage and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' terminus of the sense strand via a "self-defined Type I linker" as described above in "Linkers for Peptide Chains", one other peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' terminus of the sense strand via a linker as defined above one other peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' terminus and the 3' terminus of the sense strand via a "self-defined Type I linker" as described above in "Linkers for Peptide Chains" other than the two positions at the 5' terminus and the 3' terminus of the sense strand; 122) one C16alkyl group is conjugated to the nucleotide at the 5' terminus of the sense strand via a linker other than an "ether linkage" as defined above in "Linkers for Lipophilic Moieties" and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' terminus of the sense strand via a "self-defined Type I linker" as described above in "Linkers for Peptide Chains", one other peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' terminus of the sense strand via a linker as defined above one other peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' terminus and the 3' terminus of the sense strand via a "self-defined Type I linker" as described above in "Linkers for Peptide Chains" other than the two positions at the 5' terminus and the 3' terminus of the sense strand; 123) one C16alkyl group is conjugated to the nucleotide at the 3' terminus of the sense strand via an ether linkage and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' terminus of the sense strand via a "self-defined Type I linker" as described above in "Linkers for Peptide Chains", one other peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' terminus of the sense strand via a linker as defined above one other peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' terminus and the 3' terminus of the sense strand via a "self-defined Type I linker" as described above in "Linkers for Peptide Chains" other than the two positions at the 5' terminus and the 3' terminus of the sense strand; 124) one C16alkyl group is conjugated to a nucleotide at the 3' end of the sense strand via a "linkage other than an ether linkage" within the "linker for lipophilic moieties" defined above, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 3' end of the sense strand via a "self-defined Type I linker" within the "linker for peptide chains" described above, and one other peptide chain CHRPYIAH is conjugated to a nucleotide at the 3' end of the sense strand via a linker defined above a nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand; 125) one C16alkyl group is conjugated to a nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via an ether linkage, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 3' end of the sense strand via a "self-defined Type I linker" within the "linker for peptide chains" described above, and one other peptide chain CHRPYIAH is conjugated to a nucleotide at the 3' end of the sense strand via a linker defined above a nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand; 126) one C16alkyl group is conjugated to a nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via a "linkage other than an ether linkage" within the "linker for lipophilic moieties" defined above, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 3' end of the sense strand via a "self-defined Type I linker" within the "linker for peptide chains" described above, and one other peptide chain CHRPYIAH is conjugated to a nucleotide at the 3' end of the sense strand via a linker defined above a nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand; 127) one C16alkyl group is conjugated to a nucleotide at the 3' end of the antisense strand via an ether linkage, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 3' end of the sense strand via a "self-defined Type I linker" within the "linker for peptide chains" described above, and one other peptide chain CHRPYIAH is conjugated to a nucleotide at the 3' end of the sense strand via a linker defined above a nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand; 128) one C16alkyl group is conjugated to a nucleotide at the 3' end of the antisense strand via a "linkage other than an ether linkage" within the "linker for lipophilic moieties" defined above, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 3' end of the sense strand via a "self-defined Type I linker" within the "linker for peptide chains" described above, and one other peptide chain CHRPYIAH is conjugated to a nucleotide at the 3' end of the sense strand via a linker defined above a nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand; 129) one C16 hydrocarbyl group is conjugated to the nucleotide at the 5' terminus of the sense strand via an ether linkage and one peptide chain CHRPYIAH is conjugated via a linker as defined above one C16 hydrocarbyl group is conjugated to the nucleotide at the 5' terminus of the sense strand via an ether linkage and one peptide chain CHRPYIAH is conjugated via a linker as defined above one C16 hydrocarbyl group is conjugated to the nucleotide at the 5' terminus of the sense strand via an ether linkage and one peptide chain CHRPYIAH is conjugated via a linker as defined above 130) one C16 hydrocarbyl group is conjugated to the nucleotide at the 5' terminus of the sense strand via a linker other than an "ether linkage" within the "linkers for lipophilic moieties" as defined above and one peptide chain CHRPYIAH is conjugated via a linker as defined above one C16 hydrocarbyl group is conjugated to the nucleotide at the 5' terminus of the sense strand via an ether linkage and one peptide chain CHRPYIAH is conjugated via a linker as defined above one C16 hydrocarbyl group is conjugated to the nucleotide at the 5' terminus of the sense strand via an ether linkage and one peptide chain CHRPYIAH is conjugated via a linker as defined above 131) one C16 hydrocarbyl group is conjugated to the nucleotide at the 3' terminus of the sense strand via an ether linkage and one peptide chain CHRPYIAH is conjugated via a linker as defined above one C16 hydrocarbyl group is conjugated to the nucleotide at the 5' terminus of the sense strand via an ether linkage and one peptide chain CHRPYIAH is conjugated via a linker as defined above one C16 hydrocarbyl group is conjugated to the nucleotide at the 5' terminus of the sense strand via an ether linkage and one peptide chain CHRPYIAH is conjugated via a linker as defined above 132) one C16 hydrocarbyl group is conjugated to the nucleotide at the 3' terminus of the sense strand via a linker other than an "ether linkage" within the "linkers for lipophilic moieties" as defined above and one peptide chain CHRPYIAH is conjugated via a linker as defined above one C16 hydrocarbyl group is conjugated to the nucleotide at the 5' terminus of the sense strand via an ether linkage and one peptide chain CHRPYIAH is conjugated via a linker as defined above one C16 hydrocarbyl group is conjugated to the nucleotide at the 5' terminus of the sense strand via an ether linkage and one peptide chain CHRPYIAH is conjugated via a linker as defined above 133) one C16 hydrocarbyl group is conjugated to the nucleotide at an intermediate position other than the two positions at the 5' and 3' termini of the sense strand via an ether linkage and one peptide chain CHRPYIAH is conjugated via a linker as defined above one C16 hydrocarbyl group is conjugated to the nucleotide at the 5' terminus of the sense strand via an ether linkage and one peptide chain CHRPYIAH is conjugated via a linker as defined above one C16 hydrocarbyl group is conjugated to the nucleotide at the 5' terminus of the sense strand via an ether linkage and one peptide chain CHRPYIAH is conjugated via a linker as defined above 134) one C16alkyl group is conjugated to a nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via a "linkage other than an ether linkage" within the "linkage of a lipophilic moiety" defined above, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 5' end of the sense strand via a "linkage of a peptide chain" as defined above one other peptide chain CHRPYIAH is conjugated to a nucleotide at the 5' end of the sense strand via a "linkage of a peptide chain" as defined above a nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand; 135) one C16alkyl group is conjugated to a nucleotide at the 3' end of the antisense strand via an ether linkage, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 5' end of the sense strand via a "linkage of a peptide chain" as defined above one other peptide chain CHRPYIAH is conjugated to a nucleotide at the 5' end of the sense strand via a "linkage of a peptide chain" as defined above a nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand; 136) one C16alkyl group is conjugated to a nucleotide at the 3' end of the antisense strand via a "linkage other than an ether linkage" within the "linkage of a lipophilic moiety" defined above, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 5' end of the sense strand via a "linkage of a peptide chain" as defined above one other peptide chain CHRPYIAH is conjugated to a nucleotide at the 5' end of the sense strand via a "linkage of a peptide chain" as defined above a nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand; 137) one C16alkyl group is conjugated to a nucleotide at the 5' end of the sense strand via an ether linkage, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 5' end of the sense strand via a "self-defined Type I linkage" within the "linkage of a peptide chain" as defined above, and one other peptide chain CHRPYIAH is conjugated to a nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via a "self-defined Type I linkage" within the "linkage of a peptide chain" as defined above 138) one C16alkyl group is conjugated to a nucleotide at the 5' end of the sense strand via a "linkage other than an ether linkage" within the "linkage of a lipophilic moiety" as defined above, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 5' end of the sense strand via a "self-defined Type I linkage" within the "linkage of a peptide chain" as defined above, and one other peptide chain CHRPYIAH is conjugated to a nucleotide at the 5' end of the sense strand via a "self-defined Type I linkage" within the "linkage of a peptide chain" as defined above 139) one C16alkyl group is conjugated to the nucleotide at the 3' terminus of the sense strand through an ether linkage, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 5' terminus of the sense strand through a "self-defining Type I linker" of "linkers for peptide chains" described above, and one other peptide chain CHRPYIAH is conjugated to a nucleotide at a position intermediate to the 5' and 3' termini of the sense strand, other than at the two positions at the 5' and 3' termini of the sense strand; 140) one C16alkyl group is conjugated to the nucleotide at the 3' terminus of the sense strand through a "linker other than an ether linkage" of "linkers for lipophilic moieties" defined above, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 5' terminus of the sense strand through a "self-defining Type I linker" of "linkers for peptide chains" described above, and one other peptide chain CHRPYIAH is conjugated to a nucleotide at a position intermediate to the 5' and 3' termini of the sense strand, other than at the two positions at the 5' and 3' termini of the sense strand; 141) one C16alkyl group is conjugated to the nucleotide at a position intermediate to the 5' and 3' termini of the sense strand, other than at the two positions at the 5' and 3' termini of the sense strand, through an ether linkage, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 5' terminus of the sense strand through a "self-defining Type I linker" of "linkers for peptide chains" described above, and one other peptide chain CHRPYIAH is conjugated to a nucleotide at a position intermediate to the 5' and 3' termini of the sense strand, other than at the two positions at the 5' and 3' termini of the sense strand; 142) one C16alkyl group is conjugated to the nucleotide at a position intermediate to the 5' and 3' termini of the sense strand, other than at the two positions at the 5' and 3' termini of the sense strand, through a "linker other than an ether linkage" of "linkers for lipophilic moieties" defined above, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 5' terminus of the sense strand through a "self-defining Type I linker" of "linkers for peptide chains" described above, and one other peptide chain CHRPYIAH is conjugated to a nucleotide at a position intermediate to the 5' and 3' termini of the sense strand, other than at the two positions at the 5' and 3' termini of the sense strand; 143) one C16alkyl group is conjugated to the nucleotide at the 3' terminus of the antisense strand through an ether linkage, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 5' terminus of the sense strand through a "self-defining Type I linker" of "linkers for peptide chains" described above, and one other peptide chain CHRPYIAH is conjugated to a nucleotide at a position intermediate to the 5' and 3' termini of the sense strand, other than at the two positions at the 5' and 3' termini of the sense strand; 144) one C16alkyl group is conjugated to the nucleotide at the 3' end of the antisense strand via a "linkage other than an ether linkage" within the "linkers for lipophilic moieties" defined above, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 5' end of the sense strand via a "self-defined Type I linker" within the "linkers for peptide chains" described above, and one other peptide chain CHRPYIAH is conjugated to a nucleotide at an intermediate position on the sense strand other than the two positions at the 5' and 3' ends; 145) one C16alkyl group is conjugated to the nucleotide at the 5' end of the sense strand via an ether linkage, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 5' end of the sense strand via a "self-defined Type I linker" within the "linkers for peptide chains" defined above, and one other peptide chain CHRPYIAH is conjugated to a nucleotide at an intermediate position on the sense strand other than the two positions at the 5' and 3' ends; 146) one C16alkyl group is conjugated to the nucleotide at the 5' end of the sense strand via a "linkage other than an ether linkage" within the "linkers for lipophilic moieties" defined above, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 5' end of the sense strand via a "self-defined Type I linker" within the "linkers for peptide chains" defined above, and one other peptide chain CHRPYIAH is conjugated to a nucleotide at an intermediate position on the sense strand other than the two positions at the 5' and 3' ends; 147) one C16alkyl group is conjugated to the nucleotide at the 3' end of the sense strand via an ether linkage, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 5' end of the sense strand via a "self-defined Type I linker" within the "linkers for peptide chains" defined above, and one other peptide chain CHRPYIAH is conjugated to a nucleotide at an intermediate position on the sense strand other than the two positions at the 5' and 3' ends; 148) one C16alkyl group is conjugated to the nucleotide at the 3' end of the sense strand via a "linkage other than an ether linkage" within the "linkers for lipophilic moieties" defined above, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 5' end of the sense strand via a "self-defined Type I linker" within the "linkers for peptide chains" defined above, and one other peptide chain CHRPYIAH is conjugated to a nucleotide at an intermediate position on the sense strand other than the two positions at the 5' and 3' ends; 149) one C16alkyl group is conjugated to a nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via an ether linkage, and one peptide chain CHRPYIAH is conjugated to a nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via a linker as defined above one other peptide chain CHRPYIAH is conjugated to a nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via a "self-defined Type I linker" within the "linkers for peptide chains" described above; 150) one C16alkyl group is conjugated to a nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via a "linker other than an ether linkage" within the "linkers for lipophilic moieties" defined above, and one peptide chain CHRPYIAH is conjugated to a nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via a linker as defined above one other peptide chain CHRPYIAH is conjugated to a nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via a "self-defined Type I linker" within the "linkers for peptide chains" described above; 151) one C16alkyl group is conjugated to a nucleotide at the 3' end of the antisense strand via an ether linkage, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 3' end of the antisense strand via a linker as defined above one other peptide chain CHRPYIAH is conjugated to a nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via a "self-defined Type I linker" within the "linkers for peptide chains" described above; 152) one C16alkyl group is conjugated to a nucleotide at the 3' end of the antisense strand via a "linker other than an ether linkage" within the "linkers for lipophilic moieties" defined above, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 3' end of the antisense strand via a linker as defined above one other peptide chain CHRPYIAH is conjugated to a nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via a "self-defined Type I linker" within the "linkers for peptide chains" described above; 153) one C16alkyl group is conjugated to a nucleotide at the 5' end of the sense strand via an ether linkage, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 5' end of the sense strand via a "self-defined Type I linker" within the "linkers for peptide chains" described above, and one other peptide chain CHRPYIAH is conjugated to a nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via a linker as defined above conjugated to a nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand; 154) one C16alkyl group is conjugated to a nucleotide at the 5' end of the sense strand via a "linkage other than an ether linkage" in the "linkers for lipophilic moieties" defined above, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 5' end of the sense strand via a "self-defined Type I linker" in the "linkers for peptide chains" described above, and one other peptide chain CHRPYIAH is conjugated to a nucleotide at the 5' end of the sense strand via a linker defined above a nucleotide at an intermediate position other than the two positions at the 5' and 3' ends of the sense strand; 155) one C16alkyl group is conjugated to a nucleotide at the 3' end of the sense strand via an ether linkage, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 5' end of the sense strand via a "self-defined Type I linker" in the "linkers for peptide chains" described above, and one other peptide chain CHRPYIAH is conjugated to a nucleotide at the 5' end of the sense strand via a linker defined above a nucleotide at an intermediate position other than the two positions at the 5' and 3' ends of the sense strand; 156) one C16alkyl group is conjugated to a nucleotide at the 3' end of the sense strand via a "linkage other than an ether linkage" in the "linkers for lipophilic moieties" defined above, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 5' end of the sense strand via a "self-defined Type I linker" in the "linkers for peptide chains" described above, and one other peptide chain CHRPYIAH is conjugated to a nucleotide at the 5' end of the sense strand via a linker defined above a nucleotide at an intermediate position other than the two positions at the 5' and 3' ends of the sense strand; 157) one C16alkyl group is conjugated to a nucleotide at an intermediate position other than the two positions at the 5' and 3' ends of the sense strand via an ether linkage, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 5' end of the sense strand via a "self-defined Type I linker" in the "linkers for peptide chains" described above, and one other peptide chain CHRPYIAH is conjugated to a nucleotide at the 5' end of the sense strand via a linker defined above a nucleotide at an intermediate position other than the two positions at the 5' and 3' ends of the sense strand; 158) one C16alkyl group is conjugated to a nucleotide at an intermediate position other than the two positions at the 5' and 3' ends of the sense strand via a "linkage other than an ether linkage" in the "linkers for lipophilic moieties" defined above, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 5' end of the sense strand via a "self-defined Type I linker" in the "linkers for peptide chains" described above, and one other peptide chain CHRPYIAH is conjugated to a nucleotide at the 5' end of the sense strand via a linker defined above a nucleotide at an intermediate position other than the two positions at the 5' and 3' ends of the sense strand; 159) one C16alkyl group is conjugated to the nucleotide at the 3' terminus of the antisense strand via an ether linkage, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' terminus of the sense strand via a "user-defined Type I linker" from the "linkers for peptide chains" described hereinabove, and another peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' terminus of the sense strand via a linker as defined hereinabove a nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand; 160) one C16alkyl group is conjugated to the nucleotide at the 3' terminus of the antisense strand via a "linker other than an ether linkage" from the "linkers for lipophilic moieties" defined hereinabove, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' terminus of the sense strand via a "user-defined Type I linker" from the "linkers for peptide chains" described hereinabove, and another peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' terminus of the sense strand via a linker as defined hereinabove a nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand; 161) one C16alkyl group is conjugated to the nucleotide at the 5' terminus of the sense strand via an ether linkage, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' terminus of the sense strand via a linker as defined hereinabove a nucleotide at the 3' terminus of the sense strand, and another peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' terminus of the sense strand via a linker as defined hereinabove a nucleotide at the 3' terminus of the sense strand; 162) one C16alkyl group is conjugated to the nucleotide at the 5' terminus of the sense strand via a "linker other than an ether linkage" from the "linkers for lipophilic moieties" defined hereinabove, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' terminus of the sense strand via a linker as defined hereinabove a nucleotide at the 3' terminus of the sense strand, and another peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' terminus of the sense strand via a linker as defined hereinabove a nucleotide at the 3' terminus of the sense strand; 163) one C16alkyl group is conjugated to the nucleotide at the 3' terminus of the sense strand via an ether linkage, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' terminus of the sense strand via a linker as defined hereinabove a nucleotide at the 5' terminus of the sense strand, and another peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' terminus of the sense strand via a linker as defined hereinabove a nucleotide at the 5' terminus of the sense strand; 164) one C16alkyl group is conjugated to the nucleotide at the 3' terminus of the sense strand via a "linker other than an ether linkage" from the "linkers for lipophilic moieties" defined hereinabove, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' terminus of the sense strand via a linker as defined hereinabove one peptide chain CHRPYIAH through a linker as defined above is conjugated to the nucleotide at the 3' end of the sense strand one peptide chain CHRPYIAH through a linker as defined above is conjugated to the nucleotide at the 3' end of the sense strand 165) one C16 hydrocarbon group is conjugated to the nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand through an ether linkage, and one peptide chain CHRPYIAH through a linker as defined above one peptide chain CHRPYIAH through a linker as defined above is conjugated to the nucleotide at the 3' end of the sense strand one peptide chain CHRPYIAH through a linker as defined above is conjugated to the nucleotide at the 3' end of the sense strand 166) one C16 hydrocarbon group is conjugated to the nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand through a linkage other than an "ether linkage" within the "linkage of a lipophilic moiety" as defined above, and one peptide chain CHRPYIAH through a linker as defined above one peptide chain CHRPYIAH through a linker as defined above is conjugated to the nucleotide at the 3' end of the sense strand one peptide chain CHRPYIAH through a linker as defined above is conjugated to the nucleotide at the 3' end of the sense strand 167) one C16 hydrocarbon group is conjugated to the nucleotide at the 3' end of the antisense strand through an ether linkage, and one peptide chain CHRPYIAH through a linker as defined above one peptide chain CHRPYIAH through a linker as defined above is conjugated to the nucleotide at the 3' end of the sense strand one peptide chain CHRPYIAH through a linker as defined above is conjugated to the nucleotide at the 3' end of the sense strand 168) one C16 hydrocarbon group is conjugated to the nucleotide at the 3' end of the antisense strand through a linkage other than an "ether linkage" within the "linkage of a lipophilic moiety" as defined above, and one peptide chain CHRPYIAH through a linker as defined above one peptide chain CHRPYIAH through a linker as defined above is conjugated to the nucleotide at the 3' end of the sense strand one peptide chain CHRPYIAH through a linker as defined above is conjugated to the nucleotide at the 3' end of the sense strand 169) one C16alkyl group is conjugated to the 5' terminal nucleotide of the sense strand via an ether linkage, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 3' terminal end of the sense strand via a "self-defmed Type I linker" in the "linkers for peptide chains" described hereinabove, and another peptide chain CHRPYIAH is conjugated to a nucleotide at the 3' terminal end of the sense strand via a "self-defmed Type I linker" in the "linkers for peptide chains" described hereinabove; 170) one C16alkyl group is conjugated to the 5' terminal nucleotide of the sense strand via a "linker other than an ether linkage" in the "linkers for lipophilic moieties" defined hereinabove, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 3' terminal end of the sense strand via a "self-defmed Type I linker" in the "linkers for peptide chains" described hereinabove, and another peptide chain CHRPYIAH is conjugated to a nucleotide at the 3' terminal end of the sense strand via a "self-defmed Type I linker" in the "linkers for peptide chains" described hereinabove; 171) one C16alkyl group is conjugated to the 3' terminal nucleotide of the sense strand via an ether linkage, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 3' terminal end of the sense strand via a "self-defmed Type I linker" in the "linkers for peptide chains" described hereinabove, and another peptide chain CHRPYIAH is conjugated to a nucleotide at the 3' terminal end of the sense strand via a "self-defmed Type I linker" in the "linkers for peptide chains" described hereinabove; 172) one C16alkyl group is conjugated to the 3' terminal nucleotide of the sense strand via a "linker other than an ether linkage" in the "linkers for lipophilic moieties" defined hereinabove, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 3' terminal end of the sense strand via a "self-defmed Type I linker" in the "linkers for peptide chains" described hereinabove, and another peptide chain CHRPYIAH is conjugated to a nucleotide at the 3' terminal end of the sense strand via a "self-defmed Type I linker" in the "linkers for peptide chains" described hereinabove; 173) one C16alkyl group is conjugated to a nucleotide at a position intermediate to the 5' and 3' terminal nucleotides of the sense strand, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 3' terminal end of the sense strand via a "self-defmed Type I linker" in the "linkers for peptide chains" described hereinabove, and another peptide chain CHRPYIAH is conjugated to a nucleotide at the 3' terminal end of the sense strand via a "self-defmed Type I linker" in the "linkers for peptide chains" described hereinabove; 174) one C16alkyl group is conjugated to a nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand by a "linkage other than an ether linkage" within the "linker for lipophilic moiety" defined above, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 3' end of the sense strand by a "self-defined Type I linker" within the "linker for peptide chain" described above, and another one peptide chain CHRPYIAH is conjugated to a nucleotide at the 3' end of the sense strand by a "self-defined Type I linker" within the "linker for peptide chain" described above; 175) one C16alkyl group is conjugated to a nucleotide at the 3' end of the antisense strand by an ether linkage, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 3' end of the sense strand by a "self-defined Type I linker" within the "linker for peptide chain" described above, and another one peptide chain CHRPYIAH is conjugated to a nucleotide at the 3' end of the sense strand by a "self-defined Type I linker" within the "linker for peptide chain" described above; 176) one C16alkyl group is conjugated to a nucleotide at the 3' end of the antisense strand by a "linkage other than an ether linkage" within the "linker for lipophilic moiety" defined above, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 3' end of the sense strand by a "self-defined Type I linker" within the "linker for peptide chain" described above, and another one peptide chain CHRPYIAH is conjugated to a nucleotide at the 3' end of the sense strand by a "self-defined Type I linker" within the "linker for peptide chain" described above; 177) one C16alkyl group is conjugated to a nucleotide at the 5' end of the sense strand by an ether linkage, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 3' end of the sense strand by a "self-defined Type I linker" within the "linker for peptide chain" described above, and another one peptide chain CHRPYIAH is conjugated to a nucleotide at the 3' end of the sense strand by a "self-defined Type I linker" within the "linker for peptide chain" described above; 177) one C16alkyl group is conjugated to a nucleotide at the 5' end of the sense strand by an ether linkage, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 3' end of the sense strand by a "self-defined Type I linker" within the "linker for peptide chain" described above, and another one peptide chain CHRPYIAH is conjugated to a nucleotide at the 3' end of the sense strand by a "self-defined Type I linker" within the "linker for peptide chain" described above; 178) one C16alkyl group is conjugated to a nucleotide at the 5' end of the sense strand by a "linkage other than an ether linkage" within the "linker for lipophilic moiety" defined above, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 3' end of the sense strand by a "self-defined Type I linker" within the "linker for peptide chain" described above, and another one peptide chain CHRPYIAH is conjugated to a nucleotide at the 3' end of the sense strand by a "self-defined Type I linker" within the "linker for peptide chain" described above; 177) one C16alkyl group is conjugated to a nucleotide at the 5' end of the sense strand by an ether linkage, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 3' end of the sense strand by a "self-defined Type I linker" within the "linker for peptide chain" described above, and another one peptide chain CHRPYIAH is conjugated to a nucleotide at the 3' end of the sense strand by a "self-defined Type I linker" within the "linker for peptide chain" described above; 179) one C16alkyl group is conjugated to a nucleotide at the 3' end of the sense strand by an ether linkage, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 3' end of the sense strand by a "self-defined Type I linker" within the "linker for peptide chain" described above, and another one peptide chain CHRPYIAH is conjugated to a nucleotide at the 3' end of the sense strand by a "self-defined Type I linker" within the "linker for peptide chain" described above; one C16 hydrocarbon group is conjugated to the nucleotide at the 3' terminus of the sense strand via a "linker other than an ether linkage" of the "linkers for lipophilic moieties" defined above, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' terminus of the sense strand via a "self-made Type I linker" of the "linkers for peptide chains" described above; 180) one C16 hydrocarbon group is conjugated to the nucleotide at the 3' terminus of the sense strand via a "linker other than an ether linkage" of the "linkers for lipophilic moieties" defined above, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' terminus of the sense strand via a "self-made Type I linker" of the "linkers for peptide chains" defined above one C16 hydrocarbon group is conjugated to the nucleotide at the 3' terminus of the sense strand via a "linker other than an ether linkage" of the "linkers for lipophilic moieties" defined above, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' terminus of the sense strand via a "self-made Type I linker" of the "linkers for peptide chains" described above; 181) one C16 hydrocarbon group is conjugated to the nucleotide at the 3' terminus of the sense strand via a "linker other than an ether linkage" of the "linkers for lipophilic moieties" defined above, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' terminus of the sense strand via a "self-made Type I linker" of the "linkers for peptide chains" defined above one C16 hydrocarbon group is conjugated to the nucleotide at the 3' terminus of the sense strand via a "linker other than an ether linkage" of the "linkers for lipophilic moieties" defined above, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' terminus of the sense strand via a "self-made Type I linker" of the "linkers for peptide chains" described above; 182) one C16 hydrocarbon group is conjugated to the nucleotide at the 3' terminus of the sense strand via a "linker other than an ether linkage" of the "linkers for lipophilic moieties" defined above, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' terminus of the sense strand via a "self-made Type I linker" of the "linkers for peptide chains" defined above one C16 hydrocarbon group is conjugated to the nucleotide at the 3' terminus of the sense strand via a "linker other than an ether linkage" of the "linkers for lipophilic moieties" defined above, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' terminus of the sense strand via a "self-made Type I linker" of the "linkers for peptide chains" described above; 183) one C16 hydrocarbon group is conjugated to the nucleotide at the 3' terminus of the sense strand via a "linker other than an ether linkage" of the "linkers for lipophilic moieties" defined above, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' terminus of the sense strand via a "self-made Type I linker" of the "linkers for peptide chains" defined above one C16 hydrocarbon group is conjugated to the nucleotide at the 3' terminus of the sense strand via a "linker other than an ether linkage" of the "linkers for lipophilic moieties" defined above, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' terminus of the sense strand via a "self-made Type I linker" of the "linkers for peptide chains" described above; 184) one C16 hydrocarbon group is conjugated to the nucleotide at the 3' terminus of the sense strand via a "linker other than an ether linkage" of the "linkers for lipophilic moieties" defined above, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' terminus of the sense strand via a "self-made Type I linker" of the "linkers for peptide chains" defined above one C16 hydrocarbon group is conjugated to the nucleotide at the 3' terminus of the sense strand via a "linker other than an ether linkage" of the "linkers for lipophilic moieties" defined above, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' terminus of the sense strand via a "self-made Type I linker" of the "linkers for peptide chains" described above; 185) one C16 alkyl group is conjugated to the nucleotide at the 5' terminus of the sense strand via an ether linkage and one peptide chain CHRPYIAH is conjugated via a linker as defined above one C16 alkyl group is conjugated to the nucleotide at the 5' terminus of the sense strand via an ether linkage and one peptide chain CHRPYIAH is conjugated via a linker as defined above one C16 alkyl group is conjugated to the nucleotide at the 5' terminus of the sense strand via an ether linkage and one peptide chain CHRPYIAH is conjugated via a linker as defined above 186) one C16 alkyl group is conjugated to the nucleotide at the 5' terminus of the sense strand via a linker other than an "ether linkage" within the "linkers for lipophilic moieties" as defined above and one peptide chain CHRPYIAH is conjugated via a linker as defined above one C16 alkyl group is conjugated to the nucleotide at the 5' terminus of the sense strand via an ether linkage and one peptide chain CHRPYIAH is conjugated via a linker as defined above one C16 alkyl group is conjugated to the nucleotide at the 5' terminus of the sense strand via an ether linkage and one peptide chain CHRPYIAH is conjugated via a linker as defined above 187) one C16 alkyl group is conjugated to the nucleotide at the 3' terminus of the sense strand via an ether linkage and one peptide chain CHRPYIAH is conjugated via a linker as defined above one C16 alkyl group is conjugated to the nucleotide at the 5' terminus of the sense strand via an ether linkage and one peptide chain CHRPYIAH is conjugated via a linker as defined above one C16 alkyl group is conjugated to the nucleotide at the 5' terminus of the sense strand via an ether linkage and one peptide chain CHRPYIAH is conjugated via a linker as defined above 188) one C16 alkyl group is conjugated to the nucleotide at the 3' terminus of the sense strand via a linker other than an "ether linkage" within the "linkers for lipophilic moieties" as defined above and one peptide chain CHRPYIAH is conjugated via a linker as defined above one C16 alkyl group is conjugated to the nucleotide at the 5' terminus of the sense strand via an ether linkage and one peptide chain CHRPYIAH is conjugated via a linker as defined above one C16 alkyl group is conjugated to the nucleotide at the 5' terminus of the sense strand via an ether linkage and one peptide chain CHRPYIAH is conjugated via a linker as defined above 189) one C16 alkyl group is conjugated to the nucleotide at a position intermediate to the 5' and 3' termini of the sense strand and one peptide chain CHRPYIAH is conjugated via a linker as defined above one C16 alkyl group is conjugated to the nucleotide at the 5' terminus of the sense strand via an ether linkage and one peptide chain CHRPYIAH is conjugated via a linker as defined above one C16 alkyl group is conjugated to the nucleotide at the 5' terminus of the sense strand via an ether linkage and one peptide chain CHRPYIAH is conjugated via a linker as defined above 190) one C16alkyl group is conjugated to a nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand by a "linkage other than an ether linkage" within the "linkage of a lipophilic moiety" defined above, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 5' end of the sense strand by a "linkage of a peptide chain" as defined above one other peptide chain CHRPYIAH is conjugated to a nucleotide at the 5' end of the sense strand by a "linkage of a peptide chain" as defined above one other peptide chain CHRPYIAH is conjugated to a nucleotide at the 5' end of the sense strand by a "linkage of a peptide chain" as defined above 191) one C16alkyl group is conjugated to a nucleotide at the 3' end of the antisense strand by an ether linkage, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 5' end of the sense strand by a "linkage of a peptide chain" as defined above one other peptide chain CHRPYIAH is conjugated to a nucleotide at the 5' end of the sense strand by a "linkage of a peptide chain" as defined above one other peptide chain CHRPYIAH is conjugated to a nucleotide at the 5' end of the sense strand by a "linkage of a peptide chain" as defined above 192) one C16alkyl group is conjugated to a nucleotide at the 3' end of the antisense strand by a "linkage other than an ether linkage" within the "linkage of a lipophilic moiety" defined above, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 5' end of the sense strand by a "linkage of a peptide chain" as defined above one other peptide chain CHRPYIAH is conjugated to a nucleotide at the 5' end of the sense strand by a "linkage of a peptide chain" as defined above one other peptide chain CHRPYIAH is conjugated to a nucleotide at the 5' end of the sense strand by a "linkage of a peptide chain" as defined above 193) one C16alkyl group is conjugated to a nucleotide at the 5' end of the sense strand by an ether linkage, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 5' end of the sense strand by a "self-defined Type I linkage" within the "linkage of a peptide chain" as defined above, and one other peptide chain CHRPYIAH is conjugated to a nucleotide at the 5' end of the sense strand by a "self-defined Type I linkage" within the "linkage of a peptide chain" as defined above 194) one C16alkyl group is conjugated to a nucleotide at the 5' end of the sense strand by a "linkage other than an ether linkage" within the "linkage of a lipophilic moiety" defined above, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 5' end of the sense strand by a "self-defined Type I linkage" within the "linkage of a peptide chain" as defined above, and one other peptide chain CHRPYIAH is conjugated to a nucleotide at the 5' end of the sense strand by a "self-defined Type I linkage" within the "linkage of a peptide chain" as defined above 195) one C16 hydrocarbyl group is conjugated to the nucleotide at the 3' end of the sense strand via an ether linkage and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand via a "self-defining Type I linker" of "linkers for peptide chains" as described hereinabove and one other peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand via a "self-defining Type I linker" of "linkers for peptide chains" as described hereinabove; 196) one C16 hydrocarbyl group is conjugated to the nucleotide at the 3' end of the sense strand via a "linker other than an ether linkage" of "linkers for lipophilic moieties" as defined hereinabove and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand via a "self-defining Type I linker" of "linkers for peptide chains" as described hereinabove and one other peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand via a "self-defining Type I linker" of "linkers for peptide chains" as described hereinabove; 197) one C16 hydrocarbyl group is conjugated to the nucleotide at a position intermediate to the 5' and 3' ends of the sense strand and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand via a "self-defining Type I linker" of "linkers for peptide chains" as described hereinabove and one other peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand via a "self-defining Type I linker" of "linkers for peptide chains" as described hereinabove; 198) one C16 hydrocarbyl group is conjugated to the nucleotide at a position intermediate to the 5' and 3' ends of the sense strand via a "linker other than an ether linkage" of "linkers for lipophilic moieties" as defined hereinabove and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand via a "self-defining Type I linker" of "linkers for peptide chains" as described hereinabove and one other peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand via a "self-defining Type I linker" of "linkers for peptide chains" as described hereinabove; 199) one C16 hydrocarbyl group is conjugated to the nucleotide at the 3' end of the antisense strand and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand via a "self-defining Type I linker" of "linkers for peptide chains" as described hereinabove and one other peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand via a "self-defining Type I linker" of "linkers for peptide chains" as described hereinabove; 200) one C16alkyl group is conjugated to the nucleotide at the 3' end of the antisense strand through a "linkage other than an ether linkage" in the "linkers for lipophilic moieties" defined above, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand through a "self-defined Type I linker" in the "linkers for peptide chains" described above, and another one peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand through a "self-defined Type I linker" in the "linkers for peptide chains" described above; 201) one C16alkyl group is conjugated to the nucleotide at the 5' end of the sense strand through an ether linkage, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand through a "self-defined Type I linker" in the "linkers for peptide chains" defined above, and another one peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand through a "self-defined Type I linker" in the "linkers for peptide chains" described above; 202) one C16alkyl group is conjugated to the nucleotide at the 5' end of the sense strand through a "linkage other than an ether linkage" in the "linkers for lipophilic moieties" defined above, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand through a "self-defined Type I linker" in the "linkers for peptide chains" defined above, and another one peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand through a "self-defined Type I linker" in the "linkers for peptide chains" described above; 203) one C16alkyl group is conjugated to the nucleotide at the 3' end of the sense strand through an ether linkage, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand through a "self-defined Type I linker" in the "linkers for peptide chains" defined above, and another one peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand through a "self-defined Type I linker" in the "linkers for peptide chains" described above; 204) one C16alkyl group is conjugated to the nucleotide at the 3' end of the sense strand through a "linkage other than an ether linkage" in the "linkers for lipophilic moieties" defined above, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand through a "self-defined Type I linker" in the "linkers for peptide chains" defined above, and another one peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand through a "self-defined Type I linker" in the "linkers for peptide chains" described above; 205) one C16alkyl group is conjugated to the nucleotide at the middle position between the 5' end and the 3' end of the sense strand, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand through a "self-defined Type I linker" in the "linkers for peptide chains" defined above, one C16alkyl group is conjugated to the nucleotide at the 5' terminus of the sense strand via a "linker other than an ether linkage" of "linkers of lipophilic moieties" as defined above, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' terminus of the sense strand via a "self-made Type I linker" of "linkers of peptide chains" as defined above; 206) one C16alkyl group is conjugated to the nucleotide at the 5' terminus of the sense strand via a "linker other than an ether linkage" of "linkers of lipophilic moieties" as defined above, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' terminus of the sense strand via a "self-made Type I linker" of "linkers of peptide chains" as defined above; one C16alkyl group is conjugated to the nucleotide at the 5' terminus of the sense strand via a "linker other than an ether linkage" of "linkers of lipophilic moieties" as defined above, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' terminus of the sense strand via a "self-made Type I linker" of "linkers of peptide chains" as defined above; 207) one C16alkyl group is conjugated to the nucleotide at the 3' terminus of the antisense strand via an ether linkage, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' terminus of the sense strand via a "self-made Type I linker" of "linkers of peptide chains" as defined above; one C16alkyl group is conjugated to the nucleotide at the 5' terminus of the sense strand via a "linker other than an ether linkage" of "linkers of lipophilic moieties" as defined above, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' terminus of the sense strand via a "self-made Type I linker" of "linkers of peptide chains" as defined above; 208) one C16alkyl group is conjugated to the nucleotide at the 3' terminus of the antisense strand via a "linker other than an ether linkage" of "linkers of lipophilic moieties" as defined above, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' terminus of the sense strand via a "self-made Type I linker" of "linkers of peptide chains" as defined above; one C16alkyl group is conjugated to the nucleotide at the 5' terminus of the sense strand via a "linker other than an ether linkage" of "linkers of lipophilic moieties" as defined above, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' terminus of the sense strand via a "self-made Type I linker" of "linkers of peptide chains" as defined above; 209) one C16alkyl group is conjugated to the nucleotide at the 5' terminus of the sense strand via an ether linkage, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' terminus of the sense strand via a "self-made Type I linker" of "linkers of peptide chains" as defined above; one C16alkyl group is conjugated to the nucleotide at the 5' terminus of the sense strand via a "linker other than an ether linkage" of "linkers of lipophilic moieties" as defined above, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' terminus of the sense strand via a "self-made Type I linker" of "linkers of peptide chains" as defined above; one C16alkyl group is conjugated to the nucleotide at the 5' terminus of the sense strand via a "linker other than an ether linkage" of "linkers of lipophilic moieties" as defined above, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' terminus of the sense strand via a "self-made Type I linker" of "linkers of peptide chains" as defined above; 210) one C16alkyl group is conjugated to the nucleotide at the 5' terminus of the sense strand via a "linker other than an ether linkage" of "linkers of lipophilic moieties" as defined above, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' terminus of the sense strand via a "self-made Type I linker" of "linkers of peptide chains" as defined above; one C16alkyl group is conjugated to the nucleotide at the 5' terminus of the sense strand via a "linker other than an ether linkage" of "linkers of lipophilic moieties" as defined above, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' terminus of the sense strand via a "self-made Type I linker" of "linkers of peptide chains" as defined above; a nucleotide conjugated at an intermediate position other than the two positions at the 5' and 3' ends of the sense strand; 211) one C16 hydrocarbyl group is conjugated to a nucleotide at the 3' end of the sense strand via an ether linkage, and one peptide chain CHRPYIAH is conjugated via a linker as defined above a nucleotide conjugated at an intermediate position other than the two positions at the 5' and 3' ends of the sense strand, and one other peptide chain CHRPYIAH is conjugated via a linker as defined above a nucleotide conjugated at an intermediate position other than the two positions at the 5' and 3' ends of the sense strand; 212) one C16 hydrocarbyl group is conjugated to a nucleotide at the 3' end of the sense strand via a linker other than an "ether linkage" in "linkers for lipophilic moieties" as defined above, and one peptide chain CHRPYIAH is conjugated via a linker as defined above a nucleotide conjugated at an intermediate position other than the two positions at the 5' and 3' ends of the sense strand, and one other peptide chain CHRPYIAH is conjugated via a linker as defined above a nucleotide conjugated at an intermediate position other than the two positions at the 5' and 3' ends of the sense strand; 213) one C16 hydrocarbyl group is conjugated to a nucleotide at an intermediate position other than the two positions at the 5' and 3' ends of the sense strand via an ether linkage, and one peptide chain CHRPYIAH is conjugated via a linker as defined above a nucleotide conjugated at an intermediate position other than the two positions at the 5' and 3' ends of the sense strand, and one other peptide chain CHRPYIAH is conjugated via a linker as defined above a nucleotide conjugated at an intermediate position other than the two positions at the 5' and 3' ends of the sense strand; 214) one C16 hydrocarbyl group is conjugated to a nucleotide at an intermediate position other than the two positions at the 5' and 3' ends of the sense strand via a linker other than an "ether linkage" in "linkers for lipophilic moieties" as defined above, and one peptide chain CHRPYIAH is conjugated via a linker as defined above a nucleotide conjugated at an intermediate position other than the two positions at the 5' and 3' ends of the sense strand, and one other peptide chain CHRPYIAH is conjugated via a linker as defined above a nucleotide conjugated at an intermediate position other than the two positions at the 5' and 3' ends of the sense strand; 215) one C16alkyl group is conjugated to the nucleotide at the 3' terminus of the antisense strand via an ether linkage and one peptide chain CHRPYIAH is conjugated to the nucleotide at an intermediate position other than the two positions at the 5' and 3' termini of the sense strand via a linker as defined above one C16alkyl group is conjugated to the nucleotide at the 3' terminus of the antisense strand via an ether linkage and one peptide chain CHRPYIAH is conjugated to the nucleotide at an intermediate position other than the two positions at the 5' and 3' termini of the sense strand via a linker as defined above one C16alkyl group is conjugated to the nucleotide at the 3' terminus of the antisense strand via an ether linkage and one peptide chain CHRPYIAH is conjugated to the nucleotide at an intermediate position other than the two positions at the 5' and 3' termini of the sense strand via a linker as defined above 216) one C16alkyl group is conjugated to the nucleotide at the 3' terminus of the antisense strand via a linker other than an "ether linkage" within the "linkers for lipophilic moieties" as defined above and one peptide chain CHRPYIAH is conjugated to the nucleotide at an intermediate position other than the two positions at the 5' and 3' termini of the sense strand via a linker as defined above one C16alkyl group is conjugated to the nucleotide at the 3' terminus of the antisense strand via a linker other than an "ether linkage" within the "linkers for lipophilic moieties" as defined above and one peptide chain CHRPYIAH is conjugated to the nucleotide at an intermediate position other than the two positions at the 5' and 3' termini of the sense strand via a linker as defined above one C16alkyl group is conjugated to the nucleotide at the 3' terminus of the antisense strand via a linker other than an "ether linkage" within the "linkers for lipophilic moieties" as defined above and one peptide chain CHRPYIAH is conjugated to the nucleotide at an intermediate position other than the two positions at the 5' and 3' termini of the sense strand via a linker as defined above 217) one C16alkyl group is conjugated to the nucleotide at the 5' terminus of the sense strand via an ether linkage and one peptide chain CHRPYIAH is conjugated to the nucleotide at an intermediate position other than the two positions at the 5' and 3' termini of the sense strand via a "self-defined Type I linker" within the "linkers for peptide chains" as defined above and one other peptide chain CHRPYIAH is conjugated to the nucleotide at an intermediate position other than the two positions at the 5' and 3' termini of the sense strand via a "self-defined Type I linker" within the "linkers for peptide chains" as defined above 218) one C16alkyl group is conjugated to the nucleotide at the 5' terminus of the sense strand via a linker other than an "ether linkage" within the "linkers for lipophilic moieties" as defined above and one peptide chain CHRPYIAH is conjugated to the nucleotide at an intermediate position other than the two positions at the 5' and 3' termini of the sense strand via a "self-defined Type I linker" within the "linkers for peptide chains" as defined above and one other peptide chain CHRPYIAH is conjugated to the nucleotide at an intermediate position other than the two positions at the 5' and 3' termini of the sense strand via a "self-defined Type I linker" within the "linkers for peptide chains" as defined above 219) one C16alkyl group is conjugated to the nucleotide at the 3' terminus of the sense strand via an ether linkage and one peptide chain CHRPYIAH is conjugated to the nucleotide at an intermediate position other than the two positions at the 5' and 3' termini of the sense strand via a "self-defined Type I linker" within the "linkers for peptide chains" as defined above and one other peptide chain CHRPYIAH is conjugated to the nucleotide at an intermediate position other than the two positions at the 5' and 3' termini of the sense strand via a "self-defined Type I linker" within the "linkers for peptide chains" as defined above 220) 1 C16alkyl is conjugated to a nucleotide at the 3' end of the sense strand via a "linkage other than an ether linkage" within the "linker for lipophilic moieties" defined above, and 1 peptide chain CHRPYIAH is conjugated to a nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via a "user-defined Type I linker" within the "linker for peptide chains" described above, and another 1 peptide chain CHRPYIAH is conjugated to a nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via a "user-defined Type I linker" within the "linker for peptide chains" described above; 221) 1 C16alkyl is conjugated to a nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via an ether linkage, and 1 peptide chain CHRPYIAH is conjugated to a nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via a "user-defined Type I linker" within the "linker for peptide chains" described above, and another 1 peptide chain CHRPYIAH is conjugated to a nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via a "user-defined Type I linker" within the "linker for peptide chains" described above; 222) 1 C16alkyl is conjugated to a nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via a "linkage other than an ether linkage" within the "linker for lipophilic moieties" defined above, and 1 peptide chain CHRPYIAH is conjugated to a nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via a "user-defined Type I linker" within the "linker for peptide chains" described above, and another 1 peptide chain CHRPYIAH is conjugated to a nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via a "user-defined Type I linker" within the "linker for peptide chains" described above; 223) 1 C16alkyl is conjugated to a nucleotide at the 3' end of the sense strand via an ether linkage, and 1 peptide chain CHRPYIAH is conjugated to a nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via a "user-defined Type I linker" within the "linker for peptide chains" described above, and another 1 peptide chain CHRPYIAH is conjugated to a nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via a "user-defined Type I linker" within the "linker for peptide chains" described above; 224) one C16alkyl group is conjugated to the nucleotide at the 3' end of the antisense strand via a "linkage other than an ether linkage" within the "linkers for lipophilic moieties" defined above, and one peptide chain CHRPYIAH is conjugated to the nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via a "self-defined Type I linker" within the "linkers for peptide chains" described above, and one other peptide chain CHRPYIAH is conjugated to the nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via a "self-defined Type I linker" within the "linkers for peptide chains" described above; 225) one C16alkyl group is conjugated to the nucleotide at the 5' end of the sense strand via an ether linkage, and one peptide chain CHRPYIAH is conjugated to the nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via a "self-defined Type I linker" within the "linkers for peptide chains" defined above and one other peptide chain CHRPYIAH is conjugated to the nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via a "self-defined Type I linker" within the "linkers for peptide chains" described above; 226) one C16alkyl group is conjugated to the nucleotide at the 5' end of the sense strand via a "linkage other than an ether linkage" within the "linkers for lipophilic moieties" defined above, and one peptide chain CHRPYIAH is conjugated to the nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via a "self-defined Type I linker" within the "linkers for peptide chains" defined above and one other peptide chain CHRPYIAH is conjugated to the nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via a "self-defined Type I linker" within the "linkers for peptide chains" described above; 227) one C16alkyl group is conjugated to the nucleotide at the 3' end of the sense strand via an ether linkage, and one peptide chain CHRPYIAH is conjugated to the nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via a "self-defined Type I linker" within the "linkers for peptide chains" defined above and one other peptide chain CHRPYIAH is conjugated to the nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via a "self-defined Type I linker" within the "linkers for peptide chains" described above; 228) one C16alkyl group is conjugated to the nucleotide at the 3' end of the sense strand via a "linkage other than an ether linkage" within the "linkers for lipophilic moieties" defined above, and one peptide chain CHRPYIAH is conjugated to the nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via a "self-defined Type I linker" within the "linkers for peptide chains" defined above one C16 hydrocarbon group is conjugated to the nucleotide at the position intermediate to the two positions at the 5' and 3' ends of the sense strand via an ether linkage, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the position intermediate to the two positions at the 5' and 3' ends of the sense strand via a "self-made Type I linker" in the "linkers for peptide chains" described hereinabove; 229) one C16 hydrocarbon group is conjugated to the nucleotide at the position intermediate to the two positions at the 5' and 3' ends of the sense strand via an ether linkage, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the position intermediate to the two positions at the 5' and 3' ends of the sense strand via a linker as defined hereinabove one C16 hydrocarbon group is conjugated to the nucleotide at the position intermediate to the two positions at the 5' and 3' ends of the sense strand via an ether linkage, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the position intermediate to the two positions at the 5' and 3' ends of the sense strand via a "self-made Type I linker" in the "linkers for peptide chains" described hereinabove; 230) one C16 hydrocarbon group is conjugated to the nucleotide at the position intermediate to the two positions at the 5' and 3' ends of the sense strand via a "linker other than an ether linkage" in the "linkers for lipophilic moieties" as defined hereinabove, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the position intermediate to the two positions at the 5' and 3' ends of the sense strand via a linker as defined hereinabove one C16 hydrocarbon group is conjugated to the nucleotide at the position intermediate to the two positions at the 5' and 3' ends of the sense strand via an ether linkage, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the position intermediate to the two positions at the 5' and 3' ends of the sense strand via a "self-made Type I linker" in the "linkers for peptide chains" described hereinabove; 231) one C16 hydrocarbon group is conjugated to the nucleotide at the 3' end of the antisense strand via an ether linkage, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' end of the antisense strand via a linker as defined hereinabove one C16 hydrocarbon group is conjugated to the nucleotide at the position intermediate to the two positions at the 5' and 3' ends of the sense strand via an ether linkage, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the position intermediate to the two positions at the 5' and 3' ends of the sense strand via a "self-made Type I linker" in the "linkers for peptide chains" described hereinabove; 232) one C16 hydrocarbon group is conjugated to the nucleotide at the 3' end of the antisense strand via a "linker other than an ether linkage" in the "linkers for lipophilic moieties" as defined hereinabove, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' end of the antisense strand via a linker as defined hereinabove one C16 hydrocarbon group is conjugated to the nucleotide at the position intermediate to the two positions at the 5' and 3' ends of the sense strand via an ether linkage, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the position intermediate to the two positions at the 5' and 3' ends of the sense strand via a "self-made Type I linker" in the "linkers for peptide chains" described hereinabove. In some specific embodiments, in the oligonucleotide conjugate, the pattern of lipophilic moieties conjugated via linkers to one strand of the siRNA and the peptide chain conjugated via a linker to one strand of the siRNA is selected from the following: 1) one C16 alkyl group is conjugated via an ether linkage to the nucleotide at the 5' end of the sense strand and one peptide chain CHRPYIAH is conjugated via a linker as defined above conjugated to the nucleotide at the 3' end of the sense strand; 2) one C16 alkyl group is conjugated via an ether linkage to the nucleotide at the 3' end of the sense strand and one peptide chain CHRPYIAH is conjugated via a linker as defined above conjugated to the nucleotide at the 3' end of the sense strand; 3) one C16 alkyl group is conjugated via an ether linkage to the nucleotide at an intermediate position between the 5' and 3' ends of the sense strand and one peptide chain CHRPYIAH is conjugated via a linker as defined above conjugated to the nucleotide at the 3' end of the sense strand; 4) one C16 alkyl group is conjugated via an ether linkage to the nucleotide at the 3' end of the antisense strand and one peptide chain CHRPYIAH is conjugated via a linker as defined above conjugated to the nucleotide at the 3' end of the sense strand; 5) one C16 alkyl group is conjugated via an ether linkage to the nucleotide at the 5' end of the sense strand and one peptide chain CHRPYIAH is conjugated via a linker as defined above conjugated to the nucleotide at the 5' end of the sense strand; 6) one C16 alkyl group is conjugated via an ether linkage to the nucleotide at the 3' end of the sense strand and one peptide chain CHRPYIAH is conjugated via a linker as defined above conjugated to the nucleotide at the 5' end of the sense strand; 7) one C16 alkyl group is conjugated via an ether linkage to the nucleotide at an intermediate position between the 5' and 3' ends of the sense strand and one peptide chain CHRPYIAH is conjugated via a linker as defined above conjugated to the nucleotide at the 5' end of the sense strand; 8) one C16 alkyl group is conjugated via an ether linkage to the nucleotide at the 3' end of the antisense strand and one peptide chain CHRPYIAH is conjugated via a linker as defined above conjugated to the nucleotide at the 5' end of the sense strand; 9) one C16 alkyl group is conjugated via an ether linkage to the nucleotide at the 5' end of the sense strand and one peptide chain CHRPYIAH is conjugated via a linker as defined above conjugated to a nucleotide at an intermediate position other than the two positions at the 5' and 3' ends of the sense strand; 10) one C16 alkyl group is conjugated to a nucleotide at the 3' end of the sense strand via an ether linkage, and one peptide chain CHRPYIAH is conjugated via a linker as defined above conjugated to a nucleotide at an intermediate position other than the two positions at the 5' and 3' ends of the sense strand; 11) one C16 alkyl group is conjugated to a nucleotide at an intermediate position other than the two positions at the 5' and 3' ends of the sense strand via an ether linkage, and one peptide chain CHRPYIAH is conjugated via a linker as defined above conjugated to a nucleotide at an intermediate position other than the two positions at the 5' and 3' ends of the sense strand; 12) one C16 alkyl group is conjugated to a nucleotide at the 3' end of the antisense strand via an ether linkage, and one peptide chain CHRPYIAH is conjugated via a linker as defined above conjugated to a nucleotide at an intermediate position other than the two positions at the 5' and 3' ends of the sense strand; 13) one C16 alkyl group is conjugated to a nucleotide at the 5' end of the sense strand via an ether linkage, and one peptide chain CHRPYIAH is conjugated via a linker as defined above conjugated to a nucleotide at the 3' end of the antisense strand; 14) one C16 alkyl group is conjugated to a nucleotide at the 3' end of the sense strand via an ether linkage, and one peptide chain CHRPYIAH is conjugated via a linker as defined above conjugated to a nucleotide at the 3' end of the antisense strand; 15) one C16 alkyl group is conjugated to a nucleotide at an intermediate position other than the two positions at the 5' and 3' ends of the sense strand via an ether linkage, and one peptide chain CHRPYIAH is conjugated via a linker as defined above conjugated to a nucleotide at the 3' end of the antisense strand; 16) one C16 alkyl group is conjugated to a nucleotide at the 3' end of the antisense strand via an ether linkage, and one peptide chain CHRPYIAH is conjugated via a linker as defined above conjugated to a nucleotide at the 3' end of the antisense strand; 17) one C16 alkyl group is conjugated to a nucleotide at the 5' end of the sense strand via an ether linkage, and one peptide chain CHRPYIAH is conjugated via a linker as defined above conjugated to a nucleotide at the 3' end of the sense strand, and the other peptide chain CHRPYIAH is conjugated via a linker as defined above conjugated to the nucleotide at the 5' end of the sense strand; 18) one C16 alkyl group is conjugated to the nucleotide at the 3' end of the sense strand via an ether linkage and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand via a linker as defined above conjugated to the nucleotide at the 3' end of the sense strand, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand via a linker as defined above conjugated to the nucleotide at the 5' end of the sense strand; 19) one C16 alkyl group is conjugated to the nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand via a linker as defined above conjugated to the nucleotide at the 3' end of the sense strand, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand via a linker as defined above conjugated to the nucleotide at the 5' end of the sense strand; 20) one C16 alkyl group is conjugated to the nucleotide at the 3' end of the sense strand via an ether linkage and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand via a linker as defined above conjugated to the nucleotide at the 3' end of the sense strand, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand via a linker as defined above conjugated to the nucleotide at the 5' end of the sense strand; 21) one C16 alkyl group is conjugated to the nucleotide at the 5' end of the sense strand via an ether linkage and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' end of the sense strand via a linker as defined above conjugated to the nucleotide at the 3' end of the sense strand, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand via a linker as defined above conjugated to the nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand; 22) one C16 alkyl group is conjugated to the nucleotide at the 3' end of the sense strand via an ether linkage and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand via a linker as defined above conjugated to the nucleotide at the 3' end of the sense strand, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand via a linker as defined above conjugated to the nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand; 23) one C16 alkyl group is conjugated to the nucleotide at the middle position beyond the two positions at the 5' and 3' ends of the sense strand via an ether linkage and one peptide chain CHRPYIAH via a linker as defined above one C16 alkyl group is conjugated to the nucleotide at the 5' end of the sense strand via an ether linkage and one peptide chain CHRPYIAH via a linker as defined above one C16 alkyl group is conjugated to the nucleotide at the middle position beyond the two positions at the 5' and 3' ends of the sense strand; 24) one C16 alkyl group is conjugated to the nucleotide at the 3' end of the antisense strand via an ether linkage and one peptide chain CHRPYIAH via a linker as defined above one C16 alkyl group is conjugated to the nucleotide at the 3' end of the sense strand via an ether linkage and one peptide chain CHRPYIAH via a linker as defined above one C16 alkyl group is conjugated to the nucleotide at the middle position beyond the two positions at the 5' and 3' ends of the sense strand; 25) one C16 alkyl group is conjugated to the nucleotide at the 5' end of the sense strand via an ether linkage and one peptide chain CHRPYIAH via a linker as defined above one C16 alkyl group is conjugated to the nucleotide at the 5' end of the sense strand via an ether linkage and one peptide chain CHRPYIAH via a linker as defined above one C16 alkyl group is conjugated to the nucleotide at the middle position beyond the two positions at the 5' and 3' ends of the sense strand; 26) one C16 alkyl group is conjugated to the nucleotide at the 3' end of the sense strand via an ether linkage and one peptide chain CHRPYIAH via a linker as defined above one C16 alkyl group is conjugated to the nucleotide at the 5' end of the sense strand via an ether linkage and one peptide chain CHRPYIAH via a linker as defined above one C16 alkyl group is conjugated to the nucleotide at the middle position beyond the two positions at the 5' and 3' ends of the sense strand; 27) one C16 alkyl group is conjugated to the nucleotide at the middle position beyond the two positions at the 5' and 3' ends of the sense strand via an ether linkage and one peptide chain CHRPYIAH via a linker as defined above one C16 alkyl group is conjugated to the nucleotide at the 5' end of the sense strand via an ether linkage and one peptide chain CHRPYIAH via a linker as defined above one C16 alkyl group is conjugated to the nucleotide at the middle position beyond the two positions at the 5' and 3' ends of the sense strand; 28) one C16 alkyl group is conjugated to the nucleotide at the 3' end of the antisense strand via an ether linkage and one peptide chain CHRPYIAH via a linker as defined above conjugated to the nucleotide at the 5' end of the sense strand, and another peptide chain CHRPYIAH through a linker as defined above conjugated to the nucleotide at the 5' end and 3' end of the sense strand; 29) a C16 hydrocarbon group conjugated to the nucleotide at the 5' end of the sense strand through an ether linkage, and a peptide chain CHRPYIAH through a linker as defined above conjugated to the nucleotide at the 5' end of the sense strand, and another peptide chain CHRPYIAH through a linker as defined above conjugated to the nucleotide at the 5' end of the sense strand; 30) a C16 hydrocarbon group conjugated to the nucleotide at the 3' end of the sense strand through an ether linkage, and a peptide chain CHRPYIAH through a linker as defined above conjugated to the nucleotide at the 3' end of the sense strand, and another peptide chain CHRPYIAH through a linker as defined above conjugated to the nucleotide at the 3' end of the sense strand; 31) a C16 hydrocarbon group conjugated to the nucleotide at the 5' end and 3' end of the sense strand through an ether linkage, and a peptide chain CHRPYIAH through a linker as defined above conjugated to the nucleotide at the 3' end of the sense strand, and another peptide chain CHRPYIAH through a linker as defined above conjugated to the nucleotide at the 3' end of the sense strand; 32) a C16 hydrocarbon group conjugated to the nucleotide at the 3' end of the antisense strand through an ether linkage, and a peptide chain CHRPYIAH through a linker as defined above conjugated to the nucleotide at the 3' end of the sense strand, and another peptide chain CHRPYIAH through a linker as defined above conjugated to the nucleotide at the 3' end of the sense strand; 33) a C16 hydrocarbon group conjugated to the nucleotide at the 5' end of the sense strand through an ether linkage, and a peptide chain CHRPYIAH through a linker as defined above conjugated to the nucleotide at the 5' end of the sense strand, and another peptide chain CHRPYIAH through a linker as defined above conjugated to the nucleotide at the 5' end of the sense strand; 34) one C16 alkyl group is conjugated to the nucleotide at the 3' end of the sense strand via an ether linkage and one peptide chain CHRPYIAH via a linker as defined above one C16 alkyl group is conjugated to the nucleotide at the 5' end of the sense strand via an ether linkage and one peptide chain CHRPYIAH via a linker as defined above one C16 alkyl group is conjugated to the nucleotide at the 5' end of the sense strand; 35) one C16 alkyl group is conjugated to the nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand and one peptide chain CHRPYIAH via a linker as defined above one C16 alkyl group is conjugated to the nucleotide at the 5' end of the sense strand via an ether linkage and one peptide chain CHRPYIAH via a linker as defined above one C16 alkyl group is conjugated to the nucleotide at the 5' end of the sense strand; 36) one C16 alkyl group is conjugated to the nucleotide at the 3' end of the sense strand via an ether linkage and one peptide chain CHRPYIAH via a linker as defined above one C16 alkyl group is conjugated to the nucleotide at the 5' end of the sense strand via an ether linkage and one peptide chain CHRPYIAH via a linker as defined above one C16 alkyl group is conjugated to the nucleotide at the 5' end of the sense strand; 37) one C16 alkyl group is conjugated to the nucleotide at the 5' end of the sense strand via an ether linkage and one peptide chain CHRPYIAH via a linker as defined above one C16 alkyl group is conjugated to the nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand and one peptide chain CHRPYIAH via a linker as defined above one C16 alkyl group is conjugated to the nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand; 38) one C16 alkyl group is conjugated to the nucleotide at the 3' end of the sense strand via an ether linkage and one peptide chain CHRPYIAH via a linker as defined above one C16 alkyl group is conjugated to the nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand and one peptide chain CHRPYIAH via a linker as defined above one C16 alkyl group is conjugated to the nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand; 39) one C16 alkyl group is conjugated to the nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand and one peptide chain CHRPYIAH via a linker as defined above one C16 hydrocarbon group is conjugated to the nucleotide at the 5' end of the sense strand via an "ether linkage other than a linker for a lipophilic moiety" as defined above, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' end of the sense strand via a "peptide chain linker" as defined above one C16 hydrocarbon group is conjugated to the nucleotide at the 5' end of the sense strand via an "ether linkage other than a linker for a lipophilic moiety" as defined above, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' end of the sense strand via a "peptide chain linker" as defined above 40) one C16 hydrocarbon group is conjugated to the nucleotide at the 3' end of the antisense strand via an ether linkage, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand via a "peptide chain linker" as defined above one C16 hydrocarbon group is conjugated to the nucleotide at the 5' end of the sense strand via an "ether linkage other than a linker for a lipophilic moiety" as defined above, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' end of the sense strand via a "peptide chain linker" as defined above one C16 hydrocarbon group is conjugated to the nucleotide at the 5' end of the sense strand via an "ether linkage other than a linker for a lipophilic moiety" as defined above, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' end of the sense strand via a "peptide chain linker" as defined above In some specific embodiments, in the oligonucleotide conjugate, the pattern of the lipophilic moiety conjugated to one strand of the siRNA via a linker and the peptide chain conjugated to one strand of the siRNA via a linker is selected from the following: 1) one C16 hydrocarbon group is conjugated to the nucleotide at the 5' end of the sense strand via an "ether linkage other than a linker for a lipophilic moiety" as defined above, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' end of the sense strand via a "peptide chain linker" as defined above one C16 hydrocarbon group is conjugated to the nucleotide at the 3' end of the sense strand via an ether linkage, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand via a "peptide chain linker" as defined above 2) one C16 hydrocarbon group is conjugated to the nucleotide at the 5' end of the sense strand via an "ether linkage other than a linker for a lipophilic moiety" as defined above, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' end of the sense strand via a "peptide chain linker" as defined above 3) one C16 hydrocarbon group is conjugated to the nucleotide at the 5' end of the sense strand via an ether linkage, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' end of the sense strand via a "peptide chain linker" as defined above 4) one C16 hydrocarbon group is conjugated to the nucleotide at the 5' end and at the 3' end of the sense strand via an ether linkage, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' end of the sense strand via a "peptide chain linker" as defined above one C16 hydrocarbon group is conjugated to the nucleotide at the 3' end of the sense strand via an ether linkage, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand via a "peptide chain linker" as defined above 5) one C16 hydrocarbon group is conjugated to the nucleotide at the 5' end and at the 3' end of the sense strand via an ether linkage, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' end of the sense strand via a "peptide chain linker" as defined above 6) one C16alkyl group is conjugated to a nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via a "linkage other than an ether linkage" of the "linkers for lipophilic moieties" defined above, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 3' end of the sense strand via a "self-defined Type I linker" of the "linkers for peptide chains" described above; 7) one C16alkyl group is conjugated to a nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via a "linkage other than an ether linkage" of the "linkers for lipophilic moieties" defined above, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 3' end of the sense strand via a "self-defined Type I linker" of the "linkers for peptide chains" defined above at the 5' end of the sense strand; 8) one C16alkyl group is conjugated to a nucleotide at the 3' end of the sense strand via a "linkage other than an ether linkage" of the "linkers for lipophilic moieties" defined above, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 5' end of the sense strand via a "self-defined Type I linker" of the "linkers for peptide chains" defined above at the 5' end of the sense strand; 9) one C16alkyl group is conjugated to a nucleotide at the 3' end of the sense strand via a "linkage other than an ether linkage" of the "linkers for lipophilic moieties" defined above, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 5' end of the sense strand via a "self-defined Type I linker" of the "linkers for peptide chains" described above; 10) one C16alkyl group is conjugated to a nucleotide at the 3' end of the sense strand via an ether linkage, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 5' end of the sense strand via a "self-defined Type I linker" of the "linkers for peptide chains" described above; 11) one C16alkyl group is conjugated to a nucleotide at the 3' end of the sense strand via an ether linkage, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 5' end of the sense strand via a "self-defined Type I linker" of the "linkers for peptide chains" described above; 12) one C16alkyl group is conjugated to a nucleotide at the 3' end of the sense strand via an ether linkage, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 5' end of the sense strand via a "self-defined Type I linker" of the "linkers for peptide chains" described above; 13) one C16alkyl group is conjugated to a nucleotide at the 3' end of the sense strand via an ether linkage, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 5' end of the sense strand via a "self-defined Type I linker" of the "linkers for peptide chains" defined above at the 5' end of the sense strand; or 14) one C16alkyl group is conjugated to a nucleotide at the 3' end of the sense strand via an ether linkage, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 5' end of the sense strand via a "self-defined Type I linker" of the "linkers for peptide chains" defined above conjugated to the nucleotide at the 3' end of the sense strand. In some specific embodiments, in the oligonucleotide conjugate, the pattern of lipophilic moieties conjugated via linkers to one strand of the siRNA and the pattern of peptide chains conjugated via linkers to one strand of the siRNA are selected from the following: 1) one C16 alkyl group is conjugated via an ether linkage to the nucleotide at the 5' end of the sense strand and one peptide chain CHRPYIAH is conjugated via a linker as defined above conjugated to the nucleotide at the 3' end of the sense strand. 2) one C16 alkyl group is conjugated via an ether linkage to the nucleotide at the 5' end of the sense strand and one peptide chain CHRPYIAH is conjugated via a linker as defined above conjugated to the nucleotide at the 5' end of the sense strand. 3) one C16 alkyl group is conjugated via an ether linkage to the nucleotide at an intermediate position between the 5' and 3' ends of the sense strand and one peptide chain CHRPYIAH is conjugated via a linker as defined above conjugated to the nucleotide at the 3' end of the sense strand, and another peptide chain CHRPYIAH is conjugated via a linker as defined above conjugated to the nucleotide at the 5' end of the sense strand. 4) one C16 alkyl group is conjugated via an ether linkage to the nucleotide at an intermediate position between the 5' and 3' ends of the sense strand and one peptide chain CHRPYIAH is conjugated via a linker as defined above conjugated to the nucleotide at the 3' end of the sense strand. 5) one C16 alkyl group is conjugated via an ether linkage to the nucleotide at an intermediate position between the 5' and 3' ends of the sense strand and one peptide chain CHRPYIAH is conjugated via a linker as defined above conjugated to the nucleotide at the 5' end of the sense strand. In some specific embodiments, in the oligonucleotide conjugate, the pattern of 2-4 peptide chains conjugated via linkers to one or two strands of the siRNA is selected from the following: 1) one peptide chain CHRPYIAH is conjugated via a linker as defined above conjugated to the nucleotide at the 3' end of the sense strand, and another peptide chain CHRPYIAH is conjugated via a linker as defined above conjugated to the nucleotide at the 3' end of the sense strand. 2) one peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' end of the sense strand via a "self-defined Type I linker" in the "linkers for peptide chains" described above, and the other peptide chain CHRPYIAH is conjugated via a linker defined above conjugated to the nucleotide at the 3' end of the sense strand; 3) one peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' end of the sense strand via a "self-defined Type I linker" in the "linkers for peptide chains" described above, and the other peptide chain CHRPYIAH is conjugated via a linker defined above conjugated to the nucleotide at the 3' end of the sense strand; 4) one peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand via a linker defined above conjugated to the nucleotide at the 5' end of the sense strand, and the other peptide chain CHRPYIAH is conjugated via a linker defined above conjugated to the nucleotide at the 3' end of the sense strand; 5) one peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand via a "self-defined Type II linker" in the "linkers for peptide chains" described above, and the other peptide chain CHRPYIAH is conjugated via a linker defined above conjugated to the nucleotide at the 3' end of the sense strand; 6) one peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand via a "self-defined Type I linker" in the "linkers for peptide chains" described above, and the other peptide chain CHRPYIAH is conjugated via a linker defined above conjugated to the nucleotide at the 3' end of the sense strand; 7) one peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand via a linker defined above conjugated to the nucleotide at the 5' end and 3' end of the sense strand, and the other peptide chain CHRPYIAH is conjugated via a linker defined above conjugated to the nucleotide at the 3' end of the sense strand; 8) one peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end and 3' end of the sense strand via a "self-defined Type II linker" in the "linkers for peptide chains" described above, and the other peptide chain CHRPYIAH is conjugated via a linker defined above conjugated to the nucleotide at the 3' end of the sense strand; 9) one peptide chain CHRPYIAH conjugated to the nucleotide in the middle position, outside the two positions at the 5' and 3' ends of the sense strand, through the "self-defined type I linker" in the "linker for peptide chains" described above, and the other peptide chain CHRPYIAH conjugated to the nucleotide at the 3' end of the sense strand through the linker defined above conjugated to the nucleotide at the 3' end of the sense strand; 10) one peptide chain CHRPYIAH conjugated to the nucleotide in the middle position, outside the two positions at the 5' and 3' ends of the sense strand, through the "self-defined type I linker" in the "linker for peptide chains" described above, and the other peptide chain CHRPYIAH conjugated to the nucleotide at the 3' end of the sense strand through the linker defined above conjugated to the nucleotide at the 3' end of the sense strand, and the other peptide chain CHRPYIAH conjugated to the nucleotide at the 5' end of the sense strand through the linker defined above conjugated to the nucleotide at the 5' end of the sense strand; 11) one peptide chain CHRPYIAH conjugated to the nucleotide at the 3' end of the sense strand through the "self-defined type II linker" in the "linker for peptide chains" described above, and the other peptide chain CHRPYIAH conjugated to the nucleotide at the 3' end of the sense strand through the linker defined above conjugated to the nucleotide at the 5' end of the sense strand; 12) one peptide chain CHRPYIAH conjugated to the nucleotide at the 3' end of the sense strand through the "self-defined type I linker" in the "linker for peptide chains" described above, and the other peptide chain CHRPYIAH conjugated to the nucleotide at the 3' end of the sense strand through the linker defined above conjugated to the nucleotide at the 5' end of the sense strand; 13) one peptide chain CHRPYIAH conjugated to the nucleotide in the middle position, outside the two positions at the 5' and 3' ends of the sense strand, through the "self-defined type I linker" in the "linker for peptide chains" described above, and the other peptide chain CHRPYIAH conjugated to the nucleotide at the 3' end of the sense strand through the linker defined above conjugated to the nucleotide at the 5' end of the sense strand, and the other peptide chain CHRPYIAH conjugated to the nucleotide at the 3' end of the sense strand through the linker defined above conjugated to the nucleotide at the 5' end of the sense strand; 14) one peptide chain CHRPYIAH conjugated to the nucleotide at the 5' end of the sense strand through the "self-defined type II linker" in the "linker for peptide chains" described above, and the other peptide chain CHRPYIAH conjugated to the nucleotide at the 3' end of the sense strand through the linker defined above conjugated to the nucleotide at the 5' end of the sense strand; 15) one peptide chain CHRPYIAH conjugated to the nucleotide at the 5' end of the sense strand through the "self-defined type I linker" in the "linker for peptide chains" described above, and the other peptide chain CHRPYIAH conjugated to the nucleotide at the 3' end of the sense strand through the linker defined above conjugated to the nucleotide at the 5' end of the sense strand; 16) one peptide chain CHRPYIAH conjugated to the nucleotide in the middle position, outside the two positions at the 5' and 3' ends of the sense strand, through the "self-defined type I linker" in the "linker for peptide chains" described above, and the other peptide chain CHRPYIAH conjugated to the nucleotide at the 3' end of the sense strand through the linker defined above one peptide chain CHRPYIAH conjugated to the nucleotide at the middle position beyond the two positions at the 5' and 3' ends of the sense strand through the "self-defined type II linker" in the "linker for peptide chain" defined above, and the other peptide chain CHRPYIAH through the linker defined above conjugated to the nucleotide at the 5' end of the sense strand; 17) one peptide chain CHRPYIAH conjugated to the nucleotide at the middle position beyond the two positions at the 5' and 3' ends of the sense strand through the "self-defined type I linker" in the "linker for peptide chain" defined above, and the other peptide chain CHRPYIAH through the linker defined above conjugated to the nucleotide at the 5' end of the sense strand; 18) one peptide chain CHRPYIAH conjugated to the nucleotide at the middle position beyond the two positions at the 5' and 3' ends of the sense strand through the "self-defined type II linker" in the "linker for peptide chain" defined above, and the other peptide chain CHRPYIAH through the linker defined above conjugated to the nucleotide at the 5' end of the sense strand; 19) one peptide chain CHRPYIAH through the linker defined above conjugated to the nucleotide at the 3' end of the sense strand, and the other peptide chain CHRPYIAH through the linker defined above conjugated to the nucleotide at the middle position beyond the two positions at the 5' and 3' ends of the sense strand; 20) one peptide chain CHRPYIAH conjugated to the nucleotide at the 3' end of the sense strand through the "self-defined type II linker" in the "linker for peptide chain" defined above, and the other peptide chain CHRPYIAH through the linker defined above conjugated to the nucleotide at the middle position beyond the two positions at the 5' and 3' ends of the sense strand; 21) one peptide chain CHRPYIAH conjugated to the nucleotide at the 3' end of the sense strand through the "self-defined type I linker" in the "linker for peptide chain" defined above, and the other peptide chain CHRPYIAH through the linker defined above conjugated to the nucleotide at the middle position beyond the two positions at the 5' and 3' ends of the sense strand; 22) one peptide chain CHRPYIAH through the linker defined above conjugated to the nucleotide at the 5' end of the sense strand, and the other peptide chain CHRPYIAH through the linker defined above conjugated to the nucleotide at the middle position beyond the two positions at the 5' and 3' ends of the sense strand; 23) One peptide chain CHRPYIAH conjugated to the nucleotide at the 5' end of the sense strand via a "self-defined Type II linker" as described above and the other peptide chain CHRPYIAH conjugated to the nucleotide at the 3' end of the sense strand via a "self-defined Type II linker" as described above; conjugated to the nucleotide at the middle position other than the two positions at the 5' and 3' ends of the sense strand; 24) One peptide chain CHRPYIAH conjugated to the nucleotide at the 5' end of the sense strand via a "self-defined Type I linker" as described above and the other peptide chain CHRPYIAH conjugated to the nucleotide at the 3' end of the sense strand via a "self-defined Type I linker" as described above; conjugated to the nucleotide at the middle position other than the two positions at the 5' and 3' ends of the sense strand; 25) One peptide chain CHRPYIAH conjugated to the nucleotide at the 5' end of the sense strand via a "self-defined Type II linker" as described above and the other peptide chain CHRPYIAH conjugated to the nucleotide at the 3' end of the sense strand via a "self-defined Type II linker" as described above; conjugated to the nucleotide at the middle position other than the two positions at the 5' and 3' ends of the sense strand; conjugated to the nucleotide at the middle position other than the two positions at the 5' and 3' ends of the sense strand; 26) One peptide chain CHRPYIAH conjugated to the nucleotide at the middle position other than the two positions at the 5' and 3' ends of the sense strand via a "self-defined Type II linker" as described above and the other peptide chain CHRPYIAH conjugated to the nucleotide at the 3' end of the sense strand via a "self-defined Type II linker" as described above; conjugated to the nucleotide at the middle position other than the two positions at the 5' and 3' ends of the sense strand; 27) One peptide chain CHRPYIAH conjugated to the nucleotide at the middle position other than the two positions at the 5' and 3' ends of the sense strand via a "self-defined Type I linker" as described above and the other peptide chain CHRPYIAH conjugated to the nucleotide at the 3' end of the sense strand via a "self-defined Type I linker" as described above; conjugated to the nucleotide at the middle position other than the two positions at the 5' and 3' ends of the sense strand; 28) One peptide chain CHRPYIAH conjugated to the nucleotide at the 3' end of the sense strand via a "self-defined Type II linker" as described above and the other peptide chain CHRPYIAH conjugated to the nucleotide at the 3' end of the sense strand via a "self-defined Type II linker" as described above; 29) one peptide chain CHRPYIAH conjugated to the nucleotide at the 3' end of the sense strand via a "self-defined Type I linker" as described above in "Linkers for Peptide Chains", and another peptide chain CHRPYIAH conjugated to the nucleotide at the 3' end of the sense strand via a "self-defined Type II linker" as described above in "Linkers for Peptide Chains"; 30) one peptide chain CHRPYIAH conjugated to the nucleotide at the 5' end of the sense strand via a "self-defined Type II linker" as described above in "Linkers for Peptide Chains", and another peptide chain CHRPYIAH conjugated to the nucleotide at the 3' end of the sense strand via a "self-defined Type II linker" as described above in "Linkers for Peptide Chains"; 31) one peptide chain CHRPYIAH conjugated to the nucleotide at the 5' end of the sense strand via a "self-defined Type I linker" as described above in "Linkers for Peptide Chains", and another peptide chain CHRPYIAH conjugated to the nucleotide at the 3' end of the sense strand via a "self-defined Type II linker" as described above in "Linkers for Peptide Chains"; 32) one peptide chain CHRPYIAH conjugated to the nucleotide at a position intermediate between the 5' and 3' ends of the sense strand via a "self-defined Type II linker" as described above in "Linkers for Peptide Chains", and another peptide chain CHRPYIAH conjugated to the nucleotide at the 3' end of the sense strand via a "self-defined Type II linker" as described above in "Linkers for Peptide Chains"; 33) one peptide chain CHRPYIAH conjugated to the nucleotide at a position intermediate between the 5' and 3' ends of the sense strand via a "self-defined Type I linker" as described above in "Linkers for Peptide Chains", and another peptide chain CHRPYIAH conjugated to the nucleotide at the 3' end of the sense strand via a "self-defined Type II linker" as described above in "Linkers for Peptide Chains"; 34) one peptide chain CHRPYIAH conjugated to the nucleotide at the 3' end of the sense strand via a "self-defined Type II linker" as described above in "Linkers for Peptide Chains", and another peptide chain CHRPYIAH conjugated to the nucleotide at the 5' end of the sense strand via a "self-defined Type II linker" as described above in "Linkers for Peptide Chains"; 35) one peptide chain CHRPYIAH conjugated to the nucleotide at the 3' end of the sense strand via a "self-defined Type I linker" as described above in "Linkers for Peptide Chains", and another peptide chain CHRPYIAH conjugated to the nucleotide at the 5' end of the sense strand via a "self-defined Type II linker" as described above in "Linkers for Peptide Chains"; 36) one peptide strand CHRPYIAH conjugated to the nucleotide at the 5' end of the sense strand via a "self-defining Type II linker" in the "Linkers for Peptide Strands" described above and the other peptide strand CHRPYIAH conjugated to the nucleotide at the 5' end of the sense strand via a "self-defining Type II linker" in the "Linkers for Peptide Strands" described above; 37) one peptide strand CHRPYIAH conjugated to the nucleotide at the 5' end of the sense strand via a "self-defining Type I linker" in the "Linkers for Peptide Strands" described above and the other peptide strand CHRPYIAH conjugated to the nucleotide at the 5' end of the sense strand via a "self-defining Type II linker" in the "Linkers for Peptide Strands" described above; 38) one peptide strand CHRPYIAH conjugated to the nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via a "self-defining Type II linker" in the "Linkers for Peptide Strands" described above and the other peptide strand CHRPYIAH conjugated to the nucleotide at the 5' end of the sense strand via a "self-defining Type II linker" in the "Linkers for Peptide Strands" described above; 39) one peptide strand CHRPYIAH conjugated to the nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via a "self-defining Type I linker" in the "Linkers for Peptide Strands" described above and the other peptide strand CHRPYIAH conjugated to the nucleotide at the 5' end of the sense strand via a "self-defining Type II linker" in the "Linkers for Peptide Strands" described above; 40) one peptide strand CHRPYIAH conjugated to the nucleotide at the 3' end of the sense strand via a "self-defining Type II linker" in the "Linkers for Peptide Strands" described above and the other peptide strand CHRPYIAH conjugated to the nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via a "self-defining Type II linker" in the "Linkers for Peptide Strands" described above; 41) one peptide strand CHRPYIAH conjugated to the nucleotide at the 3' end of the sense strand via a "self-defining Type I linker" in the "Linkers for Peptide Strands" described above and the other peptide strand CHRPYIAH conjugated to the nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via a "self-defining Type II linker" in the "Linkers for Peptide Strands" described above; 42) one peptide strand CHRPYIAH conjugated to the nucleotide at the 5' end of the sense strand via a "self-defining Type II linker" in the "Linkers for Peptide Strands" described above and the other peptide strand CHRPYIAH conjugated to the nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via a "self-defining Type II linker" in the "Linkers for Peptide Strands" described above; 43) one peptide chain CHRPYIAH conjugated to the nucleotide at the 5' end of the sense strand via a "self-defining Type I linker" as described above and another peptide chain CHRPYIAH conjugated to the nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via a "self-defining Type II linker" as described above; 44) one peptide chain CHRPYIAH conjugated to the nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via a "self-defining Type II linker" as described above and another peptide chain CHRPYIAH conjugated to the nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via a "self-defining Type II linker" as described above; 45) one peptide chain CHRPYIAH conjugated to the nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via a "self-defining Type I linker" as described above and another peptide chain CHRPYIAH conjugated to the nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via a "self-defining Type II linker" as described above; 46) one peptide chain CHRPYIAH conjugated to the nucleotide at the 3' end of the sense strand via a "self-defining Type I linker" as described above and another peptide chain CHRPYIAH conjugated to the nucleotide at the 3' end of the sense strand via a "self-defining Type I linker" as described above; 47) one peptide chain CHRPYIAH conjugated to the nucleotide at the 5' end of the sense strand via a "self-defining Type I linker" as described above and another peptide chain CHRPYIAH conjugated to the nucleotide at the 3' end of the sense strand via a "self-defining Type I linker" as described above; 48) one peptide chain CHRPYIAH conjugated to the nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via a "self-defining Type I linker" as described above and another peptide chain CHRPYIAH conjugated to the nucleotide at the 3' end of the sense strand via a "self-defining Type I linker" as described above; 49) one peptide chain CHRPYIAH conjugated to the nucleotide at the 3' end of the sense strand via a "self-defining Type I linker" as described above and another peptide chain CHRPYIAH conjugated to the nucleotide at the 5' end of the sense strand via a "self-defining Type I linker" as described above; 50) one peptide strand CHRPYIAH conjugated to the nucleotide at the 5' end of the sense strand via a "self-defining Type I linker" as described above and another peptide strand CHRPYIAH conjugated to the nucleotide at the 5' end of the sense strand via a "self-defining Type I linker" as described above; 51) one peptide strand CHRPYIAH conjugated to the nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via a "self-defining Type I linker" as described above and another peptide strand CHRPYIAH conjugated to the nucleotide at the 5' end of the sense strand via a "self-defining Type I linker" as described above; 52) one peptide strand CHRPYIAH conjugated to the nucleotide at the 3' end of the sense strand via a "self-defining Type I linker" as described above and another peptide strand CHRPYIAH conjugated to the nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via a "self-defining Type I linker" as described above; 53) one peptide strand CHRPYIAH conjugated to the nucleotide at the 5' end of the sense strand via a "self-defining Type I linker" as described above and another peptide strand CHRPYIAH conjugated to the nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via a "self-defining Type I linker" as described above; 54) one peptide strand CHRPYIAH conjugated to the nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via a "self-defining Type I linker" as described above and another peptide strand CHRPYIAH conjugated to the nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via a "self-defining Type I linker" as described above; 55) one peptide strand CHRPYIAH conjugated to the nucleotide at the 3' end of the sense strand via a linker as defined above and another peptide strand CHRPYIAH conjugated to the nucleotide at the 5' end of the sense strand via a linker as defined above; one peptide strand CHRPYIAH conjugated to the nucleotide at the 3' end of the sense strand via a linker as defined above and another peptide strand CHRPYIAH conjugated to the nucleotide at the 5' end of the sense strand via a linker as defined above; one peptide strand CHRPYIAH conjugated to the nucleotide at the 3' end of the sense strand via a linker as defined above and another peptide strand CHRPYIAH conjugated to the nucleotide at the 5' end of the sense strand via a linker as defined above; 56) one peptide strand CHRPYIAH conjugated to the nucleotide at the 3' end of the sense strand via a "self-defining Type II linker" as described above and another peptide strand CHRPYIAH conjugated to the nucleotide at the 5' end of the sense strand via a linker as defined above; one peptide strand CHRPYIAH conjugated to the nucleotide at the 3' end of the sense strand via a "self-defining Type II linker" as described above and another peptide strand CHRPYIAH conjugated to the nucleotide at the 5' end of the sense strand via a linker as defined above; 57) one peptide strand CHRPYIAH is conjugated to the nucleotide at the 3' end of the sense strand via the "self-defining type I linker" in the "linkers for peptide strands" described above, and the other peptide strand CHRPYIAH is conjugated to the nucleotide at the 3' end of the antisense strand via the linker defined above conjugated to the nucleotide at the 3' end of the antisense strand; 58) one peptide strand CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand via the linker defined above conjugated to the nucleotide at the 3' end of the antisense strand; conjugated to the nucleotide at the 3' end of the antisense strand; 59) one peptide strand CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand via the "self-defining type II linker" in the "linkers for peptide strands" described above, and the other peptide strand CHRPYIAH is conjugated to the nucleotide at the 3' end of the antisense strand via the linker defined above conjugated to the nucleotide at the 3' end of the antisense strand; 60) one peptide strand CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand via the "self-defining type I linker" in the "linkers for peptide strands" described above, and the other peptide strand CHRPYIAH is conjugated to the nucleotide at the 3' end of the antisense strand via the linker defined above conjugated to the nucleotide at the 3' end of the antisense strand; 61) one peptide strand CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand via the linker defined above conjugated to the nucleotide at the 3' end of the antisense strand; conjugated to the nucleotide at the 3' end of the antisense strand; 62) one peptide strand CHRPYIAH is conjugated to the nucleotide at the 5' end and 3' end of the sense strand via the "self-defining type II linker" in the "linkers for peptide strands" described above, and the other peptide strand CHRPYIAH is conjugated to the nucleotide at the 3' end of the antisense strand via the linker defined above conjugated to the nucleotide at the 3' end of the antisense strand; 63) one peptide strand CHRPYIAH is conjugated to the nucleotide at the 5' end and 3' end of the sense strand via the "self-defining type I linker" in the "linkers for peptide strands" described above, and the other peptide strand CHRPYIAH is conjugated to the nucleotide at the 3' end of the antisense strand via the linker defined above conjugated to the nucleotide at the 3' end of the antisense strand; 64) 3-4 peptide chains CHRPYIAH conjugated to the nucleotide at the 3' end of the sense strand via a linker as defined above the nucleotide at the 3' end of the sense strand or the nucleotide at the 5' end of the sense strand; 65) 3-4 peptide chains CHRPYIAH conjugated to the nucleotide at the 3' end of the sense strand via a linker as defined above the nucleotide at the 3' end of the sense strand and the nucleotide at the 5' end of the sense strand; 66) 3-4 peptide chains CHRPYIAH conjugated to the nucleotide at the 3' end of the sense strand via a linker as defined above the nucleotide at the 3' end of the sense strand or the nucleotide at the 5' end of the sense strand; 67) 3-4 peptide chains CHRPYIAH conjugated to the nucleotide at the 3' end of the sense strand or the nucleotide at the 5' end of the sense strand via a "self-defined type II linker" among the "linkers for peptide chains" as described above; 68) 3-4 peptide chains CHRPYIAH conjugated to the nucleotide at the 3' end of the sense strand and the nucleotide at the 5' end of the sense strand via a "self-defined type II linker" among the "linkers for peptide chains" as described above; 69) 3-4 peptide chains CHRPYIAH conjugated to the nucleotide at the 3' end of the sense strand or the nucleotide at the 5' end of the sense strand via a "self-defined type II linker" among the "linkers for peptide chains" as described above; 70) 3-4 peptide chains CHRPYIAH conjugated to the nucleotide at the 3' end of the sense strand or the nucleotide at the 5' end of the sense strand via a "self-defined type I linker" among the "linkers for peptide chains" as described above; 71) 3-4 peptide chains CHRPYIAH conjugated to the nucleotide at the 3' end of the sense strand and the nucleotide at the 5' end of the sense strand via a "self-defined type I linker" among the "linkers for peptide chains" as described above; 72) 3-4 peptide chains CHRPYIAH conjugated to the nucleotide at the 3' end of the sense strand or the nucleotide at the 5' end of the sense strand via a "self-defined type I linker" among the "linkers for peptide chains" as described above. In some specific embodiments, in the oligonucleotide conjugate, wherein the pattern of 2-4 peptide chains conjugated to one or two strands of the siRNA via a linker is selected from the following: 1) a peptide chain CHRPYIAH conjugated to the nucleotide at the 3' end of the sense strand via a linker as defined above one peptide chain CHRPYIAH conjugated to the nucleotide at the 3' end of the sense strand and one peptide chain CHRPYIAH conjugated to the nucleotide at the 5' end of the sense strand, respectively; 2) 2-4 peptide chains CHRPYIAH conjugated to the nucleotide at the 3' end of the sense strand or the nucleotide at the 5' end of the sense strand via a "self-defined type II linker" among the "linkers for peptide chains" as described above; 3) 2-4 peptide chains CHRPYIAH conjugated to the nucleotide at the 3' end of the sense strand and the nucleotide at the 5' end of the sense strand via "self-defined Type II linkers" in "Linkers for Peptide Chains" described above; 4) 2-4 peptide chains CHRPYIAH conjugated to the nucleotide at the 3' end of the sense strand and the nucleotide at the 5' end of the sense strand via "self-defined Type II linkers" in "Linkers for Peptide Chains" described above; 5) 1 peptide chain CHRPYIAH conjugated to the nucleotide at the 3' end of the sense strand via a linker defined above 1 peptide chain CHRPYIAH conjugated to the nucleotide at the 5' end of the sense strand, and another peptide chain CHRPYIAH conjugated to the nucleotide at the 3' end of the sense strand via "self-defined Type I linkers" in "Linkers for Peptide Chains" described above; 6) 1 peptide chain CHRPYIAH conjugated to the nucleotide at the 5' end of the sense strand via a linker defined above 1 peptide chain CHRPYIAH conjugated to the nucleotide at the 5' end of the sense strand, and another peptide chain CHRPYIAH conjugated to the nucleotide at the 3' end of the sense strand via "self-defined Type I linkers" in "Linkers for Peptide Chains" described above; 7) 1 peptide chain CHRPYIAH conjugated to the nucleotide at the 5' end of the sense strand via a linker defined above 1 peptide chain CHRPYIAH conjugated to the nucleotide at the 5' end of the sense strand, and another peptide chain CHRPYIAH conjugated to the nucleotide at the 3' end of the sense strand via "self-defined Type I linkers" in "Linkers for Peptide Chains" described above; 8) 1 peptide chain CHRPYIAH conjugated to the nucleotide at the 5' end of the sense strand via a linker defined above 1 peptide chain CHRPYIAH conjugated to the nucleotide at the 5' end of the sense strand, and another peptide chain CHRPYIAH conjugated to the nucleotide at the 3' end of the sense strand via "self-defined Type I linkers" in "Linkers for Peptide Chains" described above; 9) 1 peptide chain CHRPYIAH conjugated to the nucleotide at the 5' end of the sense strand via a linker defined above 1 peptide chain CHRPYIAH conjugated to the nucleotide at the 5' end of the sense strand, and another peptide chain CHRPYIAH conjugated to the nucleotide at the 3' end of the sense strand via "self-defined Type I linkers" in "Linkers for Peptide Chains" described above. Production of oligonucleotides Oligonucleotides can be produced in large quantities, for example, by a variety of methods. Exemplary methods include: organic synthesis and RNA cleavage, for example, in vitro cleavage. Organic synthesis. Oligonucleotides can be prepared by separately synthesizing the individual strands of a single-stranded RNA molecule or the individual strands of a double-stranded RNA molecule, followed by annealing of the constituent strands. Large scale bioreactors, such as the OligoPilot II from Pharmacia Biotec AB (Uppsala Sweden), can be used to produce large quantities of specific RNA strands for a given siRNA. The OligoPilot II reactor can efficiently couple nucleotides using only a 1.5 molar excess of phosphoramidite nucleotides. To make the RNA strands, ribonucleotide amine esters are used. Standard cycles of monomer addition can be used to synthesize 21 to 23 nucleotide strands of siRNA. Typically, two complementary strands are made separately and then annealed, for example after release from a solid support and deprotection. Regardless of the method of synthesis, the siRNA preparation can be prepared in a solution suitable for the formulation, such as an aqueous and / or organic solution. For example, the siRNA preparation can be precipitated and re-dissolved in double distilled water, and lyophilized. The dried siRNA can then be re-suspended in a solution suitable for the intended formulation method. Preparation of double-stranded oligonucleotides conjugated to a lipophilic moiety In some embodiments, the lipophilic moiety is conjugated to the double-stranded oligonucleotide via a nucleobase, sugar moiety, or internucleosidic linkage. For example, conjugation to a purine nucleobase or derivative thereof can occur at any position including endocyclic and exocyclic atoms. In some embodiments, the 2-, 6-, 7-, or 8-position of a purine nucleobase is attached to a conjugate moiety. Conjugation to a pyrimidine nucleobase or derivative thereof can also occur at any position. In some embodiments, the 2-, 5-, and 6-positions of a pyrimidine nucleobase can be substituted with a conjugate moiety. When a lipophilic moiety is conjugated to a nucleobase, the preferred position is one that does not interfere with hybridization, i.e., does not interfere with the hydrogen bond interactions required for base pairing. In one embodiment, a lipophilic moiety can be conjugated to a nucleobase via a linker containing an alkyl, alkenyl, or amide linkage. Conjugation to a sugar moiety of a nucleoside can occur at any carbon atom. Exemplary carbon atoms of a sugar moiety to which a lipophilic moiety can be attached include the 2', 3', and 5' carbon atoms. A lipophilic moiety can also be attached to the 1' position, such as in an abasic residue. In one embodiment, a lipophilic moiety can be conjugated to a sugar moiety via a 2'-0 modification, with or without a linker. There are many methods of preparing oligonucleotide conjugates. In general, an oligonucleotide is attached to a conjugate moiety by contacting a reactive group on the oligonucleotide (e.g., OH, SH, amine, carboxyl, aldehyde, and the like) with a reactive group on the conjugate moiety. In some embodiments, one reactive group is electrophilic and the other is nucleophilic. For example, the electrophilic group can be a carbonyl-containing functional group and the nucleophilic group can be an amine or a thiol. Methods for conjugating nucleic acids and related oligomeric compounds in the presence and absence of linkers are well described in the literature, such as Manoharan, in Antisense Research and Applications, Crooke and LeBleu, eds., CRC Press, Boca Raton, Fla., 1993, Chapter 17, which is incorporated herein by reference in its entirety. In one embodiment, the first (complementary) RNA strand and the second (sense) RNA strand are synthesized separately, wherein one of the RNA strands comprises the lipophilic moiety flanking, and the first and second RNA strands can be mixed to form the dsRNA. The steps of synthesizing the RNA strands preferably involve solid-phase synthesis, wherein the individual nucleotides are joined end-to-end by forming the internucleotide 3’-5’ phosphodiester bond in successive synthesis cycles. In one embodiment, the lipophilic molecule with a phosphoramidite group is coupled to the 3’- or 5’-end of the first (complementary) or second (sense) RNA strand in the last synthesis cycle. In solid-phase synthesis of RNA, the nucleotides are initially in the form of nucleoside phosphoramidites. In each synthesis cycle, another nucleoside phosphoramidite is attached to the -OH group of the previously incorporated nucleotide. If the lipophilic molecule has a phosphoramidite group, it can be coupled to the free OH end of the RNA previously synthesized in the solid-phase synthesis in a similar way as the nucleoside phosphoramidites. The synthesis can be performed in an automated and standardized manner using a conventional RNA synthesizer. The synthesis of the lipophilic molecule with a phosphoramidite group can include phosphoramiditization of the free hydroxyl group to generate the phosphoramidite group. In general, the oligonucleotides can be synthesized using protocols known in the art, e.g., as described in patent document WO2021092371A2

[0478] 、

[0479] The content mentioned in the paragraph is incorporated herein by reference in its entirety. Pharmaceutical compositions In one aspect, the present application provides a pharmaceutical composition containing the oligonucleotide conjugate as described above as an active ingredient and a pharmaceutically acceptable carrier. The pharmaceutically acceptable carrier can be one or more of the carriers conventionally used in the field of administration of double-stranded oligonucleotides, such as, but not limited to, magnetic nanoparticles (e.g., nanoparticles based on Fe3O4 or Fe2O3), carbon nanotubes, mesoporous silicon, calcium phosphate nanoparticles, polyethylenimine (PEI), polyamidoamine (PAMAM) dendrimer, poly(L-lysine) (PLL), chitosan, 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP), poly(D&L-lactic / glycolic acid) copolymer (PLGA), poly(2-aminoethyl ethylene phosphate) (PPEEA), and poly(2-dimethylaminoethyl methacrylate) (PDMAEMA), and derivatives thereof. In some embodiments, the functional double-stranded oligonucleotide and the pharmaceutically acceptable carrier are not particularly required in the pharmaceutical composition, and in some embodiments, the weight ratio of the functional double-stranded oligonucleotide to the pharmaceutically acceptable carrier can be 1: (1-500), and in some embodiments, the weight ratio is 1: (1-50). In some embodiments, the pharmaceutical composition can further include a pharmaceutically acceptable additional excipient, which can be one or more of various preparations or compounds conventionally used in the art. For example, the pharmaceutically acceptable additional excipient can include at least one of a pH buffer, a protective agent, and an osmotic pressure adjusting agent. The pH buffer can be a tris-hydroxymethyl aminomethane hydrochloride buffer having a pH of 7.5-8.5 and / or a phosphate buffer having a pH of 5.5-8.5, for example, a phosphate buffer having a pH of 5.5-8.5. The protective agent can be at least one of myo-inositol, sorbitol, sucrose, trehalose, mannose, maltose, lactose, and glucose. The content of the protective agent can be 0.01-30% by weight, based on the total weight of the pharmaceutical composition. The osmotic pressure adjusting agent can be, for example, sodium chloride and / or potassium chloride. The osmotic pressure adjusting agent can be present in an amount such that the osmotic pressure of the pharmaceutical composition is 200-700 milliosmoles per kilogram (mOsm / kg). The amount of the osmotic pressure adjusting agent can be readily determined by one skilled in the art depending on the desired osmotic pressure. In some embodiments, the dosage of the pharmaceutical composition as formulated can be adjusted depending on the mode of administration. In some embodiments, the pharmaceutical composition can be a liquid formulation, such as an injection solution, or a lyophilized powder that is reconstituted with a liquid vehicle to form a liquid formulation. The liquid formulation can be, but is not limited to, used for subcutaneous, intramuscular, intracerebroventricular, or intrathecal injection. The pharmaceutical composition can also be, but is not limited to, delivered via eye drops, nasal administration, oropharyngeal inhalation, spray, etc. In some embodiments, the pharmaceutical composition is delivered via intrathecal injection. In some embodiments, the intrathecal injection of the pharmaceutical composition into the spinal fluid can be performed as a bolus injection or via a mini-pump that can be implanted under the skin to provide regular and constant delivery of the siRNA into the spinal fluid. In some embodiments, the intrathecal administration is via an osmotic pump implanted surgically. In some embodiments, the osmotic pump is implanted in the subarachnoid space of the spinal canal to facilitate intrathecal administration. Further details of such intrathecal delivery systems can be found in PCT / US2015 / 013253, filed January 28, 2015, the entire contents of which are incorporated herein by reference. Methods of treatment and routes of delivery Another aspect of the present application relates to a method of reducing expression of a target gene in a cell, comprising contacting the cell with a double- stranded oligonucleotide conjugate of the present application. Another aspect of the present application relates to a method of reducing expression of a target gene in a subject, comprising administering to the subject a double- stranded oligonucleotide conjugate of the present application. Another aspect of the present application relates to a method of treating a subject having a CNS disorder, comprising administering to the subject a therapeutically effective amount of a double- stranded oligonucleotide conjugate of the present application, thereby treating the subject. Exemplary CNS disorders that can be treated by the methods of the present application include Alzheimer's disease, frontotemporal dementia, Parkinson dementia, Lewy body dementia, multiple system atrophy, amyotrophic lateral sclerosis, Parkinson's disease, Angelman syndrome, Alexander disease, brain stroke, brain tumor. The double- stranded oligonucleotide conjugates of the present application can be delivered to a subject by a variety of routes, depending on the type of gene targeted and the type of disorder to be treated. In some embodiments, the double- stranded oligonucleotide conjugate is administered ocularly (e.g., intravitreally), intrathecally, or intracerebroventricularly. In some embodiments, exemplary target genes are APP, ATXN2, C9orf72, TARDBP, MAPT (Tau), HTT, SNCA, FUS, ATXN3, ATXN1, ATXN7, ATXN8, MeCP2, PRNP, SOD1, DMPK, MGMT, and TTR. In some embodiments, the target genes are SOD1 and MGMT. The oligonucleotide conjugates of the present application can be incorporated into a pharmaceutical composition suitable for administration. Such compositions typically include one or more oligonucleotide conjugates and a pharmaceutically acceptable carrier. As used herein, the language "pharmaceutically acceptable carrier" is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, its use in the compositions is contemplated. Supplementary active compounds can also be incorporated into the compositions. The pharmaceutical compositions of the present application can be administered in a number of ways depending upon whether local or systemic treatment is desired and upon the area to be treated. Administration can be topical (including ophthalmic, vaginal, rectal, intranasal, transdermal), oral or parenteral. Parenteral administration includes intravenous, subcutaneous, intraperitoneal or intramuscular injection, or intrathecal or intraventricular administration. The route and site of administration can be chosen to enhance targeting. For example, to target muscle cells, intramuscular injection into the muscle of interest would be a logical choice. Lung cells can be targeted by administering the oligonucleotide conjugate in aerosol form. Vascular endothelial cells can be targeted by coating a balloon catheter with the oligonucleotide conjugate and mechanically introducing the DNA. Formulations for topical administration can include transdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders. Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like can be necessary or desirable. Coated condoms, catheters, and bandages can also be useful. Compositions for oral administration include powders or tablets, suspensions or solutions in water, syrup, elixir or non-aqueous media, capsules, capsules, lozenges or troches. In the case of tablets, carriers which can be used include lactose, sodium citrate, and dicalcium phosphate. Various disintegrating agents can also be used such as starch and lubricants such as magnesium stearate, sodium stearyl fumarate, and talc. For oral administration in a capsule form, useful diluents can be lactose and high molecular weight polyethylene glycols. When aqueous suspensions are required for oral use, the nucleic acid compositions can be combined with emulsifying and suspending agents. If desired, certain sweetening and / or flavoring agents can be added. Compositions for intrathecal or intraventricular administration can include sterile aqueous solutions, which can also contain buffers, diluents, and other suitable additives. Formulations for parenteral administration can include sterile aqueous solutions, which can also contain buffers, diluents, and other suitable additives. Intraventricular injection can be facilitated by, for example, an intraventricular catheter attached to a reservoir. For intravenous use, the total concentration of solutes can be controlled so as to make the preparation isotonic. For ophthalmic administration, ointments or instillable liquids can be delivered by ocular delivery systems known in the art, such as applicators or eye droppers. Such compositions can include mucous simulators such as hyaluronic acid, chondroitin sulfate, hydroxypropyl methylcellulose, or poly(vinyl alcohol), preservatives such as sorbic acid, EDTA, or benzyl ammonium chloride, and usual amounts of diluents and / or carriers. In one embodiment, administration of the oligonucleotide conjugate, composition is parenteral, e.g., intravenous (e.g., in the form of a bolus or infusible fluid), intradermal, intraperitoneal, intramuscular, intrathecal, intraventricular, intracranial, subcutaneous, transmucosal, buccal, sublingual, endoscopic, rectal, oral, vaginal, topical, transpulmonary, intranasal, urethral, or ocular. Administration can be provided by the subject or another person (e.g., a medical service provider). The drug can be provided in measured doses or in a dispenser (which delivers metered doses). The term "therapeutically effective amount" is the amount of a drug present in a composition to provide a desired level in a subject to be treated to give the intended physiological response. The term "physiologically effective amount" is the amount delivered to a subject to give a desired alleviating or curative effect. Use of the oligonucleotide conjugates, pharmaceutical compositions of the application In another aspect, the application provides the use of an oligonucleotide conjugate of the application, and / or a pharmaceutical composition in the manufacture of a medicament for inhibiting target mRNA expression of a target gene expression in a cell. In some embodiments, the application provides double-stranded oligonucleotides targeting APP for early-onset familial Alzheimer's disease, ATXN2 for SCA2 (Spinocerebellar ataxia 2) and ALS, and C9orf72 for amyotrophic lateral sclerosis and frontotemporal dementia. In some embodiments, the application provides double-stranded oligonucleotides targeting TARDBP for ALS, MAPT (Tau) for frontotemporal dementia, and HTT for Huntington's disease. In some embodiments, the present application provides double-stranded oligonucleotides targeting SNCA for Parkinson's disease, FUS for ALS, ATXN3 for SCA3, ATXN1 for SCA1, ATXN7 for SCA7, ATXN8 for SCA8, ATN1 for DRPLA, MeCP2 for XLMR, PRNP for Creutzfeldt-Jakob disease, a recessive CNS disorder: Lafora disease, SOD1 for ALS, DMPK for DM1 (CNS and skeletal muscle), TTR for hATTR (CNS, eye and systemic), and MGMT for glioma. By administering the oligonucleotide conjugates and / or pharmaceutical compositions provided by the present disclosure to a subject in need thereof, the goal of preventing and / or treating a pathological condition or disease caused by the expression of a specific gene of a cell can be achieved through the mechanism of modulating gene expression. Thus, the oligonucleotide compositions and / or pharmaceutical compositions provided by the present disclosure can be used for preventing and / or treating the pathological condition or disease, or for preparing a medicament for preventing and / or treating the pathological condition or disease described herein. The term "administering / administration" as used herein refers to the placement of the oligonucleotide conjugates and / or pharmaceutical compositions into the subject's body by a method or route which results in at least partial localization of the oligonucleotide conjugates and / or pharmaceutical compositions at the desired site to produce the desired effect. Suitable routes of administration for the methods of the present disclosure include local and systemic administration. In general, local administration results in delivery of more of the oligonucleotide conjugates and / or pharmaceutical compositions to a particular site as compared to the entire body of the subject; while systemic administration results in delivery of the oligonucleotide conjugates and / or pharmaceutical compositions to substantially the entire body of the subject. The subject can be administered by any suitable route known in the art, including but not limited to oral or parenteral routes, such as intravenous administration, intramuscular administration, subcutaneous administration, transdermal administration, airway administration (aerosol), intracerebroventricular administration, intrathecal administration, nasal administration, rectal administration, and topical administration (including buccal administration and sublingual administration), intravitreal injection, ocular drop. The frequency of administration can be one or more times per day, per week, per two weeks, per three weeks, per month, per 2 months, per 3 months, per half year, or per year. The dosage of the oligonucleotide conjugates and / or pharmaceutical compositions described in the present disclosure can be a conventional dosage in the art, which can be determined according to various parameters, especially the age, weight, and gender of the subject. Toxicity and therapeutic efficacy of the oligonucleotide conjugates and / or pharmaceutical compositions described in the present disclosure can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD50 (the lethal dose for 50% of the population) and the ED50 (the dose for 50% of the population to exhibit a maximum response) in a dose-response curve. The data obtained from cell culture assays and animal studies can be used to formulate a range of dosage for human use. The amount of functional double-stranded oligonucleotide in the provided oligonucleotide conjugate and / or pharmaceutical composition to be used in the methods provided herein to inhibit expression of a particular gene in a cell is readily determined by one of skill in the art based on the desired effect to be achieved. For example, in some embodiments, the amount of functional double-stranded oligonucleotide in the provided oligonucleotide conjugate is an amount sufficient to reduce expression of the target gene and result in an extracellular concentration of 1 pM to 1 μΜ, or 0.01 nM to 100 nM, or 0.05 nM to 50 nM, or to about 5 nM at the surface of the target cell. The amount required to achieve this local concentration will vary depending on various factors, including the method of delivery, the site of delivery, the number of cell layers between the site of delivery and the target cell or tissue, whether the delivery is local or systemic, etc. The concentration at the site of delivery can be significantly higher than the concentration at the surface of the target cell or tissue. Kits The present application provides a kit comprising an effective amount of the oligonucleotide conjugate and / or pharmaceutical composition provided herein. In some embodiments, the kits described herein can provide the oligonucleotide conjugate and / or pharmaceutical composition in one container. In some embodiments, the kits described herein can comprise a container providing a pharmaceutically acceptable excipient. In some embodiments, the kits can further comprise other ingredients, such as stabilizers or preservatives, etc. In some embodiments, the kits described herein can comprise at least one other therapeutic agent in a container different from the container providing the oligonucleotide conjugate and / or pharmaceutical composition described herein. In some embodiments, the kits can comprise instructions for mixing the oligonucleotide conjugate and / or pharmaceutical composition with a pharmaceutically acceptable carrier and / or excipient or other ingredients, if any. In the kits of the present application, the oligonucleotide conjugate and pharmaceutically acceptable carrier and / or excipient, and the pharmaceutical composition and / or pharmaceutically acceptable carrier and / or excipient can be provided in any form, such as liquid form, dry form, and / or lyophilized form. In some embodiments, the oligonucleotide conjugate and pharmaceutically acceptable carrier and / or excipient, and the pharmaceutical composition and / or optional pharmaceutically acceptable excipient are substantially pure and / or sterile. In some embodiments, sterile water can be provided in the kits of the present application. The present application will be further described by way of Examples below, but the present application is not intended to be limited by any of the following Examples. Examples Unless otherwise indicated, the reagents used in the following examples are commercially available. Experimental purpose: synthesis of 2'Ome (2' O-methyl RNA), 2'F (2' fluorinated RNA), partially thio-modified siRNA sequences, and conjugation of polypeptides and nucleic acids according to requirements. Quality requirements: HPLC purity > 90.0%, MS measured molecular weight is correct. The reaction conditions in the following examples are carried out at room temperature and normal pressure, unless otherwise specified. Experimental principle: The siRNA sequence is a chemically synthesized oligonucleotide double strand, which is synthesized by a solid-phase synthesizer through multiple steps of solid-phase synthesis of siRNA containing a solid-phase carrier and a protecting group, and finally deprotection by ammonolysis and purification. Experimental procedure: Oligonucleotide sequences are synthesized using phosphoramidite technology in solid-phase synthesis. Depending on the scale, an oligo 48 nucleic acid synthesizer is used. The synthesis is carried out on a solid support made of controllable pore size glass (CPG carrier). All modified phosphoramidite monomers are purchased from Shanghai Zhiwei Technology Development Co., Ltd. All phosphoramidite monomers can be removed under alkaline conditions. All phosphoramidite monomers are dissolved in anhydrous acetonitrile (100 mM) and dried with molecular sieves. A 5-ethylmercapto tetrazole (0.6 M) acetonitrile solution is used as an activator solution. The coupling time is 200 seconds (2'OMe and 2'F). In order to introduce the phosphorothioate bond, a 0.2 M hydrogenated xanthate pyridine solution (obtained from Cole-Em) is used. For unreacted active groups, a mixture of acetic anhydride, N-methyl imidazole, pyridine and acetonitrile (N-methyl imidazole / acetonitrile is 1:4; acetic anhydride / pyridine / acetonitrile is 2:3:5) is used as a capping reagent. Lysis and deprotection of solid support-bound oligomers. After solid-phase synthesis is complete, the dried solid support is treated with an ammonia solution at 55°C for 16 hours, the solution is evaporated and the solid residue is redissolved in water. siRNA molecular weight detection method: 1. Turn on, select wavelength: select ultraviolet spectrophotometer (Shimadzu UV-1800 ultraviolet spectrophotometer), before turning on, first check if there are obstacles in the light path, then turn on the power switch and preheat for about 20 minutes, and adjust the wavelength to 260 nm; 2. Zero adjustment: the nucleic acid to be tested is an aqueous solution, select water as the blank control for zero adjustment; 3. Sample determination: dilute the sample to be tested appropriately, use the quartz colorimetric cup matched with the instrument, and determine under the condition of water as the control. Preparation Example 1: Synthesis of oligonucleotide conjugate 1 The route is as follows: (1.1) Preparation of a compound of formula (102) DMSO, 10 eq, 18.88 mg) was added to the compound shown as formula (101) (40 mg, 2400 μΐ^DMSO dissolved), then 220 μΐ^triethylamine was added and mixed by vortex, and the reaction was carried out at 25°C for 10 min. After detection, the compound shown as formula (102) was obtained by rapid precipitation and purification. The compound shown as formula (102) was characterized by MS, and the measured molecular weight was 6765.7, and the theoretical molecular weight was 6763.42. The measured value was consistent with the theoretical value, indicating that the synthesized compound was the target compound. (1.2) Preparation of the compound shown as formula (103) The polypeptide (CHRPYIAH) (10 eq, 15 mg) was dissolved in 1000 μΐ^DMSO, and then added to the compound shown as formula (102) (20 mg, 250 μΐ^PBS dissolved). After ultrasonic and vortex mixing until completely dissolved, the reaction was carried out at 25°C for 15 h, and then purified to obtain 6.7 mg of the compound shown as formula (103). The compound shown as formula (103) was characterized by MS, and the measured molecular weight was 7762.5, and the theoretical molecular weight was 7759.56. The measured value was consistent with the theoretical value, indicating that the synthesized compound was the target compound. (1.3) Preparation of the compound shown as formula (105) The compound shown as formula (104) (the measured molecular weight was 7173.8, and the theoretical molecular weight was 7172.76) was mixed with 3.5 mg of the compound shown as formula (103) in enzyme-free water, and placed in a thermal mixer at 70°C, heated to 90°C, kept at 90°C for 5 min, and slowly cooled to room temperature, and annealed to obtain 7.4 mg of the compound shown as formula (105). The compound shown as formula (104) can be obtained by conventional solid-phase synthesis. The target product shown as formula (105) was prepared and verified by HPLC detection. The sequence of the siRNA in Preparation Example 1 is shown in Table 1. Preparation Example 2: The synthesis route of the oligonucleotide conjugate 2 is as follows: (2.1) Preparation of the compound shown as formula (202) DMSO, 20 eq, 37.76 mg) was dissolved in 2000 μΐ^DMSO, and then 220 μΐ^triethylamine was added and mixed by vortex. After reaction at 25 °C for 10 min, the product was detected. After the product was confirmed, it was quickly precipitated and purified to obtain 20 mg of the compound represented by formula (202). The compound represented by formula (202) was characterized by MS, and the measured molecular weight was 6968.9, and the theoretical molecular weight was 6966.98. The measured value was consistent with the theoretical value, indicating that the synthesized product was the target compound. (2.2) Preparation of the compound represented by formula (203) The polypeptide (CHRPYIAH) (20 eq, 30 mg) was dissolved in 1000 μΐ^DMSO, and then added to the compound represented by formula (202) (20 mg, 250 μΐ^PBS) and mixed by ultrasonic and vortex until completely dissolved. After reaction at 25 °C for 15 h, the product was purified to obtain 7.1 mg of the compound represented by formula (203). The compound represented by formula (203) was characterized by MS, and the measured molecular weight was 8961.0, and the theoretical molecular weight was 8959.28. The measured value was consistent with the theoretical value, indicating that the synthesized product was the target compound. (2.3) Preparation of the compound represented by formula (205) The compound represented by formula (204) (the measured molecular weight was 7173.7, and the theoretical molecular weight was 7172.76) was mixed with 4.1 mg of the compound represented by formula (203) in enzyme-free water, and placed in a thermal mixer at 70 °C, heated to 90 °C, kept at 90 °C for 5 min, and slowly cooled to room temperature, and annealed to obtain 8 mg of the compound represented by formula (205). The compound represented by formula (204) can be obtained by conventional solid-phase synthesis. The target product represented by formula (205) was prepared and verified by HPLC. The sequences of the siRNAs in Preparation Example 2 are shown in Table 1. Preparation Example 3: Synthesis of oligonucleotide conjugate 3: Oligonucleotide conjugate 3 was prepared by a method similar to that of Preparation Example 1. (3.1) Preparation of the compound represented by formula (302) DMSO, 10 eq, 18.88 mg) was added to the compound shown as formula (301) (40 mg, 2400 μΐ^DMSO dissolved), then 220 μΐ^triethylamine was added and mixed by vortex, and the reaction was carried out at 25°C for 10 min. After detection, the compound shown as formula (302) was obtained by rapid precipitation and purification. The compound shown as formula (302) was characterized by MS, and the measured molecular weight was 7086.5, and the theoretical molecular weight was 7083.62. The measured value was consistent with the theoretical value, indicating that the synthesized compound was the target compound. (3.2) Preparation of the compound shown as formula (303) The polypeptide (CHRPYIAH) (10 eq, 15 mg) was dissolved in 1000 μΐ^DMSO, and then added to the compound shown as formula (302) (20 mg, 250 μΐ^PBS dissolved). After ultrasonic and vortex mixing until completely dissolved, the reaction was carried out at 25°C for 15 h, and then purified to obtain 6.5 mg of siRNA-SS. The siRNA-SS was characterized by MS, and the measured molecular weight was 8083.0, and the theoretical molecular weight was 8079.76. The measured value was consistent with the theoretical value, indicating that the synthesized compound was the target compound. (3.3) Preparation of the compound shown as formula (305) The compound shown as formula (304) (the measured molecular weight was 7173.8, and the theoretical molecular weight was 7172.76) was mixed with 6.2 mg of the compound shown as formula (303) in enzyme-free water, and placed in a thermal mixer at 70°C, heated to 90°C, kept at 90°C for 5 min, and slowly cooled to room temperature. Annealing obtained 12.7 mg of the compound shown as formula (305). The compound shown as formula (304) can be obtained by conventional solid phase synthesis. The target product compound shown as formula (305) was prepared and verified by HPLC detection. The sequence of siRNA in Preparation Example 3 is shown in Table 1. Preparation Example 4: Synthesis of oligonucleotide conjugate 4: Oligonucleotide conjugate 4 was prepared by a method similar to the preparation of Preparation Examples 1 and 2. (4.1) Preparation of the compound shown as formula (402) DMSO, 20 eq, 37.76 mg) and 220 μΐ^of triethylamine was added and mixed by vortex. After 10 min of reaction at 25 °C, the mixture was tested. After no error was found, the mixture was quickly precipitated and purified to obtain 21 mg of the compound of formula (402). The compound of formula (402) was characterized by MS, and the measured molecular weight was 7180.5, and the theoretical molecular weight was 7177.44. The measured value was consistent with the theoretical value, indicating that the synthesized compound was the target compound. (4.2) Preparation of the compound of formula (403) The polypeptide (CHRPYIAH) (20 eq, 30 mg) was dissolved in 1000 μΐ^of DMSO and added to the compound of formula (402) (20 mg, 250 μΐ^of PBS) and then mixed by ultrasonic and vortex until completely dissolved. After 15 h of reaction at 25 °C, the mixture was purified to obtain 7.5 mg of the compound of formula (403). The compound of formula (403) was characterized by MS, and the measured molecular weight was 9172.7, and the theoretical molecular weight was 9169.72. The measured value was consistent with the theoretical value, indicating that the synthesized compound was the target compound. (4.3) Preparation of the compound of formula (405) The compound of formula (404) (the measured molecular weight was 7173.8, and the theoretical molecular weight was 7172.76) was mixed with 7.5 mg of the compound of formula (403) in enzyme-free water, and placed in a thermal mixer at 70 °C, heated to 90 °C, kept at 90 °C for 5 min, and slowly cooled to room temperature, and annealed to obtain 14.6 mg of the compound of formula (405). The compound of formula (404) can be obtained by conventional solid-phase synthesis. The target product, the compound of formula (405), was prepared and verified by HPLC. The sequences of the siRNAs in Preparation Example 4 are shown in Table 1. Preparation Example 5: Synthesis of oligonucleotide conjugate 5: Oligonucleotide conjugate 5 was prepared by a method similar to that of Preparation Example 1. (5.1) Preparation of the compound of formula (502) DMSO, 10 eq, 18.88 mg) and 220 μΐ^of triethylamine was added and mixed by vortex. After 10 min of reaction at 25 °C, the mixture was tested. After no error was found, the mixture was quickly precipitated and purified to obtain 23 mg of the compound of formula (502). The compound of formula (502) was characterized by MS, and the measured molecular weight was 6766.3, and the theoretical molecular weight was 6763.48. The measured value was consistent with the theoretical value, indicating that the synthesized compound was the target compound. (5.2) Preparation of the compound of formula (503) The polypeptide (CHRPYIAH) (10 eq, 15 mg) was dissolved in 1000 μΐ^of DMSO and added to the compound of formula (502) (20 mg, 250 μΐ^of PBS solution). The mixture was then ultrasonically and vortexed until completely dissolved. After 15 h of reaction at 25 °C, the mixture was purified to obtain 7.9 mg of the compound of formula (503). The compound of formula (503) was characterized by MS, and the measured molecular weight was 7762.8, and the theoretical molecular weight was 7759.62. The measured value was consistent with the theoretical value, indicating that the synthesized compound was the target compound. (5.3) Preparation of the compound of formula (505) The compound of formula (504) (the measured molecular weight was 7173.8, and the theoretical molecular weight was 7172.76) was mixed with 7.9 mg of the compound of formula (503) in enzyme-free water, and placed in a thermal mixer at 70 °C, heated to 90 °C, kept at 90 °C for 5 min, and slowly cooled to room temperature. Annealing obtained 16.5 mg of the compound of formula (505). The compound of formula (504) can be obtained by conventional solid-phase synthesis. The target product, the compound of formula (505), was prepared and verified by HPLC. The sequences of the siRNAs in Preparation Example 5 are shown in Table 1. Preparation Example 6: Synthesis of oligonucleotide conjugate 6: Oligonucleotide conjugate 6 was prepared by a method similar to that of Preparation Example 1. (6.1) Preparation of the compound of formula (602) DMSO, 10 eq, 18.88 mg) was added to the compound shown as formula (601) (40 mg, 2400 μΐ^DMSO dissolved), then 220 μΐ^triethylamine was added and mixed by vortex, and the reaction was detected after 10 min at 25 °C. After no error was found, rapid precipitation was carried out for purification, and 21 mg of the compound shown as formula (602) was obtained. The compound shown as formula (602) was characterized by MS, and the measured molecular weight was 6766.1, and the theoretical molecular weight was 6763.48. The measured value was consistent with the theoretical value, indicating that the synthesized compound was the target compound. (6.2) Preparation of the compound of formula (603) The polypeptide (CHRPYIAH) (10 eq, 15 mg) was dissolved in 1000 μΐ^DMSO, and was added to the compound shown as formula (602) (20 mg, 250 μΐ^PBS dissolved), then was mixed by ultrasonic and vortex until completely dissolved, and the reaction was carried out at 25 °C for 15 h, and then purified to obtain 6.8 mg of the compound shown as formula (603). The compound shown as formula (603) was characterized by MS, and the measured molecular weight was 7763.1, and the theoretical molecular weight was 7759.62. The measured value was consistent with the theoretical value, indicating that the synthesized compound was the target compound. (6.3) Preparation of the compound of formula (605) The compound shown as formula (604) (the measured molecular weight was 7173.8, and the theoretical molecular weight was 7172.76) was mixed with 6.4 mg of the compound shown as formula (603) in enzyme-free water, and was placed in a thermal mixer at 70 °C, heated to 90 °C, kept at 90 °C for 5 min, and slowly cooled to room temperature, and annealed to obtain 13.4 mg of the compound shown as formula (605). The compound shown as formula (604) can be obtained by conventional solid-phase synthesis. The target product, the compound of formula (605), was prepared and verified by HPLC detection. The sequences of the siRNAs in Preparation Example 6 are shown in Table 1. Preparation Example 7: Synthesis of oligonucleotide conjugate 7: Oligonucleotide conjugate 7 was prepared by a preparation method similar to that of Preparation Example 1. (7.1) Preparation of the compound of formula (702) DMSO, 10 eq, 18.88 mg) was added to the compound shown as formula (701) (254 mg, 2400 μΐ^DMSO dissolved), then 220 μΐ^triethylamine was added and mixed by vortex, and the reaction was detected after 10 min at 25 °C. After no error was found, rapid precipitation was carried out for purification, and 213 mg of the compound shown as formula (702) was obtained. The compound shown as formula (702) was characterized by MS, and the measured molecular weight was 6980.4, and the theoretical molecular weight was 6978.53. The measured value was consistent with the theoretical value, indicating that the synthesized compound was the target compound. Preparation of the compound shown as formula (703) The polypeptide (CHRPYIAH) (10 eq, 15 mg) was dissolved in 1000 μΐ^DMSO, and was added to the compound shown as formula (702) (120 mg, 250 μΐ^PBS dissolved), and then was mixed by ultrasonic and vortex until completely dissolved. The reaction was purified after 15 h at 25 °C, and 79 mg of the compound shown as formula (703) was obtained. The compound shown as formula (703) was characterized by MS, and the measured molecular weight was 7978.0, and the theoretical molecular weight was 7974.67. The measured value was consistent with the theoretical value, indicating that the synthesized compound was the target compound. Preparation of the compound shown as formula (705) The compound shown as formula (704) (measured molecular weight: 6911.9, theoretical molecular weight: 6910.72) 55.3 mg was mixed with the compound shown as formula (703) 63.8 mg in enzyme-free water, and was placed in a thermal mixer at 70 °C, heated to 90 °C, kept at 90 °C for 5 min, and slowly cooled to room temperature, and annealing obtained 127.4 mg of the compound shown as formula (705). The compound shown as formula (704) can be obtained by conventional solid-phase synthesis. The compound shown as formula (705) was verified by HPLC detection. The sequence of the siRNA in Preparation Example 7 is shown in Table 1. Preparation Example 8: Synthesis of oligonucleotide conjugate 8: Oligonucleotide conjugate 8 was prepared by a method similar to the preparation method of Preparation Examples 1 and 2. (8.1) Preparation of the compound shown as formula (802) ​​​Dissolve 4-(N-maleimido methyl) cyclohexane-1-carboxylic acid succinimidyl ester (SMCC, 20 eq, 37.76 mg) in 2000 μΐ^DMSO, add to the compound of formula (801) (413 mg, 2400 μΐ^DMSO dissolved), then add 220 μΐ^triethylamine, mix well with vortex, and test after reaction at 25 °C for 10 min. After no error is found, quickly precipitate and purify to obtain 218 mg of the compound of formula (802). The compound of formula (802) is characterized by MS, the measured molecular weight is 7185.7, and the theoretical molecular weight is 7182.09. The measured value is consistent with the theoretical value, indicating that the synthesized compound is the target compound. (8.2) Preparation of the compound of formula (803) Dissolve the polypeptide (CHRPYIAH) (20 eq, 30 mg) in 1000 μΐ^DMSO, add to the compound of formula (802) (165 mg, 250 μΐ^PBS dissolved), then mix well with ultrasonic and vortex, and purify after reaction at 25 °C for 15 h to obtain 80 mg of the compound of formula (803). The compound of formula (803) is characterized by MS, the measured molecular weight is 9178.1, and the theoretical molecular weight is 9174.37. The measured value is consistent with the theoretical value, indicating that the synthesized compound is the target compound. (8.3) Preparation of the compound of formula (805) Mix 51.6 mg of the compound of formula (804) (the measured molecular weight is 6911.9, and the theoretical molecular weight is 6910.72) with 68.6 mg of the compound of formula (803) in enzyme-free water, place in a hot mixer at 70 °C, heat to 90 °C, keep at 90 °C for 5 min, and slowly cool to room temperature to obtain 129.8 mg of the compound of formula (805). The compound of formula (804) can be obtained by conventional solid-phase synthesis. Verify the preparation to obtain the target compound of formula (805) by HPLC detection. The sequences of the siRNAs in Preparation Example 8 are shown in Table 1. Reference Preparation Example: Prepare reference conjugate 1, reference conjugate 2, and reference conjugate 3 in a manner similar to the preparation method of Preparation Example 1. The MS of the products at each stage in the preparation process is as follows. Reference Conjugate 1 The measured molecular weight MS of siRNA-SS (sense strand) is 6350.4, and the theoretical molecular weight is 6351.42. The measured molecular weight of siRNA-AS (antisense strand) is 7173.7, and the theoretical molecular weight is 7172.76. The siRNA was prepared and verified by HPLC. The sequence of siRNA in reference conjugate 1 is shown in Table 1. Reference conjugate 2 (20.1) Preparation of compound of formula (2002) The compound of formula (2002) was prepared by dissolving 4-(N-maleimide methyl) cyclohexane-1-carboxylic acid succinimide ester (SMCC, 10 eq, 18.88 mg) in 2000 μΐ^DMSO, adding to the compound of formula (2001) (40 mg, 2400 μΐ^DMSO dissolved), followed by 220 μΐ^triethylamine, vortexing, and testing after 10 min at 25 °C. After verification, the compound was quickly precipitated and purified to obtain 27 mg of the compound of formula (2002). The compound of formula (2002) was characterized by MS, with an observed molecular weight of 6554.6 and a theoretical molecular weight of 6553.6. The observed value was consistent with the theoretical value, indicating that the synthesized compound was the target compound. (20.2) Preparation of compound of formula (2003) The compound of formula (2003) was prepared by dissolving the polypeptide (CHRPYIAH) (10 eq, 15 mg) in 1000 μΐ^DMSO, adding to the compound of formula (2002) (20 mg, 250 μΐ^PBS dissolved), followed by ultrasonicating and vortexing until completely dissolved, and purifying after 15 h at 25 °C to obtain 9 mg of the compound of formula (2003). The compound of formula (2003) was characterized by MS, with an observed molecular weight of 7550.8 and a theoretical molecular weight of 7549.16. The observed value was consistent with the theoretical value, indicating that the synthesized compound was the target compound. (20.3) Preparation of compound of formula (2005) The compound of formula (2005) was prepared by mixing 5.6 mg of the compound of formula (2004) (observed molecular weight: 7173.7, theoretical molecular weight: 7172.76) with 5.9 mg of the compound of formula (2003) in enzyme-free water, placing in a thermal mixer at 70 °C, heating to 90 °C, maintaining at 90 °C for 5 min, and slowly cooling to room temperature to obtain 12.5 mg of the compound of formula (2005). The compound of formula (2004) can be obtained by conventional solid-phase synthesis. The target product, the compound of formula (2005), was prepared and verified by HPLC. The sequence of siRNA in reference conjugate 2 is shown in Table 1. Reference conjugate 3 The observed molecular weight of siRNA-SS (sense strand) was 6566.0, and the theoretical molecular weight was 6564.63. The observed molecular weight of siRNA-AS (antisense strand) was 6911.9, and the theoretical molecular weight was 6910.72. The siRNA was verified by HPLC detection after preparation. The sequence of siRNA in reference conjugate 3 is shown in Table 1. Reference conjugate 4 The actual molecular weight MS of siRNA-SS (sense strand) was 8963.0, and the theoretical molecular weight was 8959.26. The actual molecular weight of siRNA-AS (antisense strand) was 7173.6, and the theoretical molecular weight was 7172.76. The siRNA was verified by HPLC detection after preparation. The sequence of siRNA in reference conjugate 4 is shown in Table 1. Table 1 Sequence information of conjugates Wherein, SS represents the sense strand, AS represents the antisense strand, UHD represents 2'-O-hexadecyluridine, AHD represents 2'-O-hexadecyl-adenosine, DRI-T8 represents the peptide chain: CHRPYIAH (i.e., Cys-His-Arg-Pro-Tyr-Ile-Ala-His), T8 represents the peptide chain: HAIYPRHC, the lowercase letter s represents that the two nucleotides adjacent to the left and right of s are connected by a phosphorothioate group or the nucleotides are connected to the peptide chain DRI-T8 by a phosphorothioate group, m represents that one nucleotide adjacent to the left of the mark m is a 2'-methoxy nucleotide, f represents that one nucleotide adjacent to the left of the mark f is a 2'-fluoro nucleotide, and VP represents that one nucleotide adjacent to the right of it is an (E)-vinyl phosphate modified nucleotide. Experimental Example 1 Activity of the oligonucleotide conjugate of the present disclosure in mice Activity test example: test the KD activity of the oligonucleotide conjugate of the present disclosure in the CNS of ICR mice In this experiment, intracerebroventricular injection (ICV, 200 μg per mouse, single administration) was used to detect the SOD1 inhibition effect of each brain region tissue in the CNS 7 days after the last administration to evaluate the delivery activity of the conjugate carrier molecule. Purpose of the experiment The KD activity of the oligonucleotide conjugate 1 prepared in Preparation Example 1 of the present disclosure in the CNS of ICR mice was evaluated. Experimental method Instrument equipment: High-throughput cryogenic grinder, ultramicro spectrophotometer, micro high-speed centrifuge, PCR instrument, brain stereotaxic instrument, qPCR instrument were mainly used. Reagent consumables: Lysis solution, DEPC water, universal RT-PCR kit, real-time fluorescent quantitative PCR kit were purchased from Solabio. Test article / control article preparation and analysis A 2 mg pack of test article reference conjugate 1 stored at -20°C was centrifuged at 5000 rpm, RT, 30 s, then 100 μL of physiological saline (pre-filtered with a sterile filter) was added, then the sample was vortexed after simple centrifugation, and then transferred to a 1.5 mL centrifuge tube, labeled and stored at -20°C until use. Both oligonucleotide conjugate 1 and oligonucleotide conjugate 2 were prepared according to the above method. Experimental animals Species and strain: ICR mice Gender: male Body weight: 26 g Source of animals: Sibeifu (Beijing) Biotechnology Co., Ltd. Housing conditions The animals were housed in a barrier environment of SPF level, with an independent air supply system, 5 animals per cage, and the air exchange rate was not less than 15 times per hour. The animal information card in each cage indicated the project number, animal group, and animal number. The animals were identified by ear tagging. The animals could eat and drink freely, and the feed and water were replaced at least twice a week. Temperature: 20-26°C; relative humidity: 40%-70%; light cycle: 12 hours of light, 12 hours of darkness (lights on at 7:00 am, lights off at 7:00 pm) Daily monitoring of experimental animals From the time the animals arrived at the facility, the experimenters conducted daily cage-side observations, and the health status and body weight of the animals were monitored at least once a week. Experimental grouping and dosing Nineteen ICR mice were divided into 3 groups, 5 in the blank group, and 7 in each of the other 2 groups. The mice were anesthetized with 10% chloral hydrate (400 mg / kg), fixed on a brain stereotaxic instrument, the scalp was cut to expose the skull, the periosteal tissue was removed with a cotton swab, a hole was drilled at AP: -0.58 mm, ML: -1.25 mm with a micro drill, and a microsyringe and an automatic dosing system were used for dosing. The needle depth was DV: -2.2 mm. The day of dosing was designated as D1, and the specific grouping is shown in the following table: Table 2: Experimental animal grouping and dosing Experimental endpoints and sample processing Seven days after the last dosing, the mice were sacrificed by the dislocation of the spine, and then the cortex, hippocampus, cerebellum, thalamus, and striatum tissues were taken and total RNA was extracted. The expression of the target gene SOD1 was detected by qPCR to evaluate the delivery activity of each conjugate vector. qRT-PCR method for detecting the expression of target gene SOD1: Primer information: Table 3 Primer information table Experimental method for extracting total RNA from tissues: Animal tissues: brain tissue samples (cortex, hippocampus, cerebellum, thalamus, striatum) were taken, and samples of the same size were taken from the same position of the same tissue and directly placed in a centrifuge tube with a label and containing RNALater preservative solution, and stored at -80°C for later use. Sample total RNA extraction: RNA samples of all samples were extracted by crude extraction method: the tissue in the RNALater preservative solution was taken out with a pipette, and 0.5 mL of tissue lysis solution was added to each centrifuge tube (since a large amount of foam will be generated during the lysis process, it is not advisable to add too much lysis solution); The treated sample was further added with 0.5 mL of lysis solution, and was placed at room temperature for 10 minutes to completely separate the nucleic acid protein complex. 200 μL of chloroform was added to the homogenate sample, the tube cap was covered, and it was mixed up and down to make the water phase and the organic phase fully contact, and was placed at room temperature for 10 min until the system was clearly layered. Centrifugation at 4°C 12000 rpm for 20 min, RNA is mainly in the upper colorless water phase, 400 μL of supernatant water phase is transferred to the corresponding labeled enzyme-free EP tube (pipette the supernatant, when the supernatant is sucked, the EP tube is inclined about 45 degrees, and the gun head should be along the liquid surface to suck the supernatant, and the gun head should not touch and suck the middle layer). 400 μL of isopropanol was added to the EP tube, and it was mixed thoroughly (6-8 times, not to be mixed by a shaker), and was placed at room temperature for 10 min. Centrifugation at 4°C 12000 rpm for 20 min, a feather-like white RNA precipitate was visible, and the supernatant was carefully sucked (20-200 μL of pipette was used to suck the supernatant). 1 mL of 70% ethanol was washed twice, and centrifugation was performed at 4°C 12000 rpm for 10 min, the ethanol in the tube was poured out, the centrifuge was turned off for 30 s, the ethanol on the tube wall was separated to the bottom of the tube, and 10 μL of pipette was used to take out the remaining supernatant, attention should be paid not to suck the precipitate; the residual ethanol was dried at room temperature. Dissolve the precipitate in a certain amount of ddH2O, mix well in a shaker, then measure the concentration of RNA with a Nanodrop, measure each sample twice with the instrument, and take the average as the final concentration. The final concentration should be maintained at 200-300 ng / μL, and the sample should meet the requirement of OD260 / 280 = 1.90-2.00. (RNA concentration quantification: use an ultramicro spectrophotometer to detect the sample concentration. Before use, clean the instrument with water for 3-5 times. Before detection, measure the concentration of other samples for 3-5 times until the measured concentration is stable, and then test the sample of this experiment.) Reverse transcription: use a universal RT-PCR kit (M-MLV) to reverse transcribe all samples into cDNA Add the following reaction components in an ice-bath RNase-free centrifuge tube: 1-5 μg total RNA or 50-500 ng mRNA, 2 μL Oligo(dT)16, RNase-free ddH2O to 14.5 μL. According to the detected RNA concentration, determine the amount of total RNA that needs to be reversed, and calculate the volume of RNA that needs to be added to each well. After incubation at 70°C for 5 min, quickly cool on ice for 2 min, briefly centrifuge to collect the reaction solution, and add the following components to each well: 4 μL of 5x M-MLV Buffer, 1 μL of dNTPs, 0.5 μL of RNasin, 1 μL of M-MLV. Incubate at 42°C for 60 min, then heat at 95°C for 5 min to terminate the reaction, and place on ice for subsequent experiments or store at -20°C. qRT-PCR detection: Design 96-well plate information; Prepare the reaction system as shown in Table 4. Table 4 Reaction system configuration parameters Sample addition sequence: first prepare a mixed solution of samples except cDNA, add to the 96-well plate, then add 1 μL of cDNA. After sample addition, cover the film, briefly centrifuge, then shake and briefly centrifuge again to ensure that the sample is located at the bottom of the sample well. The whole process needs to be carried out on ice. Reaction conditions: Hot start: 95°C, 3 min; denaturation: 95°C, 10 s; annealing / extension: 60°C / 20 s; denaturation / annealing / extension for 40 cycles Melting curve analysis (select the default settings of the instrument) Arrange the relevant experimental data and records (paper and electronic) for archiving. The results of the activity test are shown in Table 5 below. Table 5 Inhibition rate of oligonucleotide conjugate 1 on mRNA of SOD1 gene expression in the central nervous system of mice The results show that, in the ICR mice, compared with the oligonucleotide conjugated with only one C16 alkyl group (reference conjugate 1), the oligonucleotide conjugate 1 of the present application conjugated with one C16 alkyl group and one polypeptide ligand has different change trends of inhibition rate of SOD1 mRNA in different parts of the central nervous system, showing excellent tissue specificity: the inhibition rate is comparable to that of reference conjugate 1 for the cerebral cortex region and the cerebellum region; for the hippocampus region, the thalamic region and the striatum region, the inhibition rate is nearly 5%-10% higher than that of reference conjugate 1. Similarly, the KD activity of oligonucleotide conjugate 2 in the CNS of ICR mice was tested; the results are shown in Table 6 below. Table 6 Inhibition rate of oligonucleotide conjugate 2 on mRNA of SOD1 gene expression in the central nervous system of mice The results show that, compared with the oligonucleotide conjugated with only one polypeptide chain (reference conjugate 2), the oligonucleotide conjugate 2 of the present application conjugated with two polypeptide ligands has different change trends of inhibition rate of SOD1 mRNA in different parts of the central nervous system, showing excellent tissue specificity: the inhibition rate is comparable to that of reference conjugate 2 for the hippocampus region; for the cerebral cortex region, the thalamic region and the striatum region, the inhibition rate is nearly 5%-10% higher than that of reference conjugate 2; especially for the cerebral cortex region, the inhibition rate is 10% higher than that of reference conjugate 2. Similarly, the KD activity of oligonucleotide conjugate 7, oligonucleotide conjugate 8 in the CNS of ICR mice was tested; the results are shown in Table 7 below. Table 7 Inhibition rate of conjugate 7, conjugate 8 on mRNA of MGMT gene expression in the central nervous system of mice The results show that, in the ICR mice, compared with the oligonucleotide conjugated with only one C16 alkyl group (reference conjugate 3), the oligonucleotide conjugate 7 of the present application conjugated with one C16 alkyl group and one polypeptide ligand, and the oligonucleotide conjugate 8 of the present application conjugated with two polypeptide ligands, have different change trends of inhibition rate of MGMT mRNA in different parts of the central nervous system, showing excellent tissue specificity: For the hippocampus region and the cerebral cortex region, the inhibition rate of the oligonucleotide conjugate 7 of the present application conjugated with one C16 alkyl group and one polypeptide ligand is 10%-20% higher than that of reference conjugate 3; for the cerebellum region, the inhibition rate is nearly 3% higher than that of reference conjugate 3; For the cerebral cortex region and the cerebellum region, the inhibition rate of the oligonucleotide conjugate 8 of the present application conjugated with two polypeptide ligands is nearly 10% higher than that of the reference conjugate 3; for the hippocampus region, the inhibition rate is higher than that of the reference conjugate 3. Similarly, the KD activity of the oligonucleotide conjugate 1 in the CNS of ICR mice was tested; the results are shown in Table 8 below. Table 8 Inhibition rate of the conjugate 1 to the mRNA of the MGMT gene expression in the central nervous system of mice The results show that, in the ICR mice, compared with the oligonucleotide conjugated with two T8 polypeptide ligands (reference conjugate 4), the oligonucleotide conjugate 1 of the present application conjugated with one C16 hydrocarbon group and one polypeptide ligand has different change trends in the inhibition rate of the MGMT mRNA in different parts of the central nervous system, showing excellent tissue specificity: For the hippocampus region and the cerebellum region, the inhibition rate of the oligonucleotide conjugate 1 of the present application conjugated with one C16 hydrocarbon group and one polypeptide ligand is 10%-15% higher than that of the reference conjugate 4; for the cortex region, the inhibition rate is 5% higher than that of the reference conjugate 4. The above describes some embodiments of the present application in detail, but the present application is not limited to the specific details in the above embodiments, and various simple modifications can be made to the technical solutions of the present application within the technical concept of the present application, and these simple modifications all belong to the protection scope of the present application. In addition, it should be noted that each specific technical feature described in the above embodiments can be combined in any appropriate manner without contradiction, and in order to avoid unnecessary repetition, the present application will not further describe various possible combinations. In addition, various different embodiments of the present application can also be combined in any manner, as long as it does not deviate from the idea of the present application, and it should also be considered as disclosed in the present application.

Claims

An oligonucleotide conjugate comprising: a functional double stranded oligonucleotide comprising: a sense strand and an antisense strand, at least one peptide chain conjugated to one of the strands above, and at least one lipophilic moiety or at least one peptide chain conjugated to one of the strands above, wherein at least one of the peptide chains is CHRPYIAH. The oligonucleotide conjugate of claim 1, wherein, A functional double stranded oligonucleotide comprising: a sense strand and an antisense strand, one or two or three or four peptide chains conjugated to one of the strands above via a linker 1, and one or two or three or four (preferably one or two) lipophilic moieties conjugated to one of the strands above via a linker 2; or a sense strand and an antisense strand, two to four peptide chains conjugated to one or two of the strands above via a linker 1. The oligonucleotide conjugate of claim 1 or 2, wherein the peptide chain is selected from a peptide chain having 7-18 amino acids, preferably a 15, 10 or 8 peptide chain. The oligonucleotide conjugate of any one of claims 1-3, wherein, The linker 1 is selected from the following: 1) said linker 1 has the structure: wherein, terminal 1 of the linker 1 is conjugated to the end of one strand via a phosphoester bond, and terminal 2 is conjugated to the end of the peptide chain (e.g. a thiol group); 2) the linker 1 contains an ether, thioether, urea, carbonate, amine, amide, maleimide-thioether, disulfide, phosphoester, phosphodiester, sulfonamide or carbamate, hydrazone, ester, acetal or ketal, peptide bond; 3) the linker 1 is a biologically cleavable linker selected from the group consisting of DNA, RNA, disulfide, amide, functionalized monosaccharide or oligosaccharide of galactosamine, glucosamine, glucose, galactose, mannose, and combinations thereof; 4) the linker 1 is a branched linker, the branching point of the branched linker is an atom of valence of at least three, e.g. of valence four, five or six or a group exhibiting such a multiple valence; preferably, the branching point of the branched linker is selected from -N, -N(Q)-C, -O-C, -S-C, -SS-C, -C(O)N(Q)-C, -OC(O)N(Q)-C, -N(Q)C(O)-C or -N(Q)C(O)O-C; wherein Q is independently at each occurrence H or optionally substituted alkyl; further preferably, the branching point of the branched linker is glycerol or a glycerol derivative; or 5) the linker 1 is a branched linker, wherein, said linker is selected from the group consisting of -(CH2) n - n is an integer selected from the group consisting of 4 to 100, preferably 4 to 50, more preferably 4 to 18; or 6) the linker is derived from The oligonucleotide conjugate of any one of claims 1-4, wherein the peptide chain is conjugated at a position selected from the group consisting of a nucleotide at the 5' end of the sense strand, a nucleotide at the 3' end of the sense strand, a nucleotide at the 5' end of the antisense strand, a nucleotide at the 3' end of the antisense strand, a middle position nucleotide outside of the two positions at the 5' and 3' ends of the sense strand. The oligonucleotide conjugate of claim 1, wherein the lipophilic moiety is selected from an aliphatic, cycloaliphatic or polyaliphatic compound, preferably a C4-C30 hydrocarbon group (e.g. alkyl or alkenyl), more preferably a C6-C18 hydrocarbon group (e.g. alkyl or alkenyl), further preferably a C16 hydrocarbon group (e.g. alkyl or alkenyl). The oligonucleotide conjugate of claim 1 or 6, wherein the lipophilic moiety is conjugated via an ether bond linker 2. The oligonucleotide conjugate of claim 1 or 6 or 7, wherein the lipophilic moiety is conjugated via linker 2, the linker 2 contains a thioether, a urea, a carbonate, an amine, an amide, a maleimide-thioether, a disulfide, a phosphate, a phosphodiester, a sulfonamide or a carbamate, a hydrazone group, an ester group, an acetal group or a ketal group, a peptide bond, or the linker 2 is a biocleavable linker selected from the group consisting of DNA, RNA, disulfide, amide, functionalized monosaccharides or oligosaccharides of galactosamine, glucosamine, glucose, galactose, mannose, and combinations thereof. The oligonucleotide conjugate of any one of claims 1, 6-8, wherein the lipophilic moiety is conjugated at a position selected from the group consisting of a nucleotide at the 5’ end of the sense strand, a nucleotide at a middle position other than the two positions at the 5’ and 3’ ends of the sense strand, and a nucleotide at the 3’ end of the antisense strand; preferably, the lipophilic moiety is conjugated at the 2’ position of the nucleotide sugar ring at the above-mentioned position. The oligonucleotide conjugate of any one of claims 1-9, wherein, The sense strand contains a nucleotide sequence I, and the antisense strand contains a nucleotide sequence II, the nucleotide sequence I and the nucleotide sequence II are at least partially reverse complementary to form a double-stranded region, the nucleotide sequence II is at least partially reverse complementary to a target gene or a target mRNA, the target gene or the target mRNA is a target gene or a mRNA expressed by the target gene in a target cell in a target tissue or a target organ, the target cell is a TfR receptor present on the cell surface. The oligonucleotide conjugate of claim 10, wherein the nucleotide sequence I and the nucleotide sequence II each has a length of 15 to 30 nucleotides, or each has a length of 17 to 25 nucleotides, or each has a length of 19 to 23 nucleotides, for example, each has a length of 19 to 21 nucleotides; the nucleotide sequence II is substantially reverse complementary, substantially reverse complementary, or completely reverse complementary to the nucleotide sequence I; the substantially reverse complementary means that there are no more than 3 base mismatches between the two nucleotide sequences; the substantially reverse complementary means that there are no more than 1 base mismatch between the two nucleotide sequences; the completely reverse complementary means that there is no base mismatch between the two nucleotide sequences. The oligonucleotide conjugate of any one of claims 1-11, wherein the functional double-stranded oligonucleotide is a saRNA or a siRNA, preferably the double-stranded oligonucleotide is a siRNA. The oligonucleotide conjugate of any one of claims 1 to 12, wherein the sense strand and / or the antisense strand contains at least one modified nucleotide, or all nucleotides in the sense strand and / or the antisense strand are modified nucleotides or nucleotide analogs. The oligonucleotide conjugate of claim 13, wherein, The modified nucleotide or nucleotide analog is selected from a 2'-methoxy nucleotide, a 2'-fluoro nucleotide, a 2'-deoxy nucleotide, a 2',3'-seco nucleotide analog, a 2'-fluoro arabinonucleotide, a 2'-methoxyethyl nucleotide, a 2'-amino modified nucleotide, a 2'-alkyl modified nucleotide, a 3'-methoxy nucleotide, a 2'-allyl modified nucleotide, a nucleotide comprising a phosphorothioate group, a nucleotide comprising a methylphosphonate group, a nucleotide comprising a 5'-phosphate, a nucleotide comprising a 5'-phosphate mimic, a glycol modified nucleotide, an abasic nucleotide, a morpholino nucleotide, a locked nucleotide, an unlocked nucleotide, or a glycerol nucleotide. The oligonucleotide conjugate of any one of claims 1-14, wherein, One end (e.g., the 5' end) of the antisense strand comprises a phosphorus-containing group selected from a 5' phosphate (5'-P), a 5' phosphorothioate (5'-PS), a 5' phosphorodithioate (5'-PS2), a 5' vinylphosphonate group (5'-VP), a 5' methylphosphonate group (MePhos), preferably a 5' vinylphosphonate group (5'-VP). The oligonucleotide conjugate according to any one of claims 1 to 15, wherein, wherein the target gene is selected from APP, ATXN2, C9orf72, TARDBP, MAPT (Tau), HTT, SNCA, FUS, ATXN3, ATXN1, ATXN7, ATXN8, MeCP2, PRNP, SOD1, DMPK, MGMT, and TTR. The oligonucleotide conjugate according to any one of claims 1 to 16, wherein, The pattern of lipophilic moieties conjugated via linker 2 to one strand of the siRNA and the peptide chain conjugated via linker 1 to one strand of the siRNA is selected from the following: 1) one C16 hydrocarbon group is conjugated via an ether linkage to the nucleotide at the 5' end of the sense strand and one peptide chain CHRPYIAH is conjugated via linker 1 as described in item 1) of claim 4 to the nucleotide at the 3' end of the sense strand; 2) one C16 hydrocarbon group is conjugated via linker 2 as described in claim 8 to the nucleotide at the 5' end of the sense strand and one peptide chain CHRPYIAH is conjugated via linker 1 as described in item 1) of claim 4 to the nucleotide at the 3' end of the sense strand; 3) one C16 hydrocarbon group is conjugated via an ether linkage to the nucleotide at the 3' end of the sense strand and one peptide chain CHRPYIAH is conjugated via linker 1 as described in item 1) of claim 4 to the nucleotide at the 3' end of the sense strand; 4) one C16 hydrocarbon group is conjugated via linker 2 as described in claim 8 to the nucleotide at the 3' end of the sense strand and one peptide chain CHRPYIAH is conjugated via linker 1 as described in item 1) of claim 4 to the nucleotide at the 3' end of the sense strand; 5) one C16 hydrocarbon group is conjugated via an ether linkage to the nucleotide at an intermediate position outside the two positions at the 5' and 3' end of the sense strand and one peptide chain CHRPYIAH is conjugated via linker 1 as described in item 1) of claim 4 to the nucleotide at the 3' end of the sense strand; 6) one C16 alkyl group is conjugated to the middle nucleotide of the sense strand by linker 2 of claim 8, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' end of the sense strand by linker 1 of item 1) of claim 4; 7) one C16 alkyl group is conjugated to the nucleotide at the 3' end of the antisense strand by an ether linkage, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' end of the sense strand by linker 1 of item 1) of claim 4; 8) one C16 alkyl group is conjugated to the nucleotide at the 3' end of the antisense strand by linker 2 of claim 8, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' end of the sense strand by linker 1 of item 1) of claim 4; 9) one C16 alkyl group is conjugated to the nucleotide at the 5' end of the sense strand by an ether linkage, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' end of the sense strand by linker 1 of item 2) or item 3) of claim 4; 10) one C16 alkyl group is conjugated to the nucleotide at the 5' end of the sense strand by linker 2 of claim 8, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' end of the sense strand by linker 1 of item 2) or item 3) of claim 4; 11) one C16 alkyl group is conjugated to the nucleotide at the 3' end of the sense strand by an ether linkage, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' end of the sense strand by linker 1 of item 2) or item 3) of claim 4; 12) one C16 alkyl group is conjugated to the nucleotide at the 3' end of the sense strand by linker 2 of claim 8, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' end of the sense strand by linker 1 of item 2) or item 3) of claim 4; 13) one C16 alkyl group is conjugated to the middle nucleotide of the sense strand by an ether linkage, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' end of the sense strand by linker 1 of item 2) or item 3) of claim 4; 14) one C16 alkyl group is conjugated to the middle nucleotide of the sense strand by linker 2 of claim 8, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' end of the sense strand by linker 1 of item 2) or item 3) of claim 4; 15) one C16 alkyl group is conjugated to the nucleotide at the 3' end of the antisense strand by an ether linkage, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' end of the sense strand by linker 1 of item 2) or item 3) of claim 4; 16) one C16 alkyl group is conjugated to the nucleotide at the 3' end of the antisense strand by linker 2 of claim 8, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' end of the sense strand by linker 1 of item 2) or item 3) of claim 4; 17) one C16 alkyl group is conjugated to the 5' terminal nucleotide of the sense strand via an ether linkage and one peptide chain CHRPYIAH is conjugated to the 5' terminal nucleotide of the sense strand via linker 1 of item 1) of claim 4; 18) one C16 alkyl group is conjugated to the 5' terminal nucleotide of the sense strand via linker 2 of claim 8 and one peptide chain CHRPYIAH is conjugated to the 5' terminal nucleotide of the sense strand via linker 1 of item 1) of claim 4; 19) one C16 alkyl group is conjugated to the 3' terminal nucleotide of the sense strand via an ether linkage and one peptide chain CHRPYIAH is conjugated to the 5' terminal nucleotide of the sense strand via linker 1 of item 1) of claim 4; 20) one C16 alkyl group is conjugated to the 3' terminal nucleotide of the sense strand via linker 2 of claim 8 and one peptide chain CHRPYIAH is conjugated to the 5' terminal nucleotide of the sense strand via linker 1 of item 1) of claim 4; 21) one C16 alkyl group is conjugated to a nucleotide intermediate to the 5' and 3' terminal nucleotides of the sense strand via an ether linkage and one peptide chain CHRPYIAH is conjugated to the 5' terminal nucleotide of the sense strand via linker 1 of item 1) of claim 4; 22) one C16 alkyl group is conjugated to a nucleotide intermediate to the 5' and 3' terminal nucleotides of the sense strand via linker 2 of claim 8 and one peptide chain CHRPYIAH is conjugated to the 5' terminal nucleotide of the sense strand via linker 1 of item 1) of claim 4; 23) one C16 alkyl group is conjugated to the 3' terminal nucleotide of the antisense strand via an ether linkage and one peptide chain CHRPYIAH is conjugated to the 5' terminal nucleotide of the sense strand via linker 1 of item 1) of claim 4; 24) one C16 alkyl group is conjugated to the 3' terminal nucleotide of the antisense strand via linker 2 of claim 8 and one peptide chain CHRPYIAH is conjugated to the 5' terminal nucleotide of the sense strand via linker 1 of item 1) of claim 4; 25) one C16 alkyl group is conjugated to the 5' terminal nucleotide of the sense strand via an ether linkage and one peptide chain CHRPYIAH is conjugated to the 5' terminal nucleotide of the sense strand via linker 1 of item 2) or 3) of claim 4; 26) one C16 alkyl group is conjugated to the 5' terminal nucleotide of the sense strand via linker 2 of claim 8 and one peptide chain CHRPYIAH is conjugated to the 5' terminal nucleotide of the sense strand via linker 1 of item 2) or 3) of claim 4; 27) one C16 alkyl group is conjugated to the 3' terminal nucleotide of the sense strand via an ether linkage and one peptide chain CHRPYIAH is conjugated to the 5' terminal nucleotide of the sense strand via linker 1 of item 2) or 3) of claim 4; 28) one C16 alkyl group is conjugated to the nucleotide at the 3' end of the sense strand via linker 2 of claim 8, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand via linker 1 of item 2) or item 3) of claim 4; 29) one C16 alkyl group is conjugated to the nucleotide at a position intermediate to the 5' and 3' ends of the sense strand via an ether linkage, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand via linker 1 of item 2) or item 3) of claim 4; 30) one C16 alkyl group is conjugated to the nucleotide at a position intermediate to the 5' and 3' ends of the sense strand via linker 2 of claim 8, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand via linker 1 of item 2) or item 3) of claim 4; 31) one C16 alkyl group is conjugated to the nucleotide at the 3' end of the antisense strand via an ether linkage, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand via linker 1 of item 2) or item 3) of claim 4; 32) one C16 alkyl group is conjugated to the nucleotide at the 3' end of the antisense strand via linker 2 of claim 8, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand via linker 1 of item 2) or item 3) of claim 4; 33) one C16 alkyl group is conjugated to the nucleotide at the 5' end of the sense strand via an ether linkage, and one peptide chain CHRPYIAH is conjugated to the nucleotide at a position intermediate to the 5' and 3' ends of the sense strand via linker 1 of item 1) of claim 4; 34) one C16 alkyl group is conjugated to the nucleotide at the 5' end of the sense strand via linker 2 of claim 8, and one peptide chain CHRPYIAH is conjugated to the nucleotide at a position intermediate to the 5' and 3' ends of the sense strand via linker 1 of item 1) of claim 4; 35) one C16 alkyl group is conjugated to the nucleotide at the 3' end of the sense strand via an ether linkage, and one peptide chain CHRPYIAH is conjugated to the nucleotide at a position intermediate to the 5' and 3' ends of the sense strand via linker 1 of item 1) of claim 4; 36) one C16 alkyl group is conjugated to the nucleotide at the 3' end of the sense strand via linker 2 of claim 8, and one peptide chain CHRPYIAH is conjugated to the nucleotide at a position intermediate to the 5' and 3' ends of the sense strand via linker 1 of item 1) of claim 4; 37) one C16 alkyl group is conjugated to the nucleotide at a position intermediate to the 5' and 3' ends of the sense strand via an ether linkage, and one peptide chain CHRPYIAH is conjugated to the nucleotide at a position intermediate to the 5' and 3' ends of the sense strand via linker 1 of item 1) of claim 4; 38) one C16 alkyl group is conjugated to the nucleotide at the middle position other than the two positions at the 5' and 3' ends of the sense strand by the linker 2 of claim 8, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the middle position other than the two positions at the 5' and 3' ends of the sense strand by the linker 1 of item 1) in claim 4; 39) one C16 alkyl group is conjugated to the nucleotide at the 3' end of the antisense strand by an ether bond, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the middle position other than the two positions at the 5' and 3' ends of the sense strand by the linker 1 of item 1) in claim 4; 40) one C16 alkyl group is conjugated to the nucleotide at the 3' end of the antisense strand by the linker 2 of claim 8, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the middle position other than the two positions at the 5' and 3' ends of the sense strand by the linker 1 of item 1) in claim 4; 41) one C16 alkyl group is conjugated to the nucleotide at the 5' end of the sense strand by an ether bond, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the middle position other than the two positions at the 5' and 3' ends of the sense strand by the linker 1 of item 2) or item 3) in claim 4; 42) one C16 alkyl group is conjugated to the nucleotide at the 5' end of the sense strand by the linker 2 of claim 8, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the middle position other than the two positions at the 5' and 3' ends of the sense strand by the linker 1 of item 2) or item 3) in claim 4; 43) one C16 alkyl group is conjugated to the nucleotide at the 3' end of the sense strand by an ether bond, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the middle position other than the two positions at the 5' and 3' ends of the sense strand by the linker 1 of item 2) or item 3) in claim 4; 44) one C16 alkyl group is conjugated to the nucleotide at the 3' end of the sense strand by the linker 2 of claim 8, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the middle position other than the two positions at the 5' and 3' ends of the sense strand by the linker 1 of item 2) or item 3) in claim 4; 45) one C16 alkyl group is conjugated to the nucleotide at the middle position other than the two positions at the 5' and 3' ends of the sense strand by an ether bond, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the middle position other than the two positions at the 5' and 3' ends of the sense strand by the linker 1 of item 2) or item 3) in claim 4; 46) one C16 alkyl group is conjugated to the nucleotide at the middle position other than the two positions at the 5' and 3' ends of the sense strand by the linker 2 of claim 8, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the middle position other than the two positions at the 5' and 3' ends of the sense strand by the linker 1 of item 2) or item 3) in claim 4; 47) one C16 alkyl group is conjugated to the nucleotide at the 3' terminus of the antisense strand via an ether linkage and one peptide chain CHRPYIAH is conjugated to the nucleotide at a position intermediate to the 5' and 3' termini of the sense strand via linker 1 of item 2) or item 3) of claim 4; 48) one C16 alkyl group is conjugated to the nucleotide at the 3' terminus of the antisense strand via linker 2 of claim 8 and one peptide chain CHRPYIAH is conjugated to the nucleotide at a position intermediate to the 5' and 3' termini of the sense strand via linker 1 of item 2) or item 3) of claim 4; 49) one C16 alkyl group is conjugated to the nucleotide at the 5' terminus of the sense strand via an ether linkage and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' terminus of the antisense strand via linker 1 of item 1) of claim 4; 50) one C16 alkyl group is conjugated to the nucleotide at the 5' terminus of the sense strand via linker 2 of claim 8 and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' terminus of the antisense strand via linker 1 of item 1) of claim 4; 51) one C16 alkyl group is conjugated to the nucleotide at the 3' terminus of the sense strand via an ether linkage and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' terminus of the antisense strand via linker 1 of item 1) of claim 4; 52) one C16 alkyl group is conjugated to the nucleotide at the 3' terminus of the sense strand via linker 2 of claim 8 and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' terminus of the antisense strand via linker 1 of item 1) of claim 4; 53) one C16 alkyl group is conjugated to the nucleotide at a position intermediate to the 5' and 3' termini of the sense strand via an ether linkage and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' terminus of the antisense strand via linker 1 of item 1) of claim 4; 54) one C16 alkyl group is conjugated to the nucleotide at a position intermediate to the 5' and 3' termini of the sense strand via linker 2 of claim 8 and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' terminus of the antisense strand via linker 1 of item 1) of claim 4; 55) one C16 alkyl group is conjugated to the nucleotide at the 3' terminus of the antisense strand via an ether linkage and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' terminus of the antisense strand via linker 1 of item 1) of claim 4; 56) one C16 alkyl group is conjugated to the nucleotide at the 3' terminus of the antisense strand via linker 2 of claim 8 and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' terminus of the antisense strand via linker 1 of item 1) of claim 4; 57) one C16 alkyl group is conjugated to the nucleotide at the 5' terminus of the sense strand via an ether linkage and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' terminus of the antisense strand via linker 1 of item 2) or item 3) of claim 4; 58) one C16alkyl group is conjugated to the 5' terminal nucleotide of the sense strand via linker 2 of claim 8 and one peptide chain CHRPYIAH is conjugated to the 3' terminal nucleotide of the antisense strand via linker 1 of item 2 or 3 of claim 4; 59) one C16alkyl group is conjugated to the 3' terminal nucleotide of the sense strand via an ether linkage and one peptide chain CHRPYIAH is conjugated to the 3' terminal nucleotide of the antisense strand via linker 1 of item 2 or 3 of claim 4; 60) one C16alkyl group is conjugated to the 3' terminal nucleotide of the sense strand via linker 2 of claim 8 and one peptide chain CHRPYIAH is conjugated to the 3' terminal nucleotide of the antisense strand via linker 1 of item 2 or 3 of claim 4; 61) one C16alkyl group is conjugated to a nucleotide intermediate between the 5' and 3' terminal nucleotides of the sense strand via an ether linkage and one peptide chain CHRPYIAH is conjugated to the 3' terminal nucleotide of the antisense strand via linker 1 of item 2 or 3 of claim 4; 62) one C16alkyl group is conjugated to a nucleotide intermediate between the 5' and 3' terminal nucleotides of the sense strand via linker 2 of claim 8 and one peptide chain CHRPYIAH is conjugated to the 3' terminal nucleotide of the antisense strand via linker 1 of item 2 or 3 of claim 4; 63) one C16alkyl group is conjugated to the 3' terminal nucleotide of the antisense strand via an ether linkage and one peptide chain CHRPYIAH is conjugated to the 3' terminal nucleotide of the antisense strand via linker 1 of item 2 or 3 of claim 4; 64) one C16alkyl group is conjugated to the 3' terminal nucleotide of the antisense strand via linker 2 of claim 8 and one peptide chain CHRPYIAH is conjugated to the 3' terminal nucleotide of the antisense strand via linker 1 of item 2 or 3 of claim 4; 65) one C16alkyl group is conjugated to the 5' terminal nucleotide of the sense strand via an ether linkage and one peptide chain CHRPYIAH is conjugated to the 3' terminal nucleotide of the sense strand via linker 1 of item 1 of claim 4 and another peptide chain CHRPYIAH is conjugated to the 5' terminal nucleotide of the sense strand via linker 1 of item 1 of claim 4; 66) one C16alkyl group is conjugated to the 5' terminal nucleotide of the sense strand via linker 2 of claim 8 and one peptide chain CHRPYIAH is conjugated to the 3' terminal nucleotide of the sense strand via linker 1 of item 1 of claim 4 and another peptide chain CHRPYIAH is conjugated to the 5' terminal nucleotide of the sense strand via linker 1 of item 1 of claim 4; 67) one C16 alkyl group is attached to a nucleotide at the 3' end of the sense strand via an ether linkage and one peptide chain CHRPYIAH is attached to a nucleotide at the 3' end of the sense strand via linker 1 of item 1) of claim 4 and one other peptide chain CHRPYIAH is attached to a nucleotide at the 5' end of the sense strand via linker 1 of item 1) of claim 4; 68) one C16 alkyl group is attached to a nucleotide at the 3' end of the sense strand via linker 2 of claim 8 and one peptide chain CHRPYIAH is attached to a nucleotide at the 3' end of the sense strand via linker 1 of item 1) of claim 4 and one other peptide chain CHRPYIAH is attached to a nucleotide at the 5' end of the sense strand via linker 1 of item 1) of claim 4; 69) one C16 alkyl group is attached to a nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via an ether linkage and one peptide chain CHRPYIAH is attached to a nucleotide at the 3' end of the sense strand via linker 1 of item 1) of claim 4 and one other peptide chain CHRPYIAH is attached to a nucleotide at the 5' end of the sense strand via linker 1 of item 1) of claim 4; 70) one C16 alkyl group is attached to a nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via linker 2 of claim 8 and one peptide chain CHRPYIAH is attached to a nucleotide at the 3' end of the sense strand via linker 1 of item 1) of claim 4 and one other peptide chain CHRPYIAH is attached to a nucleotide at the 5' end of the sense strand via linker 1 of item 1) of claim 4; 71) one C16 alkyl group is attached to a nucleotide at the 3' end of the antisense strand via an ether linkage and one peptide chain CHRPYIAH is attached to a nucleotide at the 3' end of the sense strand via linker 1 of item 1) of claim 4 and one other peptide chain CHRPYIAH is attached to a nucleotide at the 5' end of the sense strand via linker 1 of item 1) of claim 4; 72) one C16 alkyl group is attached to a nucleotide at the 3' end of the antisense strand via linker 2 of claim 8 and one peptide chain CHRPYIAH is attached to a nucleotide at the 3' end of the sense strand via linker 1 of item 1) of claim 4 and one other peptide chain CHRPYIAH is attached to a nucleotide at the 5' end of the sense strand via linker 1 of item 1) of claim 4; 73) one C16 alkyl group is attached to a nucleotide at the 5' end of the sense strand via an ether linkage and one peptide chain CHRPYIAH is attached to a nucleotide at the 3' end of the sense strand via linker 1 of item 2) or item 3) of claim 4 and one other peptide chain CHRPYIAH is attached to a nucleotide at the 5' end of the sense strand via linker 1 of item 2) or item 3) of claim 4; 74) one C16 hydrocarbon group is conjugated to the nucleotide at the 5' end of the sense strand via linker 2 of claim 8, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' end of the sense strand via linker 1 of item 2) or 3) of claim 4, and another one peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand via linker 1 of item 2) or 3) of claim 4; 75) one C16 hydrocarbon group is conjugated to the nucleotide at the 3' end of the sense strand via an ether bond, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' end of the sense strand via linker 1 of item 2) or 3) of claim 4, and another one peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand via linker 1 of item 2) or 3) of claim 4; 76) one C16 hydrocarbon group is conjugated to the nucleotide at the 3' end of the sense strand via linker 2 of claim 8, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' end of the sense strand via linker 1 of item 2) or 3) of claim 4, and another one peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand via linker 1 of item 2) or 3) of claim 4; 77) one C16 hydrocarbon group is conjugated to the nucleotide at the middle position between the 5' end and the 3' end of the sense strand, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' end of the sense strand via linker 1 of item 2) or 3) of claim 4, and another one peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand via linker 1 of item 2) or 3) of claim 4; 78) one C16 hydrocarbon group is conjugated to the nucleotide at the middle position between the 5' end and the 3' end of the sense strand via linker 2 of claim 8, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' end of the sense strand via linker 1 of item 2) or 3) of claim 4, and another one peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand via linker 1 of item 2) or 3) of claim 4; 79) one C16 hydrocarbon group is conjugated to the nucleotide at the 3' end of the antisense strand via an ether bond, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' end of the sense strand via linker 1 of item 2) or 3) of claim 4, and another one peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand via linker 1 of item 2) or 3) of claim 4; 80) one C16 hydrocarbon group is conjugated to the nucleotide at the 3' end of the antisense strand via linker 2 of claim 8, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' end of the sense strand via linker 1 of item 2) or 3) of claim 4, and another one peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand via linker 1 of item 2) or 3) of claim 4; 81) one C16 alkyl group is conjugated to the 5' terminal nucleotide of the sense strand via an ether linkage and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 3' terminal end of the sense strand via linker 1 of item 1) of claim 4 and another peptide chain CHRPYIAH is conjugated to a nucleotide at the 5' terminal end of the sense strand via linker 1 of item 2) or 3) of claim 4; 82) one C16 alkyl group is conjugated to the 5' terminal nucleotide of the sense strand via linker 2 of claim 8 and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 3' terminal end of the sense strand via linker 1 of item 1) of claim 4 and another peptide chain CHRPYIAH is conjugated to a nucleotide at the 5' terminal end of the sense strand via linker 1 of item 2) or 3) of claim 4; 83) one C16 alkyl group is conjugated to the 3' terminal nucleotide of the sense strand via an ether linkage and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 3' terminal end of the sense strand via linker 1 of item 1) of claim 4 and another peptide chain CHRPYIAH is conjugated to a nucleotide at the 5' terminal end of the sense strand via linker 1 of item 2) or 3) of claim 4; 84) one C16 alkyl group is conjugated to the 3' terminal nucleotide of the sense strand via linker 2 of claim 8 and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 3' terminal end of the sense strand via linker 1 of item 1) of claim 4 and another peptide chain CHRPYIAH is conjugated to a nucleotide at the 5' terminal end of the sense strand via linker 1 of item 2) or 3) of claim 4; 85) one C16 alkyl group is conjugated to a nucleotide at a position intermediate to the 5' and 3' terminal ends of the sense strand and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 3' terminal end of the sense strand via linker 1 of item 1) of claim 4 and another peptide chain CHRPYIAH is conjugated to a nucleotide at the 5' terminal end of the sense strand via linker 1 of item 2) or 3) of claim 4; 86) one C16 alkyl group is conjugated to a nucleotide at a position intermediate to the 5' and 3' terminal ends of the sense strand via linker 2 of claim 8 and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 3' terminal end of the sense strand via linker 1 of item 1) of claim 4 and another peptide chain CHRPYIAH is conjugated to a nucleotide at the 5' terminal end of the sense strand via linker 1 of item 2) or 3) of claim 4; 87) one C16 alkyl group is conjugated to the 3' terminal nucleotide of the antisense strand via an ether linkage and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 3' terminal end of the sense strand via linker 1 of item 1) of claim 4 and another peptide chain CHRPYIAH is conjugated to a nucleotide at the 5' terminal end of the sense strand via linker 1 of item 2) or 3) of claim 4; 88) one C16 alkyl group is conjugated to the nucleotide at the 3' end of the antisense strand via linker 2 of claim 8, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' end of the sense strand via linker 1 of item 1) of claim 4, and another peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand via linker 1 of item 2) or 3) of claim 4; 89) one C16 alkyl group is conjugated to the nucleotide at the 5' end of the sense strand via an ether bond, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' end of the sense strand via linker 1 of item 2) or 3) of claim 4, and another peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand via linker 1 of item 1) of claim 4; 90) one C16 alkyl group is conjugated to the nucleotide at the 5' end of the sense strand via linker 2 of claim 8, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' end of the sense strand via linker 1 of item 2) or 3) of claim 4, and another peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand via linker 1 of item 1) of claim 4; 91) one C16 alkyl group is conjugated to the nucleotide at the 3' end of the sense strand via an ether bond, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' end of the sense strand via linker 1 of item 2) or 3) of claim 4, and another peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand via linker 1 of item 1) of claim 4; 92) one C16 alkyl group is conjugated to the nucleotide at the 3' end of the sense strand via linker 2 of claim 8, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' end of the sense strand via linker 1 of item 2) or 3) of claim 4, and another peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand via linker 1 of item 1) of claim 4; 93) one C16 alkyl group is conjugated to the nucleotide at a position intermediate to the 5' and 3' ends of the sense strand, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' end of the sense strand via linker 1 of item 2) or 3) of claim 4, and another peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand via linker 1 of item 1) of claim 4; 94) one C16 alkyl group is conjugated to the nucleotide at a position intermediate to the 5' and 3' ends of the sense strand via linker 2 of claim 8, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' end of the sense strand via linker 1 of item 2) or 3) of claim 4, and another peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand via linker 1 of item 1) of claim 4; 95) one C16 alkyl group is conjugated to the 3' terminal nucleotide of the antisense strand via an ether linkage and one peptide CHRPYIAH is conjugated to a nucleotide at the 3' terminal position of the sense strand via linker 1 of item 2) or 3) of claim 4 and one other peptide CHRPYIAH is conjugated to a nucleotide at the 5' terminal position of the sense strand via linker 1 of item 1) of claim 4; 96) one C16 alkyl group is conjugated to the 3' terminal nucleotide of the antisense strand via linker 2 of claim 8 and one peptide CHRPYIAH is conjugated to a nucleotide at the 3' terminal position of the sense strand via linker 1 of item 2) or 3) of claim 4 and one other peptide CHRPYIAH is conjugated to a nucleotide at the 5' terminal position of the sense strand via linker 1 of item 1) of claim 4; 97) one C16 alkyl group is conjugated to the 5' terminal nucleotide of the sense strand via an ether linkage and one peptide CHRPYIAH is conjugated to a nucleotide at the 3' terminal position of the sense strand via linker 1 of item 1) of claim 4 and one other peptide CHRPYIAH is conjugated to a nucleotide at a position intermediate the 5' and 3' terminal positions of the sense strand; 98) one C16 alkyl group is conjugated to the 5' terminal nucleotide of the sense strand via linker 2 of claim 8 and one peptide CHRPYIAH is conjugated to a nucleotide at the 3' terminal position of the sense strand via linker 1 of item 1) of claim 4 and one other peptide CHRPYIAH is conjugated to a nucleotide at a position intermediate the 5' and 3' terminal positions of the sense strand; 99) one C16 alkyl group is conjugated to the 3' terminal nucleotide of the sense strand via an ether linkage and one peptide CHRPYIAH is conjugated to a nucleotide at the 3' terminal position of the sense strand via linker 1 of item 1) of claim 4 and one other peptide CHRPYIAH is conjugated to a nucleotide at a position intermediate the 5' and 3' terminal positions of the sense strand; 100) one C16 alkyl group is conjugated to the 3' terminal nucleotide of the sense strand via linker 2 of claim 8 and one peptide CHRPYIAH is conjugated to a nucleotide at the 3' terminal position of the sense strand via linker 1 of item 1) of claim 4 and one other peptide CHRPYIAH is conjugated to a nucleotide at a position intermediate the 5' and 3' terminal positions of the sense strand; 101) one C16 alkyl group is conjugated to a nucleotide at a position intermediate the 5' and 3' terminal positions of the sense strand via an ether linkage and one peptide CHRPYIAH is conjugated to a nucleotide at the 3' terminal position of the sense strand via linker 1 of item 1) of claim 4 and one other peptide CHRPYIAH is conjugated to a nucleotide at a position intermediate the 5' and 3' terminal positions of the sense strand; 102) 1 C16 alkyl group is conjugated to the nucleotide at the middle position of the sense strand other than the two positions at the 5' and 3' ends by the linker 2 of claim 8, and 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' end of the sense strand by the linker 1 of item 1) in claim 4, and another 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the middle position of the sense strand other than the two positions at the 5' and 3' ends; 103) 1 C16 alkyl group is conjugated to the nucleotide at the 3' end of the antisense strand by an ether bond, and 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' end of the sense strand by the linker 1 of item 1) in claim 4, and another 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the middle position of the sense strand other than the two positions at the 5' and 3' ends by the linker 1 of item 1) in claim 4; 104) 1 C16 alkyl group is conjugated to the nucleotide at the 3' end of the antisense strand by the linker 2 of claim 8, and 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' end of the sense strand by the linker 1 of item 1) in claim 4, and another 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the middle position of the sense strand other than the two positions at the 5' and 3' ends by the linker 1 of item 1) in claim 4; 105) 1 C16 alkyl group is conjugated to the nucleotide at the 5' end of the sense strand by an ether bond, and 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' end of the sense strand by the linker 1 of item 2) or 3) in claim 4, and another 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the middle position of the sense strand other than the two positions at the 5' and 3' ends by the linker 1 of item 2) or 3) in claim 4; 106) 1 C16 alkyl group is conjugated to the nucleotide at the 5' end of the sense strand by the linker 2 of claim 8, and 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' end of the sense strand by the linker 1 of item 2) or 3) in claim 4, and another 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand by the linker 1 of item 2) or 3) in claim 4; 107) 1 C16 alkyl group is conjugated to the nucleotide at the 3' end of the sense strand by an ether bond, and 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' end of the sense strand by the linker 1 of item 2) or 3) in claim 4, and another 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the middle position of the sense strand other than the two positions at the 5' and 3' ends by the linker 1 of item 2) or 3) in claim 4; 108) 1 C16 alkyl group is conjugated to the nucleotide at the 3' end of the sense strand via linker 2 of claim 8, and 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' end of the sense strand via linker 1 of item 2) or 3) of claim 4, and another 1 peptide chain CHRPYIAH is conjugated to the nucleotide at a position intermediate to the 5' and 3' ends of the sense strand via linker 1 of item 2) or 3) of claim 4; 109) 1 C16 alkyl group is conjugated to the nucleotide at a position intermediate to the 5' and 3' ends of the sense strand via an ether bond, and 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' end of the sense strand via linker 1 of item 2) or 3) of claim 4, and another 1 peptide chain CHRPYIAH is conjugated to the nucleotide at a position intermediate to the 5' and 3' ends of the sense strand via linker 1 of item 2) or 3) of claim 4; 110) 1 C16 alkyl group is conjugated to the nucleotide at a position intermediate to the 5' and 3' ends of the sense strand via linker 2 of claim 8, and 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' end of the sense strand via linker 1 of item 2) or 3) of claim 4, and another 1 peptide chain CHRPYIAH is conjugated to the nucleotide at a position intermediate to the 5' and 3' ends of the sense strand via linker 1 of item 2) or 3) of claim 4; 111) 1 C16 alkyl group is conjugated to the nucleotide at the 3' end of the antisense strand via an ether bond, and 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' end of the sense strand via linker 1 of item 2) or 3) of claim 4, and another 1 peptide chain CHRPYIAH is conjugated to the nucleotide at a position intermediate to the 5' and 3' ends of the sense strand via linker 1 of item 2) or 3) of claim 4; 112) 1 C16 alkyl group is conjugated to the nucleotide at the 3' end of the antisense strand via linker 2 of claim 8, and 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' end of the sense strand via linker 1 of item 2) or 3) of claim 4, and another 1 peptide chain CHRPYIAH is conjugated to the nucleotide at a position intermediate to the 5' and 3' ends of the sense strand via linker 1 of item 2) or 3) of claim 4; 113) 1 C16 alkyl group is conjugated to the nucleotide at the 5' end of the sense strand via an ether bond, and 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' end of the sense strand via linker 1 of item 1) of claim 4, and another 1 peptide chain CHRPYIAH is conjugated to the nucleotide at a position intermediate to the 5' and 3' ends of the sense strand via linker 1 of item 2) or 3) of claim 4; 114) 1 C16 hydrocarbon group is conjugated to the nucleotide at the 5' end of the sense strand via linker 2 of claim 8, and 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' end of the sense strand via linker 1 of item 1) of claim 4, and another 1 peptide chain CHRPYIAH is conjugated to the nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via linker 1 of item 2) or 3) of claim 4; 115) 1 C16 hydrocarbon group is conjugated to the nucleotide at the 3' end of the sense strand via an ether bond, and 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' end of the sense strand via linker 1 of item 1) of claim 4, and another 1 peptide chain CHRPYIAH is conjugated to the nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via linker 1 of item 2) or 3) of claim 4; 116) 1 C16 hydrocarbon group is conjugated to the nucleotide at the 3' end of the sense strand via linker 2 of claim 8, and 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' end of the sense strand via linker 1 of item 1) of claim 4, and another 1 peptide chain CHRPYIAH is conjugated to the nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via linker 1 of item 2) or 3) of claim 4; 117) 1 C16 hydrocarbon group is conjugated to the nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via an ether bond, and 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' end of the sense strand via linker 1 of item 1) of claim 4, and another 1 peptide chain CHRPYIAH is conjugated to the nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via linker 1 of item 2) or 3) of claim 4; 118) 1 C16 hydrocarbon group is conjugated to the nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via linker 2 of claim 8, and 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' end of the sense strand via linker 1 of item 1) of claim 4, and another 1 peptide chain CHRPYIAH is conjugated to the nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via linker 1 of item 2) or 3) of claim 4; 119) 1 C16 hydrocarbon group is conjugated to the nucleotide at the 3' end of the antisense strand via an ether bond, and 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' end of the sense strand via linker 1 of item 1) of claim 4, and another 1 peptide chain CHRPYIAH is conjugated to the nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via linker 1 of item 2) or 3) of claim 4; 120) 1 C16 alkyl group is conjugated to the nucleotide at the 3' end of the antisense strand via linker 2 of claim 8, and 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' end of the sense strand via linker 1 of item 1) of claim 4, and another 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the middle position between the 5' end and the 3' end of the sense strand via linker 1 of item 2) or item 3) of claim 4; 121) 1 C16 alkyl group is conjugated to the nucleotide at the 5' end of the sense strand via an ether bond, and 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' end of the sense strand via linker 1 of item 2) or item 3) of claim 4, and another 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the middle position between the 5' end and the 3' end of the sense strand via linker 1 of item 1) of claim 4; 122) 1 C16 alkyl group is conjugated to the nucleotide at the 5' end of the sense strand via linker 2 of claim 8, and 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' end of the sense strand via linker 1 of item 2) or item 3) of claim 4, and another 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the middle position between the 5' end and the 3' end of the sense strand via linker 1 of item 1) of claim 4; 123) 1 C16 alkyl group is conjugated to the nucleotide at the 3' end of the sense strand via an ether bond, and 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' end of the sense strand via linker 1 of item 2) or item 3) of claim 4, and another 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the middle position between the 5' end and the 3' end of the sense strand via linker 1 of item 1) of claim 4; 124) 1 C16 alkyl group is conjugated to the nucleotide at the 3' end of the sense strand via linker 2 of claim 8, and 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' end of the sense strand via linker 1 of item 2) or item 3) of claim 4, and another 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the middle position between the 5' end and the 3' end of the sense strand via linker 1 of item 1) of claim 4; 125) 1 C16 alkyl group is conjugated to the nucleotide at the middle position between the 5' end and the 3' end of the sense strand, and 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' end of the sense strand via linker 1 of item 2) or item 3) of claim 4, and another 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the middle position between the 5' end and the 3' end of the sense strand via linker 1 of item 1) of claim 4; 126) 1 C16 alkyl group is conjugated to the nucleotide at the middle position of the sense strand other than the two positions at the 5' and 3' ends by the linker 2 of claim 8, and 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' end of the sense strand by the linker 1 of claim 4, item 2) or 3), and another 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the middle position of the sense strand other than the two positions at the 5' and 3' ends by the linker 1 of claim 4, item 1; 127) 1 C16 alkyl group is conjugated to the nucleotide at the 3' end of the antisense strand by an ether bond, and 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' end of the sense strand by the linker 1 of claim 4, item 2) or 3), and another 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the middle position of the sense strand other than the two positions at the 5' and 3' ends by the linker 1 of claim 4, item 1; 128) 1 C16 alkyl group is conjugated to the nucleotide at the 3' end of the antisense strand by the linker 2 of claim 8, and 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' end of the sense strand by the linker 1 of claim 4, item 2) or 3), and another 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the middle position of the sense strand other than the two positions at the 5' and 3' ends by the linker 1 of claim 4, item 1; 129) 1 C16 alkyl group is conjugated to the nucleotide at the 5' end of the sense strand by an ether bond, and 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand by the linker 1 of claim 4, item 1, and another 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the middle position of the sense strand other than the two positions at the 5' and 3' ends by the linker 1 of claim 4, item 1; 130) 1 C16 alkyl group is conjugated to the nucleotide at the 5' end of the sense strand by the linker 2 of claim 8, and 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand by the linker 1 of claim 4, item 1, and another 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the middle position of the sense strand other than the two positions at the 5' and 3' ends by the linker 1 of claim 4, item 1; 131) 1 C16 alkyl group is conjugated to the nucleotide at the 3' end of the sense strand by an ether bond, and 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand by the linker 1 of claim 4, item 1, and another 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the middle position of the sense strand other than the two positions at the 5' and 3' ends by the linker 1 of claim 4, item 1; 132) 1 C16 hydrocarbon group is conjugated to the nucleotide at the 3' end of the sense strand via linker 2 of claim 8, and 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand via linker 1 of item 1) of claim 4, and another 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the middle position of the sense strand other than the two positions at the 5' and 3' ends; 133) 1 C16 hydrocarbon group is conjugated to the nucleotide at the middle position of the sense strand other than the two positions at the 5' and 3' ends via an ether bond, and 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand via linker 1 of item 1) of claim 4, and another 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the middle position of the sense strand other than the two positions at the 5' and 3' ends; 134) 1 C16 hydrocarbon group is conjugated to the nucleotide at the middle position of the sense strand other than the two positions at the 5' and 3' ends via linker 2 of claim 8, and 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand via linker 1 of item 1) of claim 4, and another 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the middle position of the sense strand other than the two positions at the 5' and 3' ends; 135) 1 C16 hydrocarbon group is conjugated to the nucleotide at the 3' end of the antisense strand via an ether bond, and 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand via linker 1 of item 1) of claim 4, and another 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the middle position of the sense strand other than the two positions at the 5' and 3' ends; 136) 1 C16 hydrocarbon group is conjugated to the nucleotide at the 3' end of the antisense strand via linker 2 of claim 8, and 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand via linker 1 of item 1) of claim 4, and another 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the middle position of the sense strand other than the two positions at the 5' and 3' ends; 137) 1 C16 hydrocarbon group is conjugated to the nucleotide at the 5' end of the sense strand via an ether bond, and 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand via linker 1 of item 2) or 3) of claim 4, and another 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the middle position of the sense strand other than the two positions at the 5' and 3' ends; 138) 1 C16 hydrocarbon linked to the 5' terminal nucleotide of the sense strand via linker 2 of claim 8, and 1 peptide chain CHRPYIAH linked to the 5' terminal nucleotide of the sense strand via linker 1 of item 2) or 3) of claim 4, and another 1 peptide chain CHRPYIAH linked to the 5' terminal nucleotide of the sense strand via linker 1 of item 2) or 3) of claim 4; 139) 1 C16 hydrocarbon linked to the 3' terminal nucleotide of the sense strand via an ether bond, and 1 peptide chain CHRPYIAH linked to the 5' terminal nucleotide of the sense strand via linker 1 of item 2) or 3) of claim 4, and another 1 peptide chain CHRPYIAH linked to the nucleotide at the middle position of the sense strand other than the two positions at the 5' and 3' terminal ends; 140) 1 C16 hydrocarbon linked to the 3' terminal nucleotide of the sense strand via linker 2 of claim 8, and 1 peptide chain CHRPYIAH linked to the 5' terminal nucleotide of the sense strand via linker 1 of item 2) or 3) of claim 4, and another 1 peptide chain CHRPYIAH linked to the nucleotide at the middle position of the sense strand other than the two positions at the 5' and 3' terminal ends; 141) 1 C16 hydrocarbon linked to the nucleotide at the middle position of the sense strand other than the two positions at the 5' and 3' terminal ends via an ether bond, and 1 peptide chain CHRPYIAH linked to the 5' terminal nucleotide of the sense strand via linker 1 of item 2) or 3) of claim 4, and another 1 peptide chain CHRPYIAH linked to the nucleotide at the middle position of the sense strand other than the two positions at the 5' and 3' terminal ends; 142) 1 C16 hydrocarbon linked to the nucleotide at the middle position of the sense strand other than the two positions at the 5' and 3' terminal ends via linker 2 of claim 8, and 1 peptide chain CHRPYIAH linked to the 5' terminal nucleotide of the sense strand via linker 1 of item 2) or 3) of claim 4, and another 1 peptide chain CHRPYIAH linked to the nucleotide at the middle position of the sense strand other than the two positions at the 5' and 3' terminal ends; 143) 1 C16 hydrocarbon linked to the 3' terminal nucleotide of the antisense strand via an ether bond, and 1 peptide chain CHRPYIAH linked to the 5' terminal nucleotide of the sense strand via linker 1 of item 2) or 3) of claim 4, and another 1 peptide chain CHRPYIAH linked to the nucleotide at the middle position of the sense strand other than the two positions at the 5' and 3' terminal ends; 144) 1 C16 alkyl group is conjugated to the nucleotide at the 3' end of the antisense strand via linker 2 of claim 8, and 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand via linker 1 of item 2) or item 3) of claim 4, and another 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the middle position between the 5' end and the 3' end of the sense strand via linker 1 of item 2) or item 3) of claim 4; 145) 1 C16 alkyl group is conjugated to the nucleotide at the 5' end of the sense strand via an ether bond, and 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand via linker 1 of item 1) of claim 4, and another 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the middle position between the 5' end and the 3' end of the sense strand via linker 1 of item 2) or item 3) of claim 4; 146) 1 C16 alkyl group is conjugated to the nucleotide at the 5' end of the sense strand via linker 2 of claim 8, and 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand via linker 1 of item 1) of claim 4, and another 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the middle position between the 5' end and the 3' end of the sense strand via linker 1 of item 2) or item 3) of claim 4; 147) 1 C16 alkyl group is conjugated to the nucleotide at the 3' end of the sense strand via an ether bond, and 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand via linker 1 of item 1) of claim 4, and another 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the middle position between the 5' end and the 3' end of the sense strand via linker 1 of item 2) or item 3) of claim 4; 148) 1 C16 alkyl group is conjugated to the nucleotide at the 3' end of the sense strand via linker 2 of claim 8, and 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand via linker 1 of item 1) of claim 4, and another 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the middle position between the 5' end and the 3' end of the sense strand via linker 1 of item 2) or item 3) of claim 4; 149) 1 C16 alkyl group is conjugated to the nucleotide at the middle position between the 5' end and the 3' end of the sense strand via an ether bond, and 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand via linker 1 of item 1) of claim 4, and another 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the middle position between the 5' end and the 3' end of the sense strand via linker 1 of item 2) or item 3) of claim 4; 150) 1 C16 alkyl group is conjugated to the nucleotide at the middle position of the sense strand other than the two positions at the 5' and 3' ends by the linker 2 of claim 8, and 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand by the linker 1 of item 1) in claim 4, and another 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the middle position of the sense strand other than the two positions at the 5' and 3' ends by the linker 1 of item 2) or 3) in claim 4; 151) 1 C16 alkyl group is conjugated to the nucleotide at the 3' end of the antisense strand by an ether bond, and 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand by the linker 1 of item 1) in claim 4, and another 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the middle position of the sense strand other than the two positions at the 5' and 3' ends by the linker 1 of item 2) or 3) in claim 4; 152) 1 C16 alkyl group is conjugated to the nucleotide at the 3' end of the antisense strand by the linker 2 of claim 8, and 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand by the linker 1 of item 1) in claim 4, and another 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the middle position of the sense strand other than the two positions at the 5' and 3' ends by the linker 1 of item 2) or 3) in claim 4; 153) 1 C16 alkyl group is conjugated to the nucleotide at the 5' end of the sense strand by an ether bond, and 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand by the linker 1 of item 2) or 3) in claim 4, and another 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the middle position of the sense strand other than the two positions at the 5' and 3' ends by the linker 1 of item 1) in claim 4; 154) 1 C16 alkyl group is conjugated to the nucleotide at the 5' end of the sense strand by the linker 2 of claim 8, and 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand by the linker 1 of item 2) or 3) in claim 4, and another 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the middle position of the sense strand other than the two positions at the 5' and 3' ends by the linker 1 of item 1) in claim 4; 155) 1 C16 alkyl group is conjugated to the nucleotide at the 3' end of the sense strand by an ether bond, and 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand by the linker 1 of item 2) or 3) in claim 4, and another 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the middle position of the sense strand other than the two positions at the 5' and 3' ends by the linker 1 of item 1) in claim 4; 156) 1 C16 alkyl group is conjugated to the nucleotide at the 3' end of the sense strand via linker 2 of claim 8, and 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand via linker 1 of claim 4, item 2) or 3), and another 1 peptide chain CHRPYIAH is conjugated to the nucleotide at a position intermediate to the 5' and 3' ends of the sense strand via linker 1 of claim 4, item 1); 157) 1 C16 alkyl group is conjugated to the nucleotide at a position intermediate to the 5' and 3' ends of the sense strand via an ether bond, and 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand via linker 1 of claim 4, item 2) or 3), and another 1 peptide chain CHRPYIAH is conjugated to the nucleotide at a position intermediate to the 5' and 3' ends of the sense strand via linker 1 of claim 4, item 1); 158) 1 C16 alkyl group is conjugated to the nucleotide at a position intermediate to the 5' and 3' ends of the sense strand via linker 2 of claim 8, and 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand via linker 1 of claim 4, item 2) or 3), and another 1 peptide chain CHRPYIAH is conjugated to the nucleotide at a position intermediate to the 5' and 3' ends of the sense strand via linker 1 of claim 4, item 1); 159) 1 C16 alkyl group is conjugated to the nucleotide at the 3' end of the antisense strand via an ether bond, and 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand via linker 1 of claim 4, item 2) or 3), and another 1 peptide chain CHRPYIAH is conjugated to the nucleotide at a position intermediate to the 5' and 3' ends of the sense strand via linker 1 of claim 4, item 1); 160) 1 C16 alkyl group is conjugated to the nucleotide at the 3' end of the antisense strand via linker 2 of claim 8, and 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand via linker 1 of claim 4, item 2) or 3), and another 1 peptide chain CHRPYIAH is conjugated to the nucleotide at a position intermediate to the 5' and 3' ends of the sense strand via linker 1 of claim 4, item 1); 161) 1 C16 alkyl group is conjugated to the nucleotide at the 5' end of the sense strand via an ether bond, and 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' end of the sense strand via linker 1 of claim 4, item 1), and another 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' end of the sense strand via linker 1 of claim 4, item 1); 162) 1 C16alkyl group is conjugated to the nucleotide at the 5' end of the sense strand via linker 2 of claim 8, and 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' end of the sense strand via linker 1 of item 1) of claim 4, and another 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' end of the sense strand via linker 1 of item 1) of claim 4; 163) 1 C16alkyl group is conjugated to the nucleotide at the 3' end of the sense strand via an ether bond, and 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' end of the sense strand via linker 1 of item 1) of claim 4, and another 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' end of the sense strand via linker 1 of item 1) of claim 4; 164) 1 C16alkyl group is conjugated to the nucleotide at the 3' end of the sense strand via linker 2 of claim 8, and 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' end of the sense strand via linker 1 of item 1) of claim 4, and another 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' end of the sense strand via linker 1 of item 1) of claim 4; 165) 1 C16alkyl group is conjugated to the nucleotide at the middle position between the 5' end and the 3' end of the sense strand, and 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' end of the sense strand via linker 1 of item 1) of claim 4, and another 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' end of the sense strand via linker 1 of item 1) of claim 4; 166) 1 C16alkyl group is conjugated to the nucleotide at the middle position between the 5' end and the 3' end of the sense strand via linker 2 of claim 8, and 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' end of the sense strand via linker 1 of item 1) of claim 4, and another 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' end of the sense strand via linker 1 of item 1) of claim 4; 167) 1 C16alkyl group is conjugated to the nucleotide at the 3' end of the antisense strand via an ether bond, and 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' end of the sense strand via linker 1 of item 1) of claim 4, and another 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' end of the sense strand via linker 1 of item 1) of claim 4; 168) 1 C16alkyl group is conjugated to the nucleotide at the 3' end of the antisense strand via linker 2 of claim 8, and 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' end of the sense strand via linker 1 of item 1) of claim 4, and another 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' end of the sense strand via linker 1 of item 1) of claim 4; 169) one C16 hydrocarbon group is conjugated to the 5' terminal nucleotide of the sense strand via an ether linkage and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 3' terminal end of the sense strand via linker 1 of item 2) or 3) of claim 4 and another peptide chain CHRPYIAH is conjugated to a nucleotide at the 3' terminal end of the sense strand via linker 1 of item 2) or 3) of claim 4; 170) one C16 hydrocarbon group is conjugated to the 5' terminal nucleotide of the sense strand via linker 2 of claim 8 and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 3' terminal end of the sense strand via linker 1 of item 2) or 3) of claim 4 and another peptide chain CHRPYIAH is conjugated to a nucleotide at the 3' terminal end of the sense strand via linker 1 of item 2) or 3) of claim 4; 171) one C16 hydrocarbon group is conjugated to the 3' terminal nucleotide of the sense strand via an ether linkage and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 3' terminal end of the sense strand via linker 1 of item 2) or 3) of claim 4 and another peptide chain CHRPYIAH is conjugated to a nucleotide at the 3' terminal end of the sense strand via linker 1 of item 2) or 3) of claim 4; 172) one C16 hydrocarbon group is conjugated to the 3' terminal nucleotide of the sense strand via linker 2 of claim 8 and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 3' terminal end of the sense strand via linker 1 of item 2) or 3) of claim 4 and another peptide chain CHRPYIAH is conjugated to a nucleotide at the 3' terminal end of the sense strand via linker 1 of item 2) or 3) of claim 4; 173) one C16 hydrocarbon group is conjugated to a nucleotide at a position intermediate to the 5' and 3' terminal ends of the sense strand and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 3' terminal end of the sense strand via linker 1 of item 2) or 3) of claim 4 and another peptide chain CHRPYIAH is conjugated to a nucleotide at the 3' terminal end of the sense strand via linker 1 of item 2) or 3) of claim 4; 174) one C16 hydrocarbon group is conjugated to a nucleotide at a position intermediate to the 5' and 3' terminal ends of the sense strand via linker 2 of claim 8 and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 3' terminal end of the sense strand via linker 1 of item 2) or 3) of claim 4 and another peptide chain CHRPYIAH is conjugated to a nucleotide at the 3' terminal end of the sense strand via linker 1 of item 2) or 3) of claim 4; 175) one C16 hydrocarbon group is conjugated to the 3' terminal nucleotide of the antisense strand via an ether linkage and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 3' terminal end of the sense strand via linker 1 of item 2) or 3) of claim 4 and another peptide chain CHRPYIAH is conjugated to a nucleotide at the 3' terminal end of the sense strand via linker 1 of item 2) or 3) of claim 4; 176) one C16alkyl group is conjugated to the 3' terminal nucleotide of the antisense strand via linker 2 of claim 8, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 3' terminal of the sense strand via linker 1 of item 1 or item 3 of claim 4, and another peptide chain CHRPYIAH is conjugated to a nucleotide at the 3' terminal of the sense strand via linker 1 of item 2 or item 3 of claim 4; 177) one C16alkyl group is conjugated to the 5' terminal nucleotide of the sense strand via an ether linkage, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 3' terminal of the sense strand via linker 1 of item 1 of claim 4, and another peptide chain CHRPYIAH is conjugated to a nucleotide at the 3' terminal of the sense strand via linker 1 of item 2 or item 3 of claim 4; 178) one C16alkyl group is conjugated to the 5' terminal nucleotide of the sense strand via linker 2 of claim 8, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 3' terminal of the sense strand via linker 1 of item 1 of claim 4, and another peptide chain CHRPYIAH is conjugated to a nucleotide at the 3' terminal of the sense strand via linker 1 of item 2 or item 3 of claim 4; 179) one C16alkyl group is conjugated to the 3' terminal nucleotide of the sense strand via an ether linkage, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 3' terminal of the sense strand via linker 1 of item 1 of claim 4, and another peptide chain CHRPYIAH is conjugated to a nucleotide at the 3' terminal of the sense strand via linker 1 of item 2 or item 3 of claim 4; 180) one C16alkyl group is conjugated to the 3' terminal nucleotide of the sense strand via linker 2 of claim 8, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 3' terminal of the sense strand via linker 1 of item 1 of claim 4, and another peptide chain CHRPYIAH is conjugated to a nucleotide at the 3' terminal of the sense strand via linker 1 of item 2 or item 3 of claim 4; 181) one C16alkyl group is conjugated to a nucleotide at a position intermediate to the 5' and 3' terminal of the sense strand, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 3' terminal of the sense strand via linker 1 of item 1 of claim 4, and another peptide chain CHRPYIAH is conjugated to a nucleotide at the 3' terminal of the sense strand via linker 1 of item 2 or item 3 of claim 4; 182) one C16alkyl group is conjugated to a nucleotide at a position intermediate to the 5' and 3' terminal of the sense strand via linker 2 of claim 8, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 3' terminal of the sense strand via linker 1 of item 1 of claim 4, and another peptide chain CHRPYIAH is conjugated to a nucleotide at the 3' terminal of the sense strand via linker 1 of item 2 or item 3 of claim 4; 183) one C16 alkyl group is attached to the 3' terminal nucleotide of the antisense strand via an ether linkage and one peptide CHRPYIAH is attached to the 3' terminal nucleotide of the sense strand via linker 1 of item 1) of claim 4 and one other peptide CHRPYIAH is attached to the 3' terminal nucleotide of the sense strand via linker 1 of item 2) or 3) of claim 4; 184) one C16 alkyl group is attached to the 3' terminal nucleotide of the antisense strand via linker 2 of claim 8 and one peptide CHRPYIAH is attached to the 3' terminal nucleotide of the sense strand via linker 1 of item 1) of claim 4 and one other peptide CHRPYIAH is attached to the 3' terminal nucleotide of the sense strand via linker 1 of item 2) or 3) of claim 4; 185) one C16 alkyl group is attached to the 5' terminal nucleotide of the sense strand via an ether linkage and one peptide CHRPYIAH is attached to the 5' terminal nucleotide of the sense strand via linker 1 of item 1) of claim 4 and one other peptide CHRPYIAH is attached to the 5' terminal nucleotide of the sense strand via linker 1 of item 1) of claim 4; 186) one C16 alkyl group is attached to the 5' terminal nucleotide of the sense strand via linker 2 of claim 8 and one peptide CHRPYIAH is attached to the 5' terminal nucleotide of the sense strand via linker 1 of item 1) of claim 4 and one other peptide CHRPYIAH is attached to the 5' terminal nucleotide of the sense strand via linker 1 of item 1) of claim 4; 187) one C16 alkyl group is attached to the 3' terminal nucleotide of the sense strand via an ether linkage and one peptide CHRPYIAH is attached to the 5' terminal nucleotide of the sense strand via linker 1 of item 1) of claim 4 and one other peptide CHRPYIAH is attached to the 5' terminal nucleotide of the sense strand via linker 1 of item 1) of claim 4; 188) one C16 alkyl group is attached to the 3' terminal nucleotide of the sense strand via linker 2 of claim 8 and one peptide CHRPYIAH is attached to the 5' terminal nucleotide of the sense strand via linker 1 of item 1) of claim 4 and one other peptide CHRPYIAH is attached to the 5' terminal nucleotide of the sense strand via linker 1 of item 1) of claim 4; 189) one C16 alkyl group is attached to a nucleotide intermediate between the two positions of 5' and 3' terminal nucleotides of the sense strand via an ether linkage and one peptide CHRPYIAH is attached to the 5' terminal nucleotide of the sense strand via linker 1 of item 1) of claim 4 and one other peptide CHRPYIAH is attached to the 5' terminal nucleotide of the sense strand via linker 1 of item 1) of claim 4; 190) 1 C16alkyl is conjugated to the nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand by linker 2 of claim 8, and 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand by linker 1 of item 1) of claim 4, and another 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand by linker 1 of item 1) of claim 4; 191) 1 C16alkyl is conjugated to the nucleotide at the 3' end of the antisense strand by an ether bond, and 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand by linker 1 of item 1) of claim 4, and another 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand by linker 1 of item 1) of claim 4; 192) 1 C16alkyl is conjugated to the nucleotide at the 3' end of the antisense strand by linker 2 of claim 8, and 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand by linker 1 of item 1) of claim 4, and another 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand by linker 1 of item 1) of claim 4; 193) 1 C16alkyl is conjugated to the nucleotide at the 5' end of the sense strand by an ether bond, and 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand by linker 1 of item 2) or 3) of claim 4, and another 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand by linker 1 of item 2) or 3) of claim 4; 194) 1 C16alkyl is conjugated to the nucleotide at the 5' end of the sense strand by linker 2 of claim 8, and 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand by linker 1 of item 2) or 3) of claim 4, and another 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand by linker 1 of item 2) or 3) of claim 4; 195) 1 C16alkyl is conjugated to the nucleotide at the 3' end of the sense strand by an ether bond, and 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand by linker 1 of item 2) or 3) of claim 4, and another 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand by linker 1 of item 2) or 3) of claim 4; 196) 1 C16alkyl is conjugated to the nucleotide at the 3' end of the sense strand by linker 2 of claim 8, and 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand by linker 1 of item 2) or 3) of claim 4, and another 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand by linker 1 of item 2) or 3) of claim 4; 197) one C16 alkyl group is conjugated to a nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via an ether linkage, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 5' end of the sense strand via linker 1 of item 2) or 3) of claim 4, and another peptide chain CHRPYIAH is conjugated to a nucleotide at the 5' end of the sense strand via linker 1 of item 2) or 3) of claim 4; 198) one C16 alkyl group is conjugated to a nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via linker 2 of claim 8, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 5' end of the sense strand via linker 1 of item 2) or 3) of claim 4, and another peptide chain CHRPYIAH is conjugated to a nucleotide at the 5' end of the sense strand via linker 1 of item 2) or 3) of claim 4; 199) one C16 alkyl group is conjugated to a nucleotide at the 3' end of the antisense strand via an ether linkage, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 5' end of the sense strand via linker 1 of item 2) or 3) of claim 4, and another peptide chain CHRPYIAH is conjugated to a nucleotide at the 5' end of the sense strand via linker 1 of item 2) or 3) of claim 4; 200) one C16 alkyl group is conjugated to a nucleotide at the 3' end of the antisense strand via linker 2 of claim 8, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 5' end of the sense strand via linker 1 of item 2) or 3) of claim 4, and another peptide chain CHRPYIAH is conjugated to a nucleotide at the 5' end of the sense strand via linker 1 of item 2) or 3) of claim 4; 201) one C16 alkyl group is conjugated to a nucleotide at the 5' end of the sense strand via an ether linkage, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 5' end of the sense strand via linker 1 of item 1) of claim 4, and another peptide chain CHRPYIAH is conjugated to a nucleotide at the 5' end of the sense strand via linker 1 of item 2) or 3) of claim 4; 202) one C16 alkyl group is conjugated to a nucleotide at the 5' end of the sense strand via linker 2 of claim 8, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 5' end of the sense strand via linker 1 of item 1) of claim 4, and another peptide chain CHRPYIAH is conjugated to a nucleotide at the 5' end of the sense strand via linker 1 of item 2) or 3) of claim 4; 203) one C16 alkyl group is conjugated to a nucleotide at the 3' end of the sense strand via an ether linkage, and one peptide chain CHRPYIAH is conjugated to a nucleotide at the 5' end of the sense strand via linker 1 of item 1) of claim 4, and another peptide chain CHRPYIAH is conjugated to a nucleotide at the 5' end of the sense strand via linker 1 of item 2) or 3) of claim 4; 204) 1 C16 hydrocarbon group is conjugated to the nucleotide at the 3' end of the sense strand via linker 2 of claim 8, and 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand via linker 1 of item 1) of claim 4, and another 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand via linker 1 of item 2) or 3) of claim 4; 205) 1 C16 hydrocarbon group is conjugated to the nucleotide at the middle position except the two positions at the 5' and 3' ends of the sense strand via ether bond, and 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand via linker 1 of item 1) of claim 4, and another 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand via linker 1 of item 2) or 3) of claim 4; 206) 1 C16 hydrocarbon group is conjugated to the nucleotide at the middle position except the two positions at the 5' and 3' ends of the sense strand via linker 2 of claim 8, and 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand via linker 1 of item 1) of claim 4, and another 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand via linker 1 of item 2) or 3) of claim 4; 207) 1 C16 hydrocarbon group is conjugated to the nucleotide at the 3' end of the antisense strand via ether bond, and 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand via linker 1 of item 1) of claim 4, and another 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand via linker 1 of item 2) or 3) of claim 4; 208) 1 C16 hydrocarbon group is conjugated to the nucleotide at the 3' end of the antisense strand via linker 2 of claim 8, and 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand via linker 1 of item 1) of claim 4, and another 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand via linker 1 of item 2) or 3) of claim 4; 209) 1 C16 hydrocarbon group is conjugated to the nucleotide at the 5' end of the sense strand via ether bond, and 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the middle position except the two positions at the 5' and 3' ends of the sense strand via linker 1 of item 1) of claim 4, and another 1 peptide chain CHRPYIAH is conjugated to the nucleotide at the middle position except the two positions at the 5' and 3' ends of the sense strand via linker 1 of item 1) of claim 4; 210) 1 C16 alkyl group is conjugated to the nucleotide at the 5' end of the sense strand via linker 2 of claim 8, and 1 peptide chain CHRPYIAH is conjugated to the nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via linker 1 of item 1) of claim 4, and another 1 peptide chain CHRPYIAH is conjugated to the nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via linker 1 of item 1) of claim 4; 211) 1 C16 alkyl group is conjugated to the nucleotide at the 3' end of the sense strand via an ether linkage, and 1 peptide chain CHRPYIAH is conjugated to the nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via linker 1 of item 1) of claim 4, and another 1 peptide chain CHRPYIAH is conjugated to the nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via linker 1 of item 1) of claim 4; 212) 1 C16 alkyl group is conjugated to the nucleotide at the 3' end of the sense strand via linker 2 of claim 8, and 1 peptide chain CHRPYIAH is conjugated to the nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via linker 1 of item 1) of claim 4, and another 1 peptide chain CHRPYIAH is conjugated to the nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via linker 1 of item 1) of claim 4; 213) 1 C16 alkyl group is conjugated to the nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via an ether linkage, and 1 peptide chain CHRPYIAH is conjugated to the nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via linker 1 of item 1) of claim 4, and another 1 peptide chain CHRPYIAH is conjugated to the nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via linker 1 of item 1) of claim 4; 214) 1 C16 alkyl group is conjugated to the nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via linker 2 of claim 8, and 1 peptide chain CHRPYIAH is conjugated to the nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via linker 1 of item 1) of claim 4, and another 1 peptide chain CHRPYIAH is conjugated to the nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via linker 1 of item 1) of claim 4; 215) 1 C16 alkyl group is conjugated to the nucleotide at the 3' end of the antisense strand via an ether linkage, and 1 peptide chain CHRPYIAH is conjugated to the nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via linker 1 of item 1) of claim 4, and another 1 peptide chain CHRPYIAH is conjugated to the nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via linker 1 of item 1) of claim 4; 216) 1 C16alkyl group is conjugated to the nucleotide at the 3' end of the antisense strand via linker 2 of claim 8, and 1 peptide chain CHRPYIAH is conjugated to the nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via linker 1 of item 1) of claim 4, and another 1 peptide chain CHRPYIAH is conjugated to the nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via linker 1 of item 1) of claim 4; 217) 1 C16alkyl group is conjugated to the nucleotide at the 5' end of the sense strand via an ether linkage, and 1 peptide chain CHRPYIAH is conjugated to the nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via linker 1 of item 2) or 3) of claim 4, and another 1 peptide chain CHRPYIAH is conjugated to the nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via linker 1 of item 2) or 3) of claim 4; 218) 1 C16alkyl group is conjugated to the nucleotide at the 5' end of the sense strand via linker 2 of claim 8, and 1 peptide chain CHRPYIAH is conjugated to the nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via linker 1 of item 2) or 3) of claim 4, and another 1 peptide chain CHRPYIAH is conjugated to the nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via linker 1 of item 2) or 3) of claim 4; 219) 1 C16alkyl group is conjugated to the nucleotide at the 3' end of the sense strand via an ether linkage, and 1 peptide chain CHRPYIAH is conjugated to the nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via linker 1 of item 2) or 3) of claim 4, and another 1 peptide chain CHRPYIAH is conjugated to the nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via linker 1 of item 2) or 3) of claim 4; 220) 1 C16alkyl group is conjugated to the nucleotide at the 3' end of the sense strand via linker 2 of claim 8, and 1 peptide chain CHRPYIAH is conjugated to the nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via linker 1 of item 2) or 3) of claim 4, and another 1 peptide chain CHRPYIAH is conjugated to the nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via linker 1 of item 2) or 3) of claim 4; 221) one C16 alkyl group is conjugated to a nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand by an ether linkage, and one peptide chain CHRPYIAH is conjugated to a nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand by Linker 1 of item 2) or 3) of claim 4, and another peptide chain CHRPYIAH is conjugated to a nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand by Linker 1 of item 2) or 3) of claim 4; 222) one C16 alkyl group is conjugated to a nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand by Linker 2 of claim 8, and one peptide chain CHRPYIAH is conjugated to a nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand by Linker 1 of item 2) or 3) of claim 4, and another peptide chain CHRPYIAH is conjugated to a nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand by Linker 1 of item 2) or 3) of claim 4; 223) one C16 alkyl group is conjugated to a nucleotide at the 3' end of the sense strand by an ether linkage, and one peptide chain CHRPYIAH is conjugated to a nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand by Linker 1 of item 2) or 3) of claim 4, and another peptide chain CHRPYIAH is conjugated to a nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand by Linker 1 of item 2) or 3) of claim 4; 224) one C16 alkyl group is conjugated to a nucleotide at the 3' end of the sense strand by Linker 2 of claim 8, and one peptide chain CHRPYIAH is conjugated to a nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand by Linker 1 of item 2) or 3) of claim 4, and another peptide chain CHRPYIAH is conjugated to a nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand by Linker 1 of item 2) or 3) of claim 4; 225) one C16 alkyl group is conjugated to a nucleotide at the 5' end of the sense strand by an ether linkage, and one peptide chain CHRPYIAH is conjugated to a nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand by Linker 1 of item 1) of claim 4, and another peptide chain CHRPYIAH is conjugated to a nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand by Linker 1 of item 2) or 3) of claim 4; 226) 1 C16alkyl group is conjugated to the nucleotide at the 5' end of the sense strand via linker 2 of claim 8, and 1 peptide chain CHRPYIAH is conjugated to the nucleotide at a position intermediate to the 5' and 3' ends of the sense strand via linker 1 of item 1) of claim 4, and another 1 peptide chain CHRPYIAH is conjugated to the nucleotide at a position intermediate to the 5' and 3' ends of the sense strand via linker 1 of item 2) or 3) of claim 4; 227) 1 C16alkyl group is conjugated to the nucleotide at the 3' end of the sense strand via an ether bond, and 1 peptide chain CHRPYIAH is conjugated to the nucleotide at a position intermediate to the 5' and 3' ends of the sense strand via linker 1 of item 1) of claim 4, and another 1 peptide chain CHRPYIAH is conjugated to the nucleotide at a position intermediate to the 5' and 3' ends of the sense strand via linker 1 of item 2) or 3) of claim 4; 228) 1 C16alkyl group is conjugated to the nucleotide at the 3' end of the sense strand via linker 2 of claim 8, and 1 peptide chain CHRPYIAH is conjugated to the nucleotide at a position intermediate to the 5' and 3' ends of the sense strand via linker 1 of item 1) of claim 4, and another 1 peptide chain CHRPYIAH is conjugated to the nucleotide at a position intermediate to the 5' and 3' ends of the sense strand via linker 1 of item 2) or 3) of claim 4; 229) 1 C16alkyl group is conjugated to the nucleotide at a position intermediate to the 5' and 3' ends of the sense strand via an ether bond, and 1 peptide chain CHRPYIAH is conjugated to the nucleotide at a position intermediate to the 5' and 3' ends of the sense strand via linker 1 of item 1) of claim 4, and another 1 peptide chain CHRPYIAH is conjugated to the nucleotide at a position intermediate to the 5' and 3' ends of the sense strand via linker 1 of item 2) or 3) of claim 4; 230) 1 C16alkyl group is conjugated to the nucleotide at a position intermediate to the 5' and 3' ends of the sense strand via linker 2 of claim 8, and 1 peptide chain CHRPYIAH is conjugated to the nucleotide at a position intermediate to the 5' and 3' ends of the sense strand via linker 1 of item 1) of claim 4, and another 1 peptide chain CHRPYIAH is conjugated to the nucleotide at a position intermediate to the 5' and 3' ends of the sense strand via linker 1 of item 2) or 3) of claim 4; 231) one C16alkyl group is conjugated to the nucleotide at the 3' terminus of the antisense strand via an ether linkage and one peptide chain CHRPYIAH is conjugated to the nucleotide at the position intermediate to the two positions at the 5' and 3' termini of the sense strand via linker 1 of item 1) of claim 4 and one other peptide chain CHRPYIAH is conjugated to the nucleotide at the position intermediate to the two positions at the 5' and 3' termini of the sense strand via linker 1 of item 2) or 3) of claim 4; 232) one C16alkyl group is conjugated to the nucleotide at the 3' terminus of the antisense strand via linker 2 of claim 8 and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' terminus of the sense strand via linker 1 of item 1) of claim 4 and one other peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' terminus of the sense strand via linker 1 of item 2) or 3) of claim 4; Preferably, the pattern is selected from the following: 1) one C16alkyl group is conjugated to the nucleotide at the 5' terminus of the sense strand via an ether linkage and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' terminus of the sense strand via linker 1 of item 1) of claim 4; 2) one C16alkyl group is conjugated to the nucleotide at the 3' terminus of the sense strand via an ether linkage and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' terminus of the sense strand via linker 1 of item 1) of claim 4; 3) one C16alkyl group is conjugated to the nucleotide at the position intermediate to the two positions at the 5' and 3' termini of the sense strand via an ether linkage and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' terminus of the sense strand via linker 1 of item 1) of claim 4; 4) one C16alkyl group is conjugated to the nucleotide at the 3' terminus of the antisense strand via an ether linkage and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' terminus of the sense strand via linker 1 of item 1) of claim 4; 5) one C16alkyl group is conjugated to the nucleotide at the 5' terminus of the sense strand via an ether linkage and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' terminus of the sense strand via linker 1 of item 1) of claim 4; 6) one C16alkyl group is conjugated to the nucleotide at the 3' terminus of the sense strand via an ether linkage and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' terminus of the sense strand via linker 1 of item 1) of claim 4; 7) one C16alkyl group is conjugated to the nucleotide at the position intermediate to the two positions at the 5' and 3' termini of the sense strand via an ether linkage and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' terminus of the sense strand via linker 1 of item 1) of claim 4; 8) one C16alkyl group is conjugated to the nucleotide at the 3' terminus of the antisense strand via an ether linkage and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' terminus of the sense strand via linker 1 of item 1) of claim 4; 9) one C16 alkyl group is conjugated to the nucleotide at the 5' end of the sense strand via an ether linkage and one peptide chain CHRPYIAH is conjugated to the nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via linker 1 of item 1) of claim 4; 10) one C16 alkyl group is conjugated to the nucleotide at the 3' end of the sense strand via an ether linkage and one peptide chain CHRPYIAH is conjugated to the nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via linker 1 of item 1) of claim 4; 11) one C16 alkyl group is conjugated to the nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via an ether linkage and one peptide chain CHRPYIAH is conjugated to the nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via linker 1 of item 1) of claim 4; 12) one C16 alkyl group is conjugated to the nucleotide at the 3' end of the antisense strand via an ether linkage and one peptide chain CHRPYIAH is conjugated to the nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via linker 1 of item 1) of claim 4; 13) one C16 alkyl group is conjugated to the nucleotide at the 5' end of the sense strand via an ether linkage and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' end of the antisense strand via linker 1 of item 1) of claim 4; 14) one C16 alkyl group is conjugated to the nucleotide at the 3' end of the sense strand via an ether linkage and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' end of the antisense strand via linker 1 of item 1) of claim 4; 15) one C16 alkyl group is conjugated to the nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via an ether linkage and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' end of the antisense strand via linker 1 of item 1) of claim 4; 16) one C16 alkyl group is conjugated to the nucleotide at the 3' end of the antisense strand via an ether linkage and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' end of the antisense strand via linker 1 of item 1) of claim 4; 17) one C16 alkyl group is conjugated to the nucleotide at the 5' end of the sense strand via an ether linkage and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' end of the sense strand via linker 1 of item 1) of claim 4 and another peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand via linker 1 of item 1) of claim 4; 18) one C16 alkyl group is conjugated to the nucleotide at the 3' end of the sense strand via an ether linkage and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' end of the sense strand via linker 1 of item 1) of claim 4 and another peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand via linker 1 of item 1) of claim 4; 19) one C16 alkyl group is conjugated to the nucleotide at the middle position of the sense strand other than the two positions at the 5' and 3' ends, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' end of the sense strand through linker 1 of item 1) in claim 4, and another peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand through linker 1 of item 1) in claim 4; 20) one C16 alkyl group is conjugated to the nucleotide at the 3' end of the antisense strand, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' end of the sense strand through linker 1 of item 1) in claim 4, and another peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand through linker 1 of item 1) in claim 4; 21) one C16 alkyl group is conjugated to the nucleotide at the 5' end of the sense strand, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' end of the sense strand through linker 1 of item 1) in claim 4, and another peptide chain CHRPYIAH is conjugated to the nucleotide at the middle position of the sense strand other than the two positions at the 5' and 3' ends; 22) one C16 alkyl group is conjugated to the nucleotide at the 3' end of the sense strand, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' end of the sense strand through linker 1 of item 1) in claim 4, and another peptide chain CHRPYIAH is conjugated to the nucleotide at the middle position of the sense strand other than the two positions at the 5' and 3' ends; 23) one C16 alkyl group is conjugated to the nucleotide at the middle position of the sense strand other than the two positions at the 5' and 3' ends, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' end of the sense strand through linker 1 of item 1) in claim 4, and another peptide chain CHRPYIAH is conjugated to the nucleotide at the middle position of the sense strand other than the two positions at the 5' and 3' ends; 24) one C16 alkyl group is conjugated to the nucleotide at the 3' end of the antisense strand, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' end of the sense strand through linker 1 of item 1) in claim 4, and another peptide chain CHRPYIAH is conjugated to the nucleotide at the middle position of the sense strand other than the two positions at the 5' and 3' ends; 25) one C16 alkyl group is conjugated to the nucleotide at the 5' end of the sense strand, and one peptide chain CHRPYIAH is conjugated to the nucleotide at the 5' end of the sense strand through linker 1 of item 1) in claim 4, and another peptide chain CHRPYIAH is conjugated to the nucleotide at the middle position of the sense strand other than the two positions at the 5' and 3' ends; 26) one C16 alkyl group is attached to the nucleotide at the 3' end of the sense strand via an ether linkage and one peptide CHRPYIAH is attached to the nucleotide at the 5' end of the sense strand via linker 1 of item 1 of claim 4 and one other peptide CHRPYIAH is attached to the nucleotide at a position intermediate to the 5' and 3' ends of the sense strand via linker 1 of item 1 of claim 4; 27) one C16 alkyl group is attached to the nucleotide at a position intermediate to the 5' and 3' ends of the sense strand via an ether linkage and one peptide CHRPYIAH is attached to the nucleotide at the 5' end of the sense strand via linker 1 of item 1 of claim 4 and one other peptide CHRPYIAH is attached to the nucleotide at a position intermediate to the 5' and 3' ends of the sense strand via linker 1 of item 1 of claim 4; 28) one C16 alkyl group is attached to the nucleotide at the 3' end of the sense strand via an ether linkage and one peptide CHRPYIAH is attached to the nucleotide at the 5' end of the sense strand via linker 1 of item 1 of claim 4 and one other peptide CHRPYIAH is attached to the nucleotide at a position intermediate to the 5' and 3' ends of the sense strand via linker 1 of item 1 of claim 4; 29) one C16 alkyl group is attached to the nucleotide at the 5' end of the sense strand via an ether linkage and one peptide CHRPYIAH is attached to the nucleotide at the 3' end of the sense strand via linker 1 of item 1 of claim 4 and one other peptide CHRPYIAH is attached to the nucleotide at the 3' end of the sense strand via linker 1 of item 1 of claim 4; 30) one C16 alkyl group is attached to the nucleotide at the 3' end of the sense strand via an ether linkage and one peptide CHRPYIAH is attached to the nucleotide at the 3' end of the sense strand via linker 1 of item 1 of claim 4 and one other peptide CHRPYIAH is attached to the nucleotide at the 3' end of the sense strand via linker 1 of item 1 of claim 4; 31) one C16 alkyl group is attached to the nucleotide at a position intermediate to the 5' and 3' ends of the sense strand via an ether linkage and one peptide CHRPYIAH is attached to the nucleotide at the 3' end of the sense strand via linker 1 of item 1 of claim 4 and one other peptide CHRPYIAH is attached to the nucleotide at the 3' end of the sense strand via linker 1 of item 1 of claim 4; 32) one C16 alkyl group is attached to the nucleotide at the 3' end of the sense strand via an ether linkage and one peptide CHRPYIAH is attached to the nucleotide at the 3' end of the sense strand via linker 1 of item 1 of claim 4 and one other peptide CHRPYIAH is attached to the nucleotide at the 3' end of the sense strand via linker 1 of item 1 of claim 4; 33) one C16 alkyl group is attached to the 5' terminal nucleotide of the sense strand via an ether linkage and one peptide CHRPYIAH is attached to the 5' terminal nucleotide of the sense strand via linker 1 of item 1 of claim 4 and one other peptide CHRPYIAH is attached to the 5' terminal nucleotide of the sense strand via linker 1 of item 1 of claim 4; 34) one C16 alkyl group is attached to the 3' terminal nucleotide of the sense strand via an ether linkage and one peptide CHRPYIAH is attached to the 5' terminal nucleotide of the sense strand via linker 1 of item 1 of claim 4 and one other peptide CHRPYIAH is attached to the 5' terminal nucleotide of the sense strand via linker 1 of item 1 of claim 4; 35) one C16 alkyl group is attached to a nucleotide intermediate two positions from the 5' and 3' terminal nucleotide of the sense strand via an ether linkage and one peptide CHRPYIAH is attached to the 5' terminal nucleotide of the sense strand via linker 1 of item 1 of claim 4 and one other peptide CHRPYIAH is attached to the 5' terminal nucleotide of the sense strand via linker 1 of item 1 of claim 4; 36) one C16 alkyl group is attached to the 3' terminal nucleotide of the sense strand via an ether linkage and one peptide CHRPYIAH is attached to the 5' terminal nucleotide of the sense strand via linker 1 of item 1 of claim 4 and one other peptide CHRPYIAH is attached to the 5' terminal nucleotide of the sense strand via linker 1 of item 1 of claim 4; 37) one C16 alkyl group is attached to the 5' terminal nucleotide of the sense strand via an ether linkage and one peptide CHRPYIAH is attached to a nucleotide intermediate two positions from the 5' and 3' terminal nucleotide of the sense strand via linker 1 of item 1 of claim 4 and one other peptide CHRPYIAH is attached to a nucleotide intermediate two positions from the 5' and 3' terminal nucleotide of the sense strand via linker 1 of item 1 of claim 4; 38) one C16 alkyl group is attached to the 3' terminal nucleotide of the sense strand via an ether linkage and one peptide CHRPYIAH is attached to a nucleotide intermediate two positions from the 5' and 3' terminal nucleotide of the sense strand via linker 1 of item 1 of claim 4 and one other peptide CHRPYIAH is attached to a nucleotide intermediate two positions from the 5' and 3' terminal nucleotide of the sense strand via linker 1 of item 1 of claim 4; 39) one C16 alkyl group is attached to a nucleotide intermediate two positions from the 5' and 3' terminal nucleotide of the sense strand via an ether linkage and one peptide CHRPYIAH is attached to a nucleotide intermediate two positions from the 5' and 3' terminal nucleotide of the sense strand via linker 1 of item 1 of claim 4 and one other peptide CHRPYIAH is attached to a nucleotide intermediate two positions from the 5' and 3' terminal nucleotide of the sense strand via linker 1 of item 1 of claim 4; 40) one C16alkyl group is attached to the 3' terminal nucleotide of the antisense strand via an ether linkage and one peptide CHRPYIAH is attached to a nucleotide at a position intermediate to the 5' and 3' terminal nucleotides of the sense strand via linker 1 of item 1 of claim 4 and one other peptide CHRPYIAH is attached to a nucleotide at a position intermediate to the 5' and 3' terminal nucleotides of the sense strand via linker 1 of item 1 of claim 4; or the following pattern: 1) one C16alkyl group is attached to the 5' terminal nucleotide of the sense strand via linker 2 of claim 8 and one peptide CHRPYIAH is attached to the 3' terminal nucleotide of the sense strand via linker 1 of item 1 of claim 4; 2) one C16alkyl group is attached to the 5' terminal nucleotide of the sense strand via linker 2 of claim 8 and one peptide CHRPYIAH is attached to the 3' terminal nucleotide of the sense strand via linker 1 of item 2 or 3 of claim 4; 3) one C16alkyl group is attached to the 5' terminal nucleotide of the sense strand via an ether linkage and one peptide CHRPYIAH is attached to the 3' terminal nucleotide of the sense strand via linker 1 of item 2 or 3 of claim 4; 4) one C16alkyl group is attached to a nucleotide at a position intermediate to the 5' and 3' terminal nucleotides of the sense strand via an ether linkage and one peptide CHRPYIAH is attached to the 3' terminal nucleotide of the sense strand via linker 1 of item 1 of claim 4; 5) one C16alkyl group is attached to a nucleotide at a position intermediate to the 5' and 3' terminal nucleotides of the sense strand via an ether linkage and one peptide CHRPYIAH is attached to the 3' terminal nucleotide of the sense strand via linker 1 of item 2 or 3 of claim 4; 6) one C16alkyl group is attached to a nucleotide at a position intermediate to the 5' and 3' terminal nucleotides of the sense strand via linker 2 of claim 8 and one peptide CHRPYIAH is attached to the 3' terminal nucleotide of the sense strand via linker 1 of item 2 or 3 of claim 4; 7) one C16alkyl group is attached to a nucleotide at a position intermediate to the 5' and 3' terminal nucleotides of the sense strand via linker 2 of claim 8 and one peptide CHRPYIAH is attached to the 3' terminal nucleotide of the sense strand via linker 1 of item 1 of claim 4; 8) one C16alkyl group is attached to the 3' terminal nucleotide of the sense strand via linker 2 of claim 8 and one peptide CHRPYIAH is attached to the 5' terminal nucleotide of the sense strand via linker 1 of item 1 of claim 4; 9) one C16alkyl group is attached to the 3' terminal nucleotide of the sense strand via linker 2 of claim 8 and one peptide CHRPYIAH is attached to the 5' terminal nucleotide of the sense strand via linker 1 of item 2 or 3 of claim 4; 10) one C16 alkyl group is conjugated via an ether linkage to a nucleotide at the 3' end of the sense strand and one peptide chain CHRPYIAH is conjugated via linker 1 according to item 2) or 3) of claim 4 to a nucleotide at the 5' end of the sense strand; 11) one C16 alkyl group is conjugated via an ether linkage to a nucleotide at the 3' end of the sense strand and one peptide chain CHRPYIAH is conjugated via linker 1 according to item 2) or 3) of claim 4 to a nucleotide at the 5' end of the sense strand; 12) one C16 alkyl group is conjugated via an ether linkage to a nucleotide at the 3' end of the sense strand and one peptide chain CHRPYIAH is conjugated via linker 1 according to item 2) or 3) of claim 4 to a nucleotide at the 3' end of the sense strand; 13) one C16 alkyl group is conjugated via an ether linkage to a nucleotide at the 3' end of the sense strand and one peptide chain CHRPYIAH is conjugated via linker 1 according to item 1) of claim 4 to a nucleotide at the 5' end of the sense strand; or 14) one C16 alkyl group is conjugated via an ether linkage to a nucleotide at the 3' end of the sense strand and one peptide chain CHRPYIAH is conjugated via linker 1 according to item 1) of claim 4 to a nucleotide at the 3' end of the sense strand; Further preferred are the following patterns: 1) one C16 alkyl group is conjugated via an ether linkage to a nucleotide at the 5' end of the sense strand and one peptide chain CHRPYIAH is conjugated via linker 1 according to item 1) of claim 4 to a nucleotide at the 3' end of the sense strand; 2) one C16 alkyl group is conjugated via an ether linkage to a nucleotide at the 5' end of the sense strand and one peptide chain CHRPYIAH is conjugated via linker 1 according to item 1) of claim 4 to a nucleotide at the 5' end of the sense strand; 3) one C16 alkyl group is conjugated via an ether linkage to a nucleotide at a position intermediate to the 5' and 3' ends of the sense strand and one peptide chain CHRPYIAH is conjugated via linker 1 according to item 1) of claim 4 to a nucleotide at the 3' end of the sense strand and another peptide chain CHRPYIAH is conjugated via linker 1 according to item 1) of claim 4 to a nucleotide at the 5' end of the sense strand; 4) one C16 alkyl group is conjugated via an ether linkage to a nucleotide at a position intermediate to the 5' and 3' ends of the sense strand and one peptide chain CHRPYIAH is conjugated via linker 1 according to item 1) of claim 4 to a nucleotide at the 3' end of the sense strand; 5) one C16 alkyl group is conjugated via an ether linkage to a nucleotide at a position intermediate to the 5' and 3' ends of the sense strand and one peptide chain CHRPYIAH is conjugated via linker 1 according to item 1) of claim 4 to a nucleotide at the 5' end of the sense strand. The oligonucleotide conjugate according to any one of claims 1 to 16, wherein, The pattern of 2-4 peptide chains conjugated to one or both strands of the siRNA via linker 1 is selected from the following: 1) one peptide chain CHRPYIAH is conjugated via linker 1 according to item 1) of claim 4 to a nucleotide at the 3' end of the sense strand and another peptide chain CHRPYIAH is conjugated via linker 1 according to item 1) of claim 4 to a nucleotide at the 3' end of the sense strand; 2) one peptide chain CHRPYIAH conjugated to the nucleotide at the 3' end of the sense strand via linker 1 according to item 4), 5) or 6) of claim 4, and the other peptide chain CHRPYIAH conjugated to the nucleotide at the 3' end of the sense strand via linker 1 according to item 1) of claim 4; 3) one peptide chain CHRPYIAH conjugated to the nucleotide at the 3' end of the sense strand via linker 1 according to item 2) or 3) of claim 4, and the other peptide chain CHRPYIAH conjugated to the nucleotide at the 3' end of the sense strand via linker 1 according to item 1) of claim 4; 4) one peptide chain CHRPYIAH conjugated to the nucleotide at the 5' end of the sense strand via linker 1 according to item 1) of claim 4, and the other peptide chain CHRPYIAH conjugated to the nucleotide at the 3' end of the sense strand via linker 1 according to item 1) of claim 4; 5) one peptide chain CHRPYIAH conjugated to the nucleotide at the 5' end of the sense strand via linker 1 according to item 4), 5) or 6) of claim 4, and the other peptide chain CHRPYIAH conjugated to the nucleotide at the 3' end of the sense strand via linker 1 according to item 1) of claim 4; 6) one peptide chain CHRPYIAH conjugated to the nucleotide at the 5' end of the sense strand via linker 1 according to item 2) or 3) of claim 4, and the other peptide chain CHRPYIAH conjugated to the nucleotide at the 3' end of the sense strand via linker 1 according to item 1) of claim 4; 7) one peptide chain CHRPYIAH conjugated to the nucleotide at the middle position between the two positions at the 5' and 3' ends of the sense strand via linker 1 according to item 1) of claim 4, and the other peptide chain CHRPYIAH conjugated to the nucleotide at the 3' end of the sense strand via linker 1 according to item 1) of claim 4; 8) one peptide chain CHRPYIAH conjugated to the nucleotide at the middle position between the two positions at the 5' and 3' ends of the sense strand via linker 1 according to item 4), 5) or 6) of claim 4, and the other peptide chain CHRPYIAH conjugated to the nucleotide at the 3' end of the sense strand via linker 1 according to item 1) of claim 4; 9) one peptide chain CHRPYIAH conjugated to the nucleotide at the middle position between the two positions at the 5' and 3' ends of the sense strand via linker 1 according to item 2) or 3) of claim 4, and the other peptide chain CHRPYIAH conjugated to the nucleotide at the 3' end of the sense strand via linker 1 according to item 1) of claim 4; 10) one peptide chain CHRPYIAH conjugated to the nucleotide at the 3' end of the sense strand via linker 1 according to item 1) of claim 4, and the other peptide chain CHRPYIAH conjugated to the nucleotide at the 5' end of the sense strand via linker 1 according to item 1) of claim 4; 11) one peptide chain CHRPYIAH conjugated to the nucleotide at the 3' end of the sense strand via linker 1 according to item 4), 5) or 6) of claim 4, and the other peptide chain CHRPYIAH conjugated to the nucleotide at the 5' end of the sense strand via linker 1 according to item 1) of claim 4; 12) one peptide chain CHRPYIAH conjugated to the nucleotide at the 3' end of the sense strand via linker 1 according to item 2) or 3) of claim 4, and the other peptide chain CHRPYIAH conjugated to the nucleotide at the 5' end of the sense strand via linker 1 according to item 1) of claim 4; 13) one peptide chain CHRPYIAH conjugated to the nucleotide at the 5' end of the sense strand via linker 1 according to item 1) of claim 4, and the other peptide chain CHRPYIAH conjugated to the nucleotide at the 5' end of the sense strand via linker 1 according to item 1) of claim 4; 14) one peptide chain CHRPYIAH conjugated to the nucleotide at the 5' end of the sense strand via linker 1 according to item 4), 5) or 6) of claim 4, and the other peptide chain CHRPYIAH conjugated to the nucleotide at the 5' end of the sense strand via linker 1 according to item 1) of claim 4; 15) one peptide chain CHRPYIAH conjugated to the nucleotide at the 5' end of the sense strand via linker 1 according to item 2) or 3) of claim 4, and the other peptide chain CHRPYIAH conjugated to the nucleotide at the 5' end of the sense strand via linker 1 according to item 1) of claim 4; 16) one peptide chain CHRPYIAH conjugated to the nucleotide at a position intermediate between the 5' and 3' ends of the sense strand via linker 1 according to item 1) of claim 4, and the other peptide chain CHRPYIAH conjugated to the nucleotide at the 5' end of the sense strand via linker 1 according to item 1) of claim 4; 17) one peptide chain CHRPYIAH conjugated to the nucleotide at a position intermediate between the 5' and 3' ends of the sense strand via linker 1 according to item 4), 5) or 6) of claim 4, and the other peptide chain CHRPYIAH conjugated to the nucleotide at the 5' end of the sense strand via linker 1 according to item 1) of claim 4; 18) one peptide chain CHRPYIAH conjugated to the nucleotide at a position intermediate between the 5' and 3' ends of the sense strand via linker 1 according to item 2) or 3) of claim 4, and the other peptide chain CHRPYIAH conjugated to the nucleotide at the 5' end of the sense strand via linker 1 according to item 1) of claim 4; 19) one peptide chain CHRPYIAH conjugated to the nucleotide at the 3' end of the sense strand via linker 1 according to item 1) of claim 4, and the other peptide chain CHRPYIAH conjugated to the nucleotide at a position intermediate between the 5' and 3' ends of the sense strand via linker 1 according to item 1) of claim 4; 20) one peptide chain CHRPYIAH conjugated to the nucleotide at the 3' end of the sense strand via linker 1 according to item 4), 5) or 6) of claim 4, and the other peptide chain CHRPYIAH conjugated to the nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via linker 1 according to item 1 of claim 4; 21) one peptide chain CHRPYIAH conjugated to the nucleotide at the 3' end of the sense strand via linker 1 according to item 2) or 3) of claim 4, and the other peptide chain CHRPYIAH conjugated to the nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via linker 1 according to item 1 of claim 4; 22) one peptide chain CHRPYIAH conjugated to the nucleotide at the 5' end of the sense strand via linker 1 according to item 1 of claim 4, and the other peptide chain CHRPYIAH conjugated to the nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via linker 1 according to item 1 of claim 4; 23) one peptide chain CHRPYIAH conjugated to the nucleotide at the 5' end of the sense strand via linker 1 according to item 4), 5) or 6) of claim 4, and the other peptide chain CHRPYIAH conjugated to the nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via linker 1 according to item 1 of claim 4; 24) one peptide chain CHRPYIAH conjugated to the nucleotide at the 5' end of the sense strand via linker 1 according to item 2) or 3) of claim 4, and the other peptide chain CHRPYIAH conjugated to the nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via linker 1 according to item 1 of claim 4; 25) one peptide chain CHRPYIAH conjugated to the nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via linker 1 according to item 1 of claim 4, and the other peptide chain CHRPYIAH conjugated to the nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via linker 1 according to item 1 of claim 4; 26) one peptide chain CHRPYIAH conjugated to the nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via linker 1 according to item 4), 5) or 6) of claim 4, and the other peptide chain CHRPYIAH conjugated to the nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via linker 1 according to item 1 of claim 4; 27) one peptide chain CHRPYIAH conjugated to the nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via linker 1 according to item 2) or 3) of claim 4, and the other peptide chain CHRPYIAH conjugated to the nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via linker 1 according to item 1 of claim 4; 28) one peptide chain CHRPYIAH conjugated to the nucleotide at the 3' end of the sense strand via linker 1 according to item 4), 5) or 6) of claim 4, and another peptide chain CHRPYIAH conjugated to the nucleotide at the 3' end of the sense strand via linker 1 according to item 4), 5) or 6) of claim 4; 29) one peptide chain CHRPYIAH conjugated to the nucleotide at the 5' end of the sense strand via linker 1 according to item 2) or 3) of claim 4, and another peptide chain CHRPYIAH conjugated to the nucleotide at the 3' end of the sense strand via linker 1 according to item 4), 5) or 6) of claim 4; 30) one peptide chain CHRPYIAH conjugated to the nucleotide at the 5' end of the sense strand via linker 1 according to item 4), 5) or 6) of claim 4, and another peptide chain CHRPYIAH conjugated to the nucleotide at the 3' end of the sense strand via linker 1 according to item 4), 5) or 6) of claim 4; 31) one peptide chain CHRPYIAH conjugated to the nucleotide at the 5' end of the sense strand via linker 1 according to item 2) or 3) of claim 4, and another peptide chain CHRPYIAH conjugated to the nucleotide at the 3' end of the sense strand via linker 1 according to item 4), 5) or 6) of claim 4; 32) one peptide chain CHRPYIAH conjugated to the nucleotide at a position intermediate between the 5' and 3' ends of the sense strand via linker 1 according to item 4), 5) or 6) of claim 4, and another peptide chain CHRPYIAH conjugated to the nucleotide at the 3' end of the sense strand via linker 1 according to item 4), 5) or 6) of claim 4; 33) one peptide chain CHRPYIAH conjugated to the nucleotide at a position intermediate between the 5' and 3' ends of the sense strand via linker 1 according to item 2) or 3) of claim 4, and another peptide chain CHRPYIAH conjugated to the nucleotide at the 3' end of the sense strand via linker 1 according to item 4), 5) or 6) of claim 4; 34) one peptide chain CHRPYIAH conjugated to the nucleotide at the 3' end of the sense strand via linker 1 according to item 4), 5) or 6) of claim 4, and another peptide chain CHRPYIAH conjugated to the nucleotide at the 5' end of the sense strand via linker 1 according to item 4), 5) or 6) of claim 4; 35) one peptide chain CHRPYIAH conjugated to the nucleotide at the 3' end of the sense strand via linker 1 according to item 2) or 3) of claim 4, and another peptide chain CHRPYIAH conjugated to the nucleotide at the 5' end of the sense strand via linker 1 according to item 4), 5) or 6) of claim 4; 36) one peptide chain CHRPYIAH conjugated to the nucleotide at the 5' end of the sense strand via linker 1 according to item 4), 5) or 6) of claim 4, and another peptide chain CHRPYIAH conjugated to the nucleotide at the 5' end of the sense strand via linker 1 according to item 4), 5) or 6) of claim 4; 37) one peptide chain CHRPYIAH conjugated to the nucleotide at the 5' end of the sense strand via linker 1 according to item 2) or 3) of claim 4, and another peptide chain CHRPYIAH conjugated to the nucleotide at the 5' end of the sense strand via linker 1 according to item 4), 5) or 6) of claim 4; 38) one peptide chain CHRPYIAH conjugated to the nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via linker 1 according to item 4), 5) or 6) of claim 4, and another peptide chain CHRPYIAH conjugated to the nucleotide at the 5' end of the sense strand via linker 1 according to item 4), 5) or 6) of claim 4; 39) one peptide chain CHRPYIAH conjugated to the nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via linker 1 according to item 2) or 3) of claim 4, and another peptide chain CHRPYIAH conjugated to the nucleotide at the 5' end of the sense strand via linker 1 according to item 4), 5) or 6) of claim 4; 40) one peptide chain CHRPYIAH conjugated to the nucleotide at the 3' end of the sense strand via linker 1 according to item 4), 5) or 6) of claim 4, and another peptide chain CHRPYIAH conjugated to the nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via linker 1 according to item 4), 5) or 6) of claim 4; 41) one peptide chain CHRPYIAH conjugated to the nucleotide at the 3' end of the sense strand via linker 1 according to item 2) or 3) of claim 4, and another peptide chain CHRPYIAH conjugated to the nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via linker 1 according to item 4), 5) or 6) of claim 4; 42) one peptide chain CHRPYIAH conjugated to the nucleotide at the 5' end of the sense strand via linker 1 according to item 4), 5) or 6) of claim 4, and another peptide chain CHRPYIAH conjugated to the nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via linker 1 according to item 4), 5) or 6) of claim 4; 43) one peptide chain CHRPYIAH conjugated to the nucleotide at the 5' end of the sense strand via linker 1 according to item 2) or 3) of claim 4, and another peptide chain CHRPYIAH conjugated to the nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via linker 1 according to item 4), 5) or 6) of claim 4; 44) one peptide chain CHRPYIAH conjugated to the middle nucleotide between the two positions of the 5' and 3' ends of the sense strand by linker 1 of item 4), 5) or 6) of claim 4, and another peptide chain CHRPYIAH conjugated to the middle nucleotide between the two positions of the 5' and 3' ends of the sense strand by linker 1 of item 4), 5) or 6) of claim 4; 45) one peptide chain CHRPYIAH conjugated to the middle nucleotide between the two positions of the 5' and 3' ends of the sense strand by linker 1 of item 2) or 3) of claim 4, and another peptide chain CHRPYIAH conjugated to the middle nucleotide between the two positions of the 5' and 3' ends of the sense strand by linker 1 of item 4), 5) or 6) of claim 4; 46) one peptide chain CHRPYIAH conjugated to the nucleotide of the 3' end of the sense strand by linker 1 of item 2) or 3) of claim 4, and another peptide chain CHRPYIAH conjugated to the nucleotide of the 3' end of the sense strand by linker 1 of item 2) or 3) of claim 4; 47) one peptide chain CHRPYIAH conjugated to the nucleotide of the 5' end of the sense strand by linker 1 of item 2) or 3) of claim 4, and another peptide chain CHRPYIAH conjugated to the nucleotide of the 3' end of the sense strand by linker 1 of item 2) or 3) of claim 4; 48) one peptide chain CHRPYIAH conjugated to the middle nucleotide between the two positions of the 5' and 3' ends of the sense strand by linker 1 of item 2) or 3) of claim 4, and another peptide chain CHRPYIAH conjugated to the nucleotide of the 3' end of the sense strand by linker 1 of item 2) or 3) of claim 4; 49) one peptide chain CHRPYIAH conjugated to the nucleotide of the 3' end of the sense strand by linker 1 of item 2) or 3) of claim 4, and another peptide chain CHRPYIAH conjugated to the nucleotide of the 5' end of the sense strand by linker 1 of item 2) or 3) of claim 4; 50) one peptide chain CHRPYIAH conjugated to the nucleotide of the 5' end of the sense strand by linker 1 of item 2) or 3) of claim 4, and another peptide chain CHRPYIAH conjugated to the nucleotide of the 5' end of the sense strand by linker 1 of item 2) or 3) of claim 4; 51) one peptide chain CHRPYIAH conjugated to the middle nucleotide between the two positions of the 5' and 3' ends of the sense strand by linker 1 of item 2) or 3) of claim 4, and another peptide chain CHRPYIAH conjugated to the nucleotide of the 5' end of the sense strand by linker 1 of item 2) or 3) of claim 4; 52) one peptide chain CHRPYIAH conjugated to the nucleotide at the 3' end of the sense strand via linker 1 according to item 2) or 3) of claim 4, and another peptide chain CHRPYIAH conjugated to the nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via linker 1 according to item 2) or 3) of claim 4; 53) one peptide chain CHRPYIAH conjugated to the nucleotide at the 5' end of the sense strand via linker 1 according to item 2) or 3) of claim 4, and another peptide chain CHRPYIAH conjugated to the nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via linker 1 according to item 2) or 3) of claim 4; 54) one peptide chain CHRPYIAH conjugated to the nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via linker 1 according to item 2) or 3) of claim 4, and another peptide chain CHRPYIAH conjugated to the nucleotide at a position intermediate to the two positions at the 5' and 3' ends of the sense strand via linker 1 according to item 2) or 3) of claim 4; 55) one peptide chain CHRPYIAH conjugated to the nucleotide at the 3' end of the sense strand via linker 1 according to item 1) of claim 4, and another peptide chain CHRPYIAH conjugated to the nucleotide at the 3' end of the antisense strand via linker 1 according to item 1) of claim 4; 56) one peptide chain CHRPYIAH conjugated to the nucleotide at the 3' end of the sense strand via linker 1 according to item 4), 5) or 6) of claim 4, and another peptide chain CHRPYIAH conjugated to the nucleotide at the 3' end of the antisense strand via linker 1 according to item 1) of claim 4; 57) one peptide chain CHRPYIAH conjugated to the nucleotide at the 3' end of the sense strand via linker 1 according to item 2) or 3) of claim 4, and another peptide chain CHRPYIAH conjugated to the nucleotide at the 3' end of the antisense strand via linker 1 according to item 1) of claim 4; 58) one peptide chain CHRPYIAH conjugated to the nucleotide at the 5' end of the sense strand via linker 1 according to item 1) of claim 4, and another peptide chain CHRPYIAH conjugated to the nucleotide at the 3' end of the antisense strand via linker 1 according to item 1) of claim 4; 59) one peptide chain CHRPYIAH conjugated to the nucleotide at the 5' end of the sense strand via linker 1 according to item 4), 5) or 6) of claim 4, and another peptide chain CHRPYIAH conjugated to the nucleotide at the 3' end of the antisense strand via linker 1 according to item 1) of claim 4; 60) one peptide chain CHRPYIAH conjugated to the nucleotide at the 5' end of the sense strand via linker 1 according to item 2) or 3) of claim 4, and another peptide chain CHRPYIAH conjugated to the nucleotide at the 3' end of the antisense strand via linker 1 according to item 1) of claim 4; 61) one peptide chain CHRPYIAH is conjugated to the nucleotide in the middle position between the two positions at the 5' end and the 3' end of the sense strand by linker 1 according to item 1) of claim 4, and another peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' end of the antisense strand by linker 1 according to item 1) of claim 4; 62) one peptide chain CHRPYIAH is conjugated to the nucleotide in the middle position between the two positions at the 5' end and the 3' end of the sense strand by linker 1 according to item 4), 5) or 6) of claim 4, and another peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' end of the antisense strand by linker 1 according to item 1) of claim 4; 63) one peptide chain CHRPYIAH is conjugated to the nucleotide in the middle position between the two positions at the 5' end and the 3' end of the sense strand by linker 1 according to item 2) or 3) of claim 4, and another peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' end of the antisense strand by linker 1 according to item 1) of claim 4; 64) 3-4 peptide chains CHRPYIAH are conjugated to the nucleotide at the 3' end or the 5' end of the sense strand by linker 1 according to item 1) of claim 4; 65) 3-4 peptide chains CHRPYIAH are conjugated to the nucleotide at the 3' end and the 5' end of the sense strand by linker 1 according to item 1) of claim 4; 66) 3-4 peptide chains CHRPYIAH are conjugated to the nucleotide at the 3' end or the 5' end of the antisense strand by linker 1 according to item 1) of claim 4; 67) 3-4 peptide chains CHRPYIAH are conjugated to the nucleotide at the 3' end or the 5' end of the sense strand by linker 1 according to item 4), 5) or 6) of claim 4; 68) 3-4 peptide chains CHRPYIAH are conjugated to the nucleotide at the 3' end and the 5' end of the sense strand by linker 1 according to item 4), 5) or 6) of claim 4; 69) 3-4 peptide chains CHRPYIAH are conjugated to the nucleotide at the 3' end or the 5' end of the antisense strand by linker 1 according to item 4), 5) or 6) of claim 4; 70) 3-4 peptide chains CHRPYIAH are conjugated to the nucleotide at the 3' end or the 5' end of the sense strand by linker 1 according to item 2) or 3) of claim 4; 71) 3-4 peptide chains CHRPYIAH are conjugated to the nucleotide at the 3' end and the 5' end of the sense strand by linker 1 according to item 2) or 3) of claim 4; 72) 3-4 peptide chains CHRPYIAH are conjugated to the nucleotide at the 3' end or the 5' end of the antisense strand by linker 1 according to item 2) or 3) of claim 4; Preferably, the pattern is selected from the following: 1) one peptide chain CHRPYIAH is conjugated to the nucleotide at the 3' end and the 5' end of the sense strand by linker 1 according to item 1) of claim 4, respectively, and two peptide chains CHRPYIAH are conjugated at each end; 2) 2-4 peptide chains CHRPYIAH conjugated to the nucleotide at the 3' end of the sense strand or the nucleotide at the 5' end of the sense strand by linker 1 according to item 4), 5) or 6) of claim 4; 3) 2-4 peptide chains CHRPYIAH conjugated to the nucleotide at the 3' end of the sense strand and the nucleotide at the 5' end of the sense strand by linker 1 according to item 4), 5) or 6) of claim 4; 4) 2-4 peptide chains CHRPYIAH conjugated to the nucleotide at the 3' end of the antisense strand or the nucleotide at the 5' end of the antisense strand by linker 1 according to item 4), 5) or 6) of claim 4; 5) 1 peptide chain CHRPYIAH conjugated to the nucleotide at the 3' end of the sense strand by linker 1 according to item 1) of claim 4, and another peptide chain CHRPYIAH conjugated to the nucleotide at the middle position between the two positions at the 5' end and the 3' end of the sense strand by linker 1 according to item 2) or 3) of claim 4; 6) 1 peptide chain CHRPYIAH conjugated to the nucleotide at the 5' end of the sense strand by linker 1 according to item 1) of claim 4, and another peptide chain CHRPYIAH conjugated to the nucleotide at the middle position between the two positions at the 5' end and the 3' end of the sense strand by linker 1 according to item 2) or 3) of claim 4; 7) 1 peptide chain CHRPYIAH conjugated to the nucleotide at the 3' end of the antisense strand by linker 1 according to item 1) of claim 4, and another peptide chain CHRPYIAH conjugated to the nucleotide at the middle position between the two positions at the 5' end and the 3' end of the sense strand by linker 1 according to item 2) or 3) of claim 4; 8) 1 peptide chain CHRPYIAH conjugated to the nucleotide at the 3' end of the antisense strand by linker 1 according to item 1) of claim 4, and another peptide chain CHRPYIAH conjugated to the nucleotide at the 3' end of the sense strand by linker 1 according to item 2) or 3) of claim 4; 9) 1 peptide chain CHRPYIAH conjugated to the nucleotide at the 3' end of the antisense strand by linker 1 according to item 1) of claim 4, and another peptide chain CHRPYIAH conjugated to the nucleotide at the 5' end of the sense strand by linker 1 according to item 2) or 3) of claim 4. The oligonucleotide conjugate according to any one of claims 1 to 18, wherein, The oligonucleotide conjugate has the following structure: Oligonucleotide conjugate 1: SS (5'-3'): (UHD)sUmsUmUmAfAmUfCfCfUmCmAmCmUmCmUmAmAmAms(DRI-T8) AS (5'-3'): VPUmsUfsUmAmGmAfGmUmGmAmGmGmAmUfUmAfAmAmAmsUmsGm Oligonucleotide conjugate 2: SS (5'-3'): (DRI-T8)sUmsUmsUmUmAfAmUfCfCfUmCmAmCmUmCmUmAmAmAms(DRI-T8) AS (5'-3'): VPUmsUfsUmAmGmAfGmUmGmAmGmGmAmUfUmAfAmAmAmsUmsGm VPUmsUfsUmAmGmAfGmUmGmAmGmGmAmUfUmAfAmAmAmsUmsGm Oligonucleotide conjugate 3: SS (5'-3'): (DRI-T8)s(UHD)sUmsUmUmAfAmUfCfCfUmCmAmCmUmCmUmAmAmAm AS (5'-3'): VPUmsUfsUmAmGmAfGmUmGmAmGmGmAmUfUmAfAmAmAmsUmsGm Oligonucleotide conjugate 4: SS (5'-3'): (DRI-T8)sUmsUmsUmUmAf(AHD)UfCfCfUmCmAmCmUmCmUmAmAmAms(DRI-T8) AS (5'-3'): VPUmsUfsUmAmGmAfGmUmGmAmGmGmAmUfUmAfAmAmAmsUmsGm Oligonucleotide conjugate 5: SS (5'-3'): UmsUmsUmUmAf(AHD)UfCfCfUmCmAmCmUmCmUmAmAmAms(DRI-T8) AS (5'-3'): VPUmsUfsUmAmGmAfGmUmGmAmGmGmAmUfUmAfAmAmAmsUmsGm Oligonucleotide conjugate 6: SS (5'-3'): (DRI-T8)sUmsUmsUmUmAf(AHD)UfCfCfUmCmAmCmUmCmUmAmAmAm AS (5'-3'): VPUmsUfsUmAmGmAfGmUmGmAmGmGmAmUfUmAfAmAmAmsUmsGm Oligonucleotide conjugate 7: SS (5'-3'): (UHD)sGmsCmUmGfAmAfGfGfUmUmGmUmGmAmAmAmUmUms(DRI-T8) AS (5'-3'): AmsAfsUmUmUmCfAmCmAmAmCmCmUmUfCmAfGmCmAmsGmsCm Oligonucleotide conjugate 8: SS (5'-3'): (DRI-T8)sUmsGmsCmUmGfAmAfGfGfUmUmGmUmGmAmAmAmUmUms(DRI-T8) AS (5'-3'): AmsAfsUmUmUmCfAmCmAmAmCmCmUmUfCmAfGmCmAmsGmsCm 。 A pharmaceutical composition, wherein, The pharmaceutical composition comprises the oligonucleotide conjugate of any one of claims 1 to 19, and a pharmaceutically acceptable carrier. The pharmaceutical composition according to claim 20, wherein, The pharmaceutically acceptable carrier is a delivery vehicle; preferably, the siRNA is encapsulated by the delivery vehicle. Use of the oligonucleotide conjugate of any one of claims 1 to 19, of the pharmaceutical composition of claim 20 or 21, for the manufacture of a medicament for the treatment and / or prevention of a pathological condition or disease associated with a target gene; The pharmaceutically acceptable carrier is a delivery vehicle; preferably, the siRNA is encapsulated by the delivery vehicle. Preferably, the target gene is selected from the group consisting of APP, ATXN2, C9orf72, TARDBP, MAPT (Tau), HTT, SNCA, FUS, ATXN3, ATXN1, ATXN7, ATXN8, MeCP2, PRNP, SOD1, DMPK, MGMT and TTR. The use of claim 22, wherein the disease is selected from the group consisting of central nervous system diseases, ophthalmic diseases, heart-related diseases, muscle-related diseases, tumor diseases; Preferably, the central nervous system diseases include, but are not limited to, Alzheimer's disease, frontotemporal dementia, Parkinson's dementia, Lewy body dementia, multiple system atrophy, amyotrophic lateral sclerosis, Parkinson's disease, Angelman syndrome, Alexander disease, brain stroke, brain tumor; The ophthalmic diseases include, but are not limited to, dry eye syndrome, age-related macular degeneration, glaucoma, intraocular viral infection diseases; The heart-related diseases include, but are not limited to, arrhythmia, myocardial ischemia; The muscle-related diseases include, but are not limited to, Duchenne muscular dystrophy (DMD), facioscapulohumeral muscular dystrophy (FSHD). A method of inhibiting the expression of a target gene in a cell, the method comprising contacting an effective amount of the oligonucleotide conjugate of any one of claims 1-19 and / or the pharmaceutical composition of any one of claims 20-21 with the cell. The method of claim 24, wherein the target gene is APP, ATXN2, C9orf72, TARDBP, MAPT (Tau), HTT, SNCA, FUS, ATXN3, ATXN1, ATXN7, ATXN8, MeCP2, PRNP, SOD1, DMPK, MGMT or TTR. A kit comprising an effective dose of the oligonucleotide conjugate of any one of claims 1-19 and / or the pharmaceutical composition of any one of claims 20-21.

Images